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SUMMARY 
 
Scope of the submission 
The submitted evidence related to the use of eltrombopag for the treatment of chronic idiopathic 
(immune) thrombocytopenic purpura (ITP) in adults who have a platelet count <30 x 109/L and 
are: 
 
• Refractory to splenectomy; or are 
• Inadequate responders to corticosteroids and have medical contraindications to splenectomy. 
 
Summary of submitted clinical effectiveness evidence 
Evidence on clinical effectiveness of eltrombopag came from three RCTs.  
 
Efficacy 
Platelet response rates (≥ 50 x 10 9/L) after 6-week treatment ranged from 27% (8/29, 30mg/day) 
to 80% (21/26, 75mg/day).  58% (44/76) of participants had a platelet count ≥ 50 x 10 9/L and at 
least twice the baseline count. Median cumulative duration of platelet response after 6-month 
eltrombopag treatment was 13.4 weeks amongst non-splenectomised, and 6.0 weeks amongst 
splenectomised. 22% [11/50] of those splenectomised required rescue medication.  The 
percentage amongst those not splenectomised was 17% [14/85].  Overall 44% (12/27) reduced 
dose/frequency of concomitant ITP medications compared with baseline.  
 
The efficacy of administration of eltrombopag plus standard care was significantly better than 
placebo plus standard care in the above outcomes except for: platelet response (≥ 50 x 10 9/L) 
after 6-week 30mg/day eltrombopag treatment (27% vs. 11%, p=0.070); the need for rescue 
medication during 6-month treatment in splenectomised participants (48% vs. 22%, p=0.055); 
and the reduction in dose/frequency of concomitant ITP medications taken at baseline in 
splenectomised participants during 6-month treatment (39% vs. 44%, p=0.714).  It is unclear for 
duration of platelet response during 6-month treatment, whether rescue treatment was taken into 
account. 
 
Safety 
Risk of any grade of bleeding (WHO grade 1-4) during 6-month eltrombopag treatment was 76% 
(65/85) amongst non-splenectomised participants and 82% (41/50) amongst splenectomised 
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participants. Risks of clinically significant bleeding (WHO grade 2-4) was 29% (25/85) amongst 
non-splenectomised participants and 38% (19/50) amongst splenectomised participants. 
Conflicting information on bleeding of 13% overall was also reported.  It is unclear which data 
are most relevant to this review.   
 
Risks of any adverse events were also inconsistently reported as either 47% or 57%-87% at six 
months.  Risks of serious adverse events (not defined) ranged from 3% (2/76, 6-week) to 20% 
(6/30, 6-week).  Risks and types of adverse events appeared to be similar between the 
eltrombopag group and placebo group.  
 
The risk of liver function disturbances for eltrombopag was higher (8% to 13%) compared with 
placebo (3% to 7%). No cases of bone marrow fibrosis, phototoxicity, cardio- or renal- toxicity 
occurred during the intervention. 
 
Comparing efficacy between eltrombopag and romiplostim 
Overall, for durable response eltrombopag may be less effective than romiplostim (manufacturer 
reported OR 0.26 [95% CI 0.03 to 2.62], ERG OR 1.04 [95% CI 0.32 to 3.44]) and overall 
response (manufacturer reported OR 0.17 [95% CI 0.03 to 0.82], ERG OR 0.26 [95% CI 0.07, 
0.97]). In the manufacturer’s analysis, all participants withdrawing prematurely or lost to follow-
up were counted as non-responders (worst scenario). In the ERG’s further analysis, all such 
participants were counted as responders (best scenario). As data were not available on the 
splenectomy status of withdrawals in the eltrombopag trial, a breakdown by splenectomy status 
was not possible in the further analysis conducted by the ERG. 
 
Comparator treatments 
No attempt was made to statistically or narratively synthesise data on effectiveness of 
comparators.  The manufacturer stated that best available evidence was used to generate values 
for the long-term economic model. However, alternative evidence could have been used. 
 
Summary of submitted cost-effectiveness evidence 
The manufacturer submitted two economic evaluations and models analysing the cost-
effectiveness of eltrombopag for the treatment of adult ITP. 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
 vi 
Watch and Rescue model: 
The watch and rescue model, compares eltrombopag plus standard care with standard care alone, 
where standard care is where patients received rescue medication in response to clinical need.  
The model was based on the double blinded RAISE RCT with uptake rates of the drug 
determined from an internal GlaxoSmithKline study.   
 
The incremental cost per QALY for the base case analyses for splenectomised and non–
splenectomised patients are £78,253 and £90,471 respectively. Sensitivity analyses varying the 
risk of death, target platelet counts, and use of concomitant medications did not reduce the 
incremental cost per QALY greatly.  A probabilistic analysis showed that there is little or no 
chance of eltrombopag being cost-effective at a threshold of £30,000 per QALY.  Substantial 
reductions in the price of eltrombopag would be required to obtain a cost per QALY of £30,000. 
 
The ERG conducted additional sensitivity analyses around the source of cost data for managing 
bleeds, discount rate, and the annual risk of bleeding.  Only by combining these changes into an 
optimistic multivariate sensitivity analysis did the incremental cost per QALY begin to approach 
£30,000. 
 
Long term care model: 
The manufacturer provided a second model to assess the cost-effectiveness of a smaller patient 
group with more severe ITP requiring long-term continuous treatment.  The Markov model 
provided aimed to assess the most cost-effective sequence of treatments (rituximab, romiplostim, 
IVIg, Anti-D [only those with a spleen] and eltrombopag).  Given the input parameters used, the 
model was very similar for the two patient groups. 
 
In the analyses conducted by the manufacturer a treatment sequence of rituximab, eltrombopag, 
romiplostim and IVIg was the least costly but least effective.  No other sequences had an 
incremental cost per QALY approaching £30,000.  The manufacturer reported that treatment 
sequences including eltrombopag dominated the same sequences without eltrombopag when 
patients have received prior treatment with rituximab.  The manufacturer’s deterministic 
sensitivity analysis varied the response rate used in the model and the model time horizon.  These 
did not greatly change the results. 
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The ERG’s further univariant analyses (varying the discount rate, changing response rates of 
eltrombopag in line with the meta-analysis, allowing romiplostim to respond over a 12 week 
period and varying the assumption of a fatal bleeding event between 0%-100%) did not greatly 
alter the results.  Plausible combinations of changes could change which treatment sequence was 
least costly but least effective but again no other sequence had an ICER approaching £30,000.  
Introducing a standard of care sequence where patients only received rescue medication resulted 
in the no active treatment sequence being associated with an ICER below £50,000. 
 
Commentary on robustness of submitted evidence 
The overall quality of the RCTs used to support the watch and rescue model appear reasonable 
and the ERG found no evidence that any data of consequence were omitted from the submission.  
Only indirect evidence relating to relatively short follow-ups was used in the long-term model 
and the use of these data introduces a bias of unknown direction and magnitude.  Due to the lack 
of other suitable data, two different measures of utilities were used (the SF-6D and the EQ-5D).  
Furthermore, apart from bleeding no other utility decrements e.g. for other adverse events, were 
included in the models. Information on other parameters for both models can be questioned but 
even when assumptions were varied the incremental costs per QALYs remained well above 
£30,000.   
 
Key issues 
Overall, the key issues for a decision maker to note are as follows: 
 
Effectiveness 
• Eltrombopag appears to be a safe treatment for ITP. 
• Eltrombopag has short term efficacy for the treatment of ITP. 
• There is no robust evidence on long-term efficacy of eltrombopag. 
• Eltrombopag appears to be less effective in achieving an overall response rate than 
romiplostim in a 6-month intervention period. 
• There is no robust evidence on the effectiveness of eltrombopag compared to other relevant 
comparators. 
 
Watch and Rescue model 
• Substantial reductions in the cost of eltrombopag are needed before the incremental cost per 
QALY is less than £30,000. 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
 viii 
• If the chance of dying from a bleeding event increases towards the upper boundary 
considered by the manufacturer, and the price of eltrombopag is reduced then it is plausible 
that the cost per QALY could be reduced to less than £30,000. 
• Other than bleeding no adverse events are modelled.  The bias this causes is unknown.   
 
Long term treatment model 
• Using non-randomised non-comparative data may result in biased estimates.  The magnitude 
and direction of these biases is uncertain. 
• Inclusion of the indirect treatment comparison of eltrombopag with romiplostim along with 
other plausible changes in the effectiveness of romiplostim substantially alters the order of 
treatments in terms of cost-effectiveness.  A decision is needed as to whether such data are 
sufficiently robust. 
• Inclusion of the standard of care sequence results in no active treatment sequence having an 
ICER below £30,000.  It is unclear whether such a standard of care sequence is plausible. 
• When excluding a standard of care sequence, a sequence where eltrombopag is used after 
rituximab is the least costly but least effective sequence.  None of the other sequences have 
an ICER below £30,000. 
• Restricting the time horizon to 2 years then a treatment sequence where eltrombopag is given 
after rituximab is most likely to be cost-effective.  A 50 year time horizon favours a sequence 
involving romiplostim.   
• Many assumptions are used to estimate the target patient population and the numbers of 
patients who will require long-term treatments.  It is unclear how applicable these are. 
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1  INTRODUCTION TO ERG REPORT  
 
The remit of the evidence review group (ERG) is to comment on the clinical and cost-
effectiveness evidence submitted to the National Institute for Health and Clinical Excellence 
(NICE) as part of the single technology review process.  Evidence has been submitted to 
NICE by GlaxoSmithKline (GSK) UK.  The information considered by the ERG related to a 
main submission report, a systematic review report, a response report, and a CD with results 
of the eltrombopag trials.  The ERG also conducted further analysis on the indirect 
comparison of eltrombopag and romiplostim and further economic modelling. 
 
The submitted evidence related to the use of eltrombopag for the treatment of chronic 
immune or idiopathic thrombocytopenic purpura (ITP).  Two patient populations were 
considered:   
1. Splenectomised patients who are refractory to other treatments.  
2. Non-splenectomised patients who have inadequate response to first-line treatment and for 
whom splenectomy is contraindicated. 
In the economic model, two distinct care pathways were considered: 
1. Watch and rescue management.  
2. Long-term continuous management. 
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2  BACKGROUND 
 
Platelets are bloods cells whose role is to arrest bleeding by plugging any breeches in the 
vascular system and to initiate and propagate blood coagulation. Immune thrombocytopenic 
purpura (ITP) is an autoimmune condition where antibodies are formed against the body’s 
own platelets. Antibody binding leads to increased clearance of platelets by the 
reticuloendothelial system, predominately in the spleen, and possibly reduced platelet 
production. If the rate of clearance exceeds the rate of production the platelet count will fall. 
The normal platelet count is 140-400 x 109/L but spontaneous bleeding does not usually occur 
until the platelet count falls below 30 x 109/L. Higher platelet counts, however, are required 
for certain operative procedures (e.g. major surgery or invasive diagnostic procedures) to be 
performed. 
 
ITP can occur in any age group, although this submission is limited to adult patients. It is also 
associated with certain medical conditions e.g. other autoimmune diseases, HIV and hepatitis 
C. ITP may present as bleeding and/or bruising or be asymptomatic and picked up on blood 
counts taken for other reasons. Diagnosis of chronic ITP remains one of exclusion of other 
causes of thrombocytopenia.  
 
No large registry data exist from the UK on the incidence of adult ITP but a case series from 
Newcastle1 suggested an incidence of 1.13 per 100,000 per year which is lower than a Danish 
study which reported an incidence of 3.2 per 100,000 per year2 and the British Committee for 
Standards in Haematology (BCSH)3 which quotes an American review4 which in turn quotes 
two American papers5,6 for its incidence in the UK of 5.8-6.6 per 100,000 per year.  
Spontaneous remission of adult ITP is rare. Both BCSH3 and the American Society for 
Hematology (ASH)7 recommend treatment in their guidelines if the platelet count is below 30 
x 109/L, if there is bleeding, or if an operative procedure requires a higher platelet count. The 
new International Consensus Report, an industry funded expert led guideline, gives similar 
recommendations but does not make the distinction of a platelet count of 30 x 109/L as a 
trigger for treatment. In the UK there are only three licensed medical therapies for first-line 
treatment of ITP (corticosteroids, intravenous immunoglobulin (IVIg) and anti-D) and 
evidence for these and other therapies for ITP is very limited and often confined to case 
series. Recently anti-D has been withdrawn as a treatment for ITP from the European market 
by the manufacturer due to safety concerns (although it is still marketed as a treatment for ITP 
in the USA and in the UK other unlicensed preparations of anti-D are available). The BCSH 
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guidelines quote a response rate of 66% with 33% achieving long term remission with 
steroids and a response rate of 75% with IVIg, but response to IVIg is not long lasting. 
Splenectomy, a surgical treatment, is possibly curative in 66% of patients8 but carries 
mortality from the operation itself and has the long term complications of asplenia.  It is 
recommended as second line treatment for those patients who are fit enough when first line 
treatment fails. 
Eleven to 35% of patients fail to respond to first and second line treatments or require 
unacceptably high doses of steroids.3 Data for other treatments, which are all immune-
suppressants and carry considerable side-effects, are limited. Other treatments that have been 
investigated include cyclophosphamide, vinca alkaloids, high dose steroids, danazol, 
azathioprine, ciclosporin, rituximab, mycophenolate mofetil, dapsone, Campath, autologous 
stem cell transplantation, interferon and combination chemotherapy. Recently however 
thrombopoietin analogues and receptor agonists (romiplostim and eltrombopag respectively) 
have been demonstrated to increase platelet production and count in randomised controlled 
trials in ITP patients failing first line therapies. Romiplostim has been licensed in Europe for 
the treatment of ITP and was approved for use by the Scottish Medicines Consortium for 
adult chronic ITP splenectomised patients who are refractory to other treatments (e.g. 
corticosteroids, immunoglobulins) and for restricted use as second line treatment for adult 
non-splenectomised patients where surgery is contra-indicated.9 Romiplostim has undergone a 
single technology assessment by NICE, the outcome of which is awaited. 
Retrospective cohorts have demonstrated variable mortality from refractory ITP while the 
largest pooled case series10 demonstrated age-adjusted mortality rates from bleeding of 0.004, 
0.012, and 0.130 deaths per patient-year for age groups younger than 40, 40 to 60, and older 
than 60 years, respectively. However, there was wide variation in the quality of the data and 
the case series went as far back as 1954, raising the question whether these data can be 
applied to modern practice. More recent case series have demonstrated lower mortality but 
considerable treatment related mortality and morbidity.11 
2.1  Critique of manufacturer’s description of underlying health problem 
The manufacturer’s submission clearly details the problem of treating chronic refractory ITP 
and the need for new safe treatments. 
 
2.2  Critique of manufacturer’s overview of current service provision  
The manufacturer acknowledges the lack of good quality evidence in the area of chronic ITP 
and the absence of NICE guidelines. They correctly identify that the best clinical guidance 
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available are guidelines from the ASH and the BCSH. Both the BCSH and ASH guidelines 
are from expert groups who prepare ‘best evidence’ guidelines which are peer reviewed prior 
to publication. Unfortunately these guidelines were published in 1996 and 2003 respectively 
and may be out of date and much of the evidence is expert opinion. As noted above the new 
international consensus guidelines12 were published after the manufacturer’s submission had 
been made. The guideline recommendations do not differ greatly from the previously 
published UK3 and USA7 guidelines except recommending the thrombopoietin agonists 
(romiplostim and eltrombopag) be used as possible second line agents after the failure, or 
unacceptable side-effects, of steroids, IVIg and anti-D. They list other possible second line 
treatments as splenectomy, vinca-alkaloids, rituximab, mycophenolate mofetil, dapsone, 
danazol, cyclophosphamide, ciclosporin and azathioprine but list them alphabetically rather 
than giving any preferences. 
 
Because of the lack of licensed second and third line therapies and good quality evidence for 
the treatment of ITP the manufacturer contacted seven UK experts to determine current UK 
practice. It is unclear the extent to which these expert opinions mirror current UK practice, 
which may lead to potential bias in the submission. However the experts’ views on current 
practice were similar to the above guidelines. The manufacturer was requested to provide 
information on any conflict of interests these experts may have and whether they were 
remunerated.  In response they stated that the experts were paid using British Medical 
Association guidelines but did not discuss conflicts of interest.  
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3 CRITIQUE OF MANUFACTURER’S DEFINITION OF DECISION 
PROBLEM 
 
3.1  Population 
The manufacturer’s submission states that the drug is to be used for adult patients with ITP 
requiring treatment who are: 
• Splenectomised and refractory to other treatments; or as  
• Second line treatment to those who have medical contraindications to splenectomy. 
Due to the lack of good registry data the prevalence of the above patients in the UK can only 
be estimated, as acknowledged by the manufacturer. The manufacturer uses the prevalence 
(23.6 per 100,000) calculated from a USA database13 to estimate the prevalence in the UK. 
They consulted an epidemiologist who runs a UK ITP database and he confirmed by personal 
communication that the prevalence in the UK was similar to the USA. As with the incidence, 
the reported prevalence varies considerably. A study not mentioned by the manufacturer had 
determined the prevalence of ITP using the UK general practice database of between 2.1 to 
8.1 per 100,000,14 while Segal and colleagues estimate a prevalence rate of 9.5 per 100,000.15 
A GSK funded survey (DEMAND) of 50 UK haematologists then determined the proportion 
of patients that would likely be suitable for treatment with eltrombopag (8.6% of total ITP 
population). From this it was estimated that there were approximately 850 patients with 
chronic ITP who were suitable for eltrombopag treatment. There is no way of determining if 
the manufacturer’s assumptions about the numbers of patients are correct and there is likely to 
be considerable uncertainty surrounding this estimate.  
The manufacturer’s expert opinion also claims that the RCTs’ participants, of whom only a 
small proportion was from the UK (22/433), were similar to the UK ITP population. The 
patients who entered into the RCTs were heavily pre-treated, probably more so than the 
average UK patient who would be eligible for eltrombopag, with 37.9% having received three 
or more treatments.  It is also unclear as to the reasons why those non-splenectomised 
participants in the trials had not received a splenectomy, whether it was because they were 
medically unfit, as in the proposed indication, or had not had the procedure for other reasons. 
3.2  Intervention  
The technology submitted is a thrombopoietin agonist (eltrombopag) that is given as a daily 
oral tablet with the aim of increasing the platelet production and hence count in ITP. The drug 
is titrated dependent on the platelet count, starting at a dose of 50mg daily (25mg for those of 
East Asian ancestry [reason for lower dose unclear]), aiming for a platelet count of between 
50 and 200 x 109/L (normal range 140-400 x 109/L).  
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3.3  Comparators  
The manufacturer’s panel of experts split the type of ITP patient into two groups and 
suggested the following comparators: 
• Those undergoing ‘watch and rescue’ management, where the comparators were 
corticosteroids, IVIg, rituximab, immunosuppressant agents, romiplostim and, in those 
who have not had a splenectomy, anti-D. 
• Those requiring long-term treatment, where the comparators were romiplostim, IVIg, 
rituximab and anti-D. 
 
These are all the reasonable comparators as described for second-line treatment in the latest 
international consensus document.12 They are all available in the UK with the current 
exception of the licensed preparation of anti-D. The only drugs licensed for the treatment of 
ITP are steroids, anti-D, IVIg and romiplostim.  
 
Both romiplostim and eltrombopag are thrombopoietin agonists, with romiplostim being 
delivered by weekly subcutaneous injection during a hospital out-patient visit while 
eltrombopag is a daily oral preparation.  
 
3.4  Outcomes  
The outcomes included by the manufacturer are appropriate. They include mortality, 
reduction in symptoms, adverse effects of treatment, quality of life and need for rescue 
therapies. The greatest emphasis, however, is on platelet count, response rate and duration of 
response, which may not be appropriate. As the international consensus document12 states 
there is no set platelet count below which a patient should be treated, instead treatment should 
be based on bleeding risk and side-effects of treatments. Therefore platelet count is less 
important than symptoms, adverse effects and quality of life. All three of the eltrombopag 
RCTs (TRA100773A, TRA100773B and TRA102537 RAISE) include bleeding symptoms, 
quality of life and drug side-effects as secondary outomes.  
 
3.5  Time frame 
ITP is a chronic condition with patients often requiring multiple courses of one or more 
treatments over their lifetime, with spontaneous remissions outwith the first few weeks rare. 
Any economic analysis must therefore look at long-term outcomes and the requirement for 
prolonged treatments. This can be illustrated by the cohort presented by Stasi and 
colleagues.16 One hundred and twenty-one patients were treated with prednisolone (1 mg/kg 
for 1 month); refractory or relapsed cases then underwent splenectomy and/or other 
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therapeutic modalities. At last follow-up (between 48 and 151 months) 43 patients were in 
complete remission and free from therapy, 52 were still on therapy, 11 had died (5 due to ITP) 
with the remainder (15) having ITP but not requiring treatment.  
 
3.6  Relevant factors 
It should also be considered that the economic model considers patients who are taking 
unlicensed products (immunosuppresants, including rituximab) before the licensed products 
(romiplostim and possibly eltrombopag), and hence going against their licensed and proposed 
licensed indications. 
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4 CLINICAL EFFECTIVENESS  
 
4.1  Critique of manufacturer’s approach 
 
4.1.1  Description of manufacturer’s search strategy and critique 
Details of the literature searches undertaken on 16th June 2009 are reported in Appendix 2 of 
the manufacturer’s submission.  MEDLINE, EMBASE and the Cochrane Library were 
searched. These searches were supplemented by hand searching of the proceedings of the 
European Haematology Association and American Society of Hematology for the years 2004-
2009. The authors state that reference lists were also screened for additional studies. While 
other databases such as Science Citation Index, CINAHL and Biosis would have been 
appropriate to search, the included sources are the most important ones and as such should 
have provided adequate coverage of the literature. 
 
The search strategies that were used are reproduced in full and are therefore reproducible. The 
approach adopted was to carry out one search to find all relevant clinical and quality of life 
information on the intervention and comparators included in the systematic review. The 
searches were constructed using three sets of terms: (a) ITP terms, (b) 
intervention/comparator terms, and (c) methodology terms. These were correctly combined 
using the Boolean operator OR for each set of terms. Then the summaries of each set were 
combined using AND. Both controlled vocabulary terms and free text terms were used but 
some key terms were omitted which may have compromised the sensitivity of the search. For 
example, free text searching did not always include common variations. Most notable 
omissions were variation for “thrombocytopenic” (thrombocytopaenic and thrombocytopenia) 
and ”romiplstim” (nplate, AMG 532, AMG531 and remiplistim). 
 
The methodology parts of the MEDLINE and EMBASE search strategies were the weakest 
sections and were difficult to follow. This was largely due to the duplicate use of some 
controlled vocabulary terms both as single terms and as part of higher order exploded terms. 
For example in MEDLINE, controlled clinical trial/ is captured by exp clinical trial/ and 
prospective studies/ by exp cohort studies/. Some appropriate terms were excluded, for 
example the MeSH terms comparative study/ quality of life/ and quality adjusted life years/ 
and EMTREE terms controlled study/, major clinical study/ and exp quality of life/. The 
strategy would also have benefited from additional methodology – related text terms. 
 
The search strategy used in the Cochrane Library also included a methodology section. This 
seemed unnecessary since each database has already been filtered for trials (CENTRAL) or 
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systematic reviews (DARE and CDSR) or HTA assessments (HTA database) and risked 
compromising the sensitivity of the search.  
 
No details were provided on the separate searches that were undertaken for clinical 
information for the long-term economic model. It is unclear why this was done because the 
systematic review should have identified all relevant studies. 
 
Due to concerns over the sensitivity of the manufacturer’s searches, the ERG undertook 
independent searches for eltrombopag and the clinical effectiveness of the comparators. 
MEDLINE, MEDLINE In-Process, EMBASE CDSR, DARE and HTA databases were 
searched. The eltrombopag search comprised ITP related and eltrombopag terms only to 
maximise the sensitivity of the search.  The multifile search in MEDLINE and EMBASE for 
comparators was similar to the structure of the manufacturer’s search but included additional 
controlled vocabulary and text terms. The terms used relating to methodology included those 
used in the Cochrane Highly Sensitive RCT filter and the Centre for Reviews and 
Dissemination (CRD) systematic review filter.17 Details are provided in Appendix 1.  
 
4.1.2 Statement of the inclusion/exclusion criteria used in the study selection and 
comment on whether they were appropriate 
 
The inclusion criteria used in the study selection for the systematic review are tabulated in 
Table 4.1. 
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Table 4.1 Details of the inclusion criteria for the systematic review 
Population Adults (≥ 18 years) with ITP (mean/median platelet counts ≤ 30 x 109/L) as a 
primary diagnosis. Patients with ITP due to other causes were excluded. 
Interventions 
and 
comparators 
Evaluated ≥ 1 of  
• Eltrombopag 
• Romiplostim 
• Corticosteroids (dexamethasone, methylprednisolone) 
• Danazol  
• Dapsone  
• Intravenous immunoglobulin (IVIg) 
• Anti-D immunoglobulin,  
• Rituximab 
• Immuosuppressive agents (azathioprine, ciclosporin, mycophenolate 
mofetil) 
• Cytotoxic agents (vincristine, cyclophosphamide) 
• Splenectomy   
• Autologous stem cell transplantation or 
• Any combination of the above treatments. 
Outcomes Efficacy outcomes included: 
• Platelet count  
- Median platelet count 
- Response rate 
- Durability of response 
• Need for rescue treatment or concurrent treatment 
• Symptom reduction 
Safety outcomes included: 
• Headache 
• Nausea 
• Nasopharyngitis 
• Diarrhoea and vomiting 
• Bleeding (incidence, severity and outcome) 
• Mortality 
Health related quality of life outcomes 
Economic outcomes included: 
• Total costs 
• Total effectiveness 
• Life years gained 
• Quality adjusted life years (QALYs) gained 
• Cost per life year gained 
• Cost per QALY 
Study design Prospective clinical studies (RCTs, non-randomised comparative studies, case 
series) with a sample size of ≥ 10 patients, and cost -effectiveness and cost-
utility studies of agents used to treat ITP. 
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For population, the decision problem specified that one group of patients considered should 
be non-splenectomised patients who have inadequate response to first-line treatment and for 
whom splenectomy is contraindicated. However, no definition on contraindication to 
splenectomy was set and evidence from studies that included patients who may be suitable for 
splenectomy was subsequently included in the review. The manufacturer stated that this was 
the case and the licensed use of eltrombopag is indeed more restrictive.  
 
In terms of study design, only evidence from prospective studies was considered by the 
manufacturer. As a consequence only a limited amount of data was identified for some 
interventions, for example cyclophosphamide (one study) and mycophenolate mofetil (two 
studies).  Retrospective studies for these interventions might have been considered and 
indeed, contrary to the inclusion criteria, were included for some comparators in the 
submission.  
 
With regard to the additional review conducted for the economic evaluation, the inclusion 
criteria were limited to large RCTs or published meta-analyses reporting IVIg, anti-D, 
rituximab, or romiplostim in adult chronic ITP patients.  Studies of these designs should have 
formed a subset of the systematic review described above.  However, this was not the case.   
 
4.1.3 Table of identified studies 
The manufacturer identified 20 RCTs and 93 non-randomised comparative studies or case 
series, of which three RCTs (TRA100773A,18 TRA100773B,19 RAISE20), one case series 
(REPEAT),21 and two ongoing studies (EXTEND,22 TRA108132LENS23) reported on 
eltrombopag. Table 4.2 summarises the characteristics of the studies reporting eltrombopag, 
all of which were funded by the manufacturer.  The ERG did not identify any additional 
studies reporting eltrombopag.  
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Table 4.2 Studies reporting eltrombopag 
Study, design, links 
with other  studies  
N, Population, baseline 
platelet count,  spleen 
status 
Intervention, duration  Publication 
status 
TRA100773A, RCT  117 participants with 
chronic ITP who had 
relapsed or were refractory 
to ≥ 1 prior ITP therapies, < 
30 x109/L, a mixture of 
splenectomised and non-
splenectomised patients.  
A, eltrombopag 30, 50 or 
75 mg/day orally, 6 
weeks 
B, placebo, 6 weeks 
Published  
TRA100773B, RCT  
 
 
114 participants. Other 
characteristics as above.  
 
A, eltrombopag 50 
mg/day orally, 6 weeks 
B, placebo, 6 weeks 
Published  
TRA102537RAISE, 
RCT 
197 participants. Other 
characteristics as above. 
A, eltrombopag 50 
mg/day orally, 6 months 
B, placebo, 6 month 
Conference 
abstracts  
TRA108057REPEAT, 
Case series  
66 with chronic ITP who 
had  ≥ 1 prior ITP therapies, 
≥ 20 x109/L and ≤ 50 
x109/L, a mixture of 
splenectomised and non-
splenectomised patients. 
Eltrombopag 50 mg/day 
in 3 cycles (up to 6 
weeks) of repeated 
intermittent dosing 
Conference 
abstracts  
On-going studies    
TRA105325EXTEND, 
case series, an extension 
of eltrombopag 
intervention in adults 
who were previously 
enrolled in an 
eltrombopag study (not 
specified which study) 
207 by 07 Jan 2008, 88% ≤ 
50 x109/L. 
Eltrombopag 50 mg/day 
orally as starting dose, 15 
months  
Due to complete 
in June 2012; 
conference 
abstracts  
TRA108132LENS, 
long-term follow up of 
adults who were 
previously enrolled in a 
phase II or III 
eltrombopag study (not 
specified which study). 
Not reported Eltrombopag, no other 
information reported  
Due to complete 
in April 2013; 
unpublished. 
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For comparator treatments, 36/113 (32%) studies including children or adolescents (< 18 
years old), i.e. not meeting the review’s stated inclusion criteria, were also included (Table 
4.3). Another two retrospective studies reporting on dapsone were also included although the 
inclusion criteria stated that for case series only prospective studies were considered. 
 
Table 4.3 Studies included inappropriately in the systematic review1  
Study ID Reason  
Dexamethasone  
Arruda 199624 Borst 200425 Cheng 200326 Stasi 200027 Included patients  < 18 years old 
IVIg  
Newland 200128 Pacetti 199729 Salama 200830 Reding198831(Cited 
as Sautter 1998 in manufacturer’s report) 
Included patients  < 18 years old 
Anti-D  
Bussel 199132 Rodeghiero  199233 Unsal 200434 Included patients  < 18 years old 
Splenectomy  
Badea 200435 Bourgeois 200336 Cascavilla 200937 Fenaux  198938 
Gadenstatter 200239 Houwerzijl  200840 Ismet 200441 Kwon 200542 
Mazzuconi 199943 Syed 200744 Szold 200245 Winde 199646 Zamir 
199647 
Included patients  < 18 years old 
Rituximab  
Alasfoor 200948 Arnold 200749 Garcia–Chavez 200750 Stasi 200151 
Zaja 200852 
Included patients  < 18 years old 
Peňalver 200653 Included patients  < 18 years 
old, also a retrospective study 
Danazol  
Kondo 199254 Nalli 198855 Included patients  < 18 years old 
Dapsone  
Hernandez 199556 Included patients  < 18 years old 
Godeau 199757 Godeau 199358 Retrospective study 
Mycophenolate mofetil  
Provan 200659 Included patients  < 18 years old 
Vinca alkaloid  
Kueh 198260 Szczepanik 200761 Included patients  < 18 years old 
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4.1.4 Relevant studies not included in the submission 
The ERG conducted independent literature searches to identify additional studies. The 
manufacturer did not mention the ASH guidance on IVIg and corticosteroids7 and a 
systematic review reporting on IVIg (Table 4.4).62 
 
Table 4.4 Relevant studies/reviews missed in the systematic review  
Study ID Study design 
IVIg  
George 1996 (ASH guideline)7 Summary of 14 case series 
Chen 200862 Systematic review consisting of 28 RCTs 
Danazol  
Mylvaganam 198963 Prospective case series, n=15 
Ciclosporin  
Emilia 200264 Prospective case series, n=12 
Kappers-Klunne 200165 Prospective case series, n=20 
 
4.1.5 Description and critique of the manufacturer’s approach to validity assessment 
Only the methodological quality of the included RCTs was assessed. A 13-item checklist 
(recommended by NICE in the guidance to manufacturers for the submission of evidence) 
was used to assess the three eltrombopag RCTs. A separate 7-item checklist (recommended in 
the Cochrane Reviewer’s handbook version 4.2.6) was used to assess the 17 RCTs reporting 
on the effectiveness of comparator treatments. Two reviewers assessed study quality 
independently.  
 
The ERG considered the quality assessment tools appropriate for appraising RCTs, although 
it is unclear why separate instruments were used for the eltrombopag and comparator RCTs.  
Ideally the same tool should have been used for all RCTs.  In addition, the latest version of 
the Cochrane Handbook for Systematic Reviews of Interventions (version 5.0.2) recommends 
using a new quality assessment tool for RCTs (Cochrane risk of bias tool).66 
 
The manufacturer’s submission did not critically appraise non-randomised comparative 
studies or case series included in the review.  The manufacturer did not explain why non-
randomised studies were not quality assessed in their response to the ERG’s clarification 
queries (Clarification response: C34).  
 
An interactive voice response system was used to conceal the treatment allocation in the 
eltrombopag RCTs. In each RCT the randomisation was stratified according to concomitant 
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ITP medication, splenectomy, and baseline platelet count, with a block size of 4 within each 
stratum. The ERG considered the randomisation procedure to be appropriate. 
 
The participants and outcome assessors were blinded. Matching placebo was used to blind 
participants, who were identified by a unique subject number during the study. The ERG 
queried how the blinding was maintained in the three eltrombopag RCTs other than using 
placebo and what the criteria for unblinding were. The manufacturer clarified that an 
investigator or other physician managing the patient could have unblinded the participant’s 
treatment code when there was a medical emergency or in the event of a serious medical 
condition, when knowledge of the investigational product was essential for the clinical 
management and welfare of the subject (clarification response: C7). However, the 
manufacturer did not provide information on whether any participants were unblinded and, if 
so, whether their treatment continued after unblinding. It is unclear to what extent, if any, this 
introduced a potential bias into the analysis. It must also be considered that, as participants in 
the treatment arm with chronically low platelet counts significantly improved their platelet 
counts compared with placebo, then knowledge of the platelet count may lead to knowledge 
of the randomisation. 
 
4.1.6 Description and critique of the manufacturer’s outcome selection 
The three eltrombopag RCTs used slightly different outcomes. Table 4.5 summarises the 
outcomes used in each RCT, their validity and appropriateness. The ERG considered that all 
outcomes were appropriate. The outcomes were either objective or well accepted in ITP 
practice and research, with some validated in ITP patients.  
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Table 4.5 Appropriateness of outcome selection in the three eltrombopag RCTs 
Outcome and definition Validity  Appropriate 
Y/N 
Trial(s) used the 
outcome  
Primary outcome    
Proportion or odds of participants with a 
platelet count of ≥ 50 x 109/L at the end of 
the intervention 
Well  accepted  Y  All three RCTs 
Secondary outcomes    
Efficacy     
Proportion of participants with at least 75% 
of assessments ≥ 50 x 109/L and ≤ 400 x 
109/L 
Objective measure Y TRA102537RAISE 
 
Odds of participants with a platelet count of 
50 x 109/L during the intervention period 
Well  accepted Y TRA100773B 
TRA102537RAISE 
Proportion of participants with platelet count 
of 50 x 109/L and at least x 2 the baseline 
amount 
Objective measure Y TRA100773B 
 
Maximum duration of response Objective measure Y TRA102537RAISE 
Proportion of participants with a reduction in 
use of concomitant ITP medications from 
baseline 
Objective measure Y TRA102537RAISE 
 
Safety     
Incidence and severity of bleeding, measured 
using WHO criteria 
Well accepted Y All three RCTs 
Proportion of participants receiving a rescue 
treatment (new ITP medication, increased 
dose of a concomitant ITP medication from 
baseline, platelet transfusion, and/or 
splenectomy) during the intervention period 
Objective measure Y TRA102537RAISE 
 
Safety and tolerability Clinician reported 
(well accepted) 
Y TRA100773A 
TRA100773B 
Safety and tolerability, adverse events 
graded according to the National Cancer 
Institute (NCI) Common Toxicity Criteria 
for adverse events. 
Well accepted Y TRA102537RAISE 
 
Outcomes of participants incurring a 
haemostatic challenge (collected 
retrospectively) 
Clinician reported 
(well accepted) 
Y All three RCTs 
Quality of life    
Health-related quality of life (HR-QoL), 
measured using SF-36v2 tool 
Validated in ITP 
patients 
Y All three RCTs 
HR-QoL measured using FACT-Th subscale 
measuring the impact of thrombocytopenia 
on daily activities and mental health  
Validated in cancer 
patients with 
thrombocytopenia 
Y TRA102537RAISE 
 
Other outcomes    
Serum thrombopoietin level, measured using 
immunosorbent assay 
Well accepted Y TRA100773A 
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4.1.7  Description and critique of the statistical approach used 
4.1.7.1 Eltrombopag 
The statistical approaches used for the three eltrombopag RCTs were reported in detail and 
they were very similar across studies. 
 
Patient baseline characteristics were tabulated by treatment group. Information on age, sex, 
race, splenectomy status, concomitant ITP medication, platelet counts, and number of prior 
therapies were described. Logistic-regression was then used for primary outcomes with 
adjustment for stratification variables, i.e. use of concomitant ITP medications, splenectomy 
status, and baseline platelet count. If the null hypothesis was rejected by logistic regression, 
the odds of the response rate between placebo group and eltrombopag group were compared.  
 
All RCTs were adequately powered for their statistical purpose. Assuming 60% of 
participants would respond to eltrombopag and 25% to placebo, each trial had a 90% 
statistical power at the 5% level (1% for RAISE trial) of significance (2-sided) to detect a 
30% difference in platelet response rate between eltrombopag group and placebo group. 
 
The manufacturer stated that an ITT analysis was used, i.e. all participants were analysed in 
the group to which they were randomised. However, a small number of randomised patients 
(8/109 [7.3%] in TRA100773A, 2/102 [2%] in TRA100773B) were excluded from the 
efficacy analysis because of a baseline platelet count ≥ 30 x 109/L or because a baseline 
platelet count was not available (Clarification response: C10, C11). Excluding already 
randomised patients who did not meet inclusion criteria is a pragmatic practice but not 
including them in the final analysis contravenes the principles of ITT analysis. Any degree of 
exclusion following randomisation may break the balance of the baseline patient 
characteristics achieved by randomisation.  
 
In studies TRA100773A and B (6-week trials), when participants withdrew prematurely 
because of a platelet count reaching more than 200 x 109/L, the last-observation-carried-
forward (LOCF) imputation was applied and participants were classified as responders in the 
final analysis. The ERG considered such a way of dealing with missing data here is 
appropriate.  
 
4.1.7.2 Comparators 
The characteristics and results of studies reporting on comparator treatments were tabulated in 
the systematic review report but no statistical synthesis was undertaken.  
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Information on the response rates for IVIg, anti-D, rituximab, and romiplostim was needed 
for the long-term economic model. The manufacturer reported that they aimed to use the data 
from the highest available level of evidence. For example meta-analysis and RCTs, as well as 
large case series (Clarification response: B6). However, evidence from only one or two 
studies/reviews was used for each comparator treatment. Although the manufacturer 
consulted two ITP experts in the UK (Dr Drew Provan, Dr Adrian Newland) to help clinically 
validate the assumptions made in the cost-effectiveness approaches, the ERG nevertheless 
considered the way of generating values for comparator treatments in the long-term economic 
model as representing a potentially biased selection of evidence. As the manufacturer has 
identified a considerable amount of evidence for these comparators in the systematic review, 
descriptive statistics might have been considered such as the median and range of results 
across studies as an alternative source of values.   
 
4.1.7.3 Meta-analysis  
Meta-analysis of the three eltrombopag RCTs was carried out for response rates (50-400 x 
109/L) at day 43 of the RCTs (end point of TRA100773A&B, midpoint of the RAISE trial). 
The response rates for the three eltrombopag groups in the TRA100773A trial were summed 
for this purpose. The ERG considered the use of meta-analysis here as appropriate. 
 
4.1.7.4 Indirect comparison 
No RCTs identified in the manufacturer’s systematic review directly compared eltrombopag 
with any of the comparator treatments. Two RCTs reported by Kuter and colleagues67 
reporting romiplostim which also used placebo-plus-standard-care in the control group were 
compared with the RAISE eltrombopag RCT using a mixed treatment comparison. None of 
the other included RCTs used placebo as a comparator treatment.  
 
Data were available for two outcomes in the mixed treatment analysis: durable platelet 
response rate and overall platelet response rate. The platelet response rate in the RAISE study 
was calculated post hoc so that the criteria for platelet response were the same for the 
eltrombopag and romiplostim RCTs. Durable platelet response was defined as a weekly 
platelet count ≥ 5 0 x  10 9/L during six or more weeks of the last eight weeks of treatment 
excluding those who received rescue medication at any time during the study. Overall platelet 
response was defined as durable plus transient response (four or more weekly responses ≥ 50 
x 109/L during the study without a durable platelet response from week 2 to 25).  
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• Concerns on combining the two romiplostim trials 
The results in Figures 6.10 and 6.12 in the manufacturer’s report are confusing. There is no 
acknowledgement in them that “Kuter 2008” refers to, technically, two separate RCTs and 
that the odds ratio calculations for “all subjects” are from a Mantel-Haenszel fixed effects 
meta-analysis, and not the odds ratio estimate and confidence interval that would be 
calculated from the data given for “all subjects”, i.e. the totals of the two trials.  
 
The question of how to combine the two trials by Kuter and colleagues67 to get an estimate for 
the odds ratio for all subjects is not straightforward. However, in our opinion a Mantel-
Haenszel meta-analysis is inappropriate. In most meta-analyses an important issue is whether 
the populations used in the different trials are homogeneous.  In this case it is clear that the 
two populations being meta-analysed are heterogeneous: one considered splenectomised 
patients and the other considered non-splenectomised patients. Analysis exploring other 
methods of amalgamation is shown in Section 7.3.1. 
 
• Concerns on assuming participants who did not complete the trials are non-responders 
In the RAISE trial and the two romiplostim RCTs (all 6-month trials), participants who did 
not complete the trials, i.e. withdrew prematurely due to adverse effects, lack of efficacy, non-
compliance, protocol violation, patient choice, or loss to follow-up were counted as non-
responders. However, the distributions of, and reasons for, not completing the intervention 
amongst the eltrombopag group and romiplostim groups were uneven. More participants 
withdrew prematurely in the RAISE trial than in the romiplostim trials (Table 4.6). Assuming 
all participants who withdrew were non-responders is an extreme scenario (worst scenario). It 
is unclear whether this introduces a bias for or against eltrombopag and further analysis, 
reported in Section 7.3.2, has been conducted by the ERG to explore this issue further.  
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Table 4.6  Number and reasons of premature withdrawals in RAISE trial and 
romiplostim RCTs 
Reasons  Eltrombopag Romiplostim (non-
splenectomised) 
Romiplostim 
(splenectomised) 
Eltr. Placebo Romi. Placebo Romi. Placebo 
23/135 (17%) 7/62 (11%) 2/41 (5%) 4/21 (19%) 2/42 (5%) 2/21 (10%) 
Adverse events 13 4 2 1 1 0 
Withdrew consent 4 2 0 2 1 0 
Deaths  0 0 0 0 0 2 
Pregnancy  0 0 0 1 0 0 
Other  1 1 0 0 0 0 
Loss to follow-up 3 0 0 0 0 0 
Lack of efficacy 1 0 0 0 0 0 
Non-compliance 1 0 0 0 0 0 
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4.1.8  Summary statement of manufacturer’s approach 
The ERG’s main concerns with regard to the manufacturer’s approach were: 
• Intention to treat analysis was not applied in TRA100773A & B trials as the manufacturer 
stated, in that not all participants who were randomised were included in the analysis. 
• Participants who withdrew from the RAISE trial and romiplostim trials were counted as 
non-responders. As there were more such participants in the eltrombopag group than in the 
romiplostim groups, the indirect comparison results might have favoured romiplostim.  
• Highly selective data (from one or two studies/reviews) were used for comparator 
treatments in the long-term economic model. 
 
Other concerns: 
• The characteristics of the non-splenectomised participants in the eltrombopag RCTs were 
not in line with the licensed use for eltrombopag (i.e. such participants should be 
contraindicated for splenectomy).  
• There may have been participants or clinicians who were unblinded to the intervention 
during the eltrombopag RCTs. 
• In the manufacturer’s systematic review, 32% (36/113) of studies not meeting the 
inclusion/exclusion criteria were included and two reviews were missed.  
• The methodological quality of included non-randomised comparative studies and case 
series was not assessed.   
 
4.2 Summary of submitted evidence 
4.2.1 Eltrombopag  
The manufacturer reported the results from three eltrombopag RCTs. The ERG has 
summarised the results by outcome in order to allow comparison across studies.  
 
A. Efficacy 
A1. Platelet response (≥ 50 x 109/L) at the end of the intervention  
Platelet response, defined as ≥ 50 x 109/L at the end of the intervention, was reported for 
studies TRA100773A and B. Platelet response rates after 6-week eltrombopag treatment 
ranged from 26.6% (8/29, 30mg/day) to 80.0% (21/26, 75mg/day). Statistically significantly 
more participants in the eltrombopag group responded to treatment compared with the 
placebo group (p<0.001), apart from the 30mg/day eltrombopag group (p=0.070) (Table 4.7). 
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Table 4.7  Platelet response (≥ 50 x 109/L) at the end of intervention  
 Placebo  Eltrombopag 
30mg 
Eltrombopag 
50mg 
Eltrombopag 
75mg 
TRA100773A (6-week intervention) 
Responders, n/N (%)  3/27 (11.1%) 8/29 (26.6%) 19/27 (70.4%) 21/26 (80.8%) 
Odds ratio (relative to 
placebo), 95% CI 
Not available 3.1 (0.7, 13.8) 22.0 (4.7, 102.2) 38.8 (7.6, 197.7) 
p-value Not available 0.070 < 0.001 < 0.001 
TRA100773B (6-week intervention)a 
Responders, n/N (%) 6/37b (16.2%) - 43/73b (58.9%) 
Odds ratio (relative to 
placebo), 95% CI 
Not available - 9.6 (3.3, 27.9) 
p-value Not available - < 0.001 
aInitial dose used was 50mg/day, adjusted to 75mg/day during treatment in some participants. 
bOne patient was not evaluable and was not included in the analysis. 
 
Results were presented separately by splenectomy status for TRA100773B. Amongst the non-
splenectomised, 56.8% (20/35) of participants in the eltrombopag group had a platelet 
response ≥ 50 x 109/L at the end of the intervention compared with 16.7% (4/24) in the 
placebo group. The results for splenectomised participants were similar (62.1% [19/31] vs. 
15.4% [2/14]). 
 
Meta-analysis was carried out to combine response rates (50-400 x 109/L) between 
eltrombopag and placebo at day 43 of the three RCTs (end point of TRA100773A and B, mid 
point of the RAISE trial) (Figure 4.1). The results show that statistically significantly more 
participants responded to eltrombopag than to placebo overall (164/290 vs. 17/126, OR 8.39, 
95% CI 4.77 to 14.75). The results were similar amongst non-splenectomised and 
splenectomised participants. 
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Figure 4.1  Response rates (50-400 x 109/L) for eltrombopag and placebo at day 43 
 
Source: Clarification report, A3. 
 
A2. Platelet response (≥ 50 x 109/L) at any point during the intervention 
The odds ratio of a platelet response (≥ 50 x 10 9/L) at any point during the intervention for  
eltrombopag and placebo was reported for the TRA100773B and RAISE trials. The actual 
numbers of participants who responded were not reported. In the TRA100773B trial (6-week 
intervention) statistically significantly more participants responded to eltrombopag than to 
placebo (OR 8.8, 95% CI 3.5 to 21.9, p<0.0001). Results were similar in the RAISE trial (6-
month intervention) (OR 8.2, 95% CI 3.6 to 18.7, p<0.001).  
 
A3. Platelet response (≥ 50 x 10 9/L) and at least 2x baseline count at the end of the 
intervention 
A platelet count ≥ 50 x 109/L and at least 2x the baseline count was reported for the 
TRA100773B trial at the end of the intervention. Statistically significantly more participants 
in the eltrombopag group met this criterion compared with the placebo group (58% [44/76] 
vs. 14% [5/38], p<0.001).  
 
A4. Median platelet counts at each point of assessment 
Median platelet counts at each point of assessment were reported for the RAISE trial. The 
median platelet counts for the eltrombopag arm began to rise after one week of treatment and 
remained above 50 x 109/L throughout the 6-month treatment period. The median platelet 
counts for the placebo arm did not rise above 30 x 109/L throughout the study.  
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A5. Duration of platelet response 
Duration of platelet response (continuous and cumulative number of weeks of response) was 
reported for the RAISE trial. However, it was not clear whether rescue treatments were taken 
into account when reporting this information.  
 
The median duration of the maximum continuous response in the eltrombopag group was 8.1 
weeks compared with 0 weeks in the placebo group.  
 
The median cumulative weeks of response in the eltrombopag group was 10.9 weeks 
compared with 0 weeks in the placebo group. Amongst non-splenectomised participants, this 
was 13.4 weeks (range 0 to 26.1 weeks) in the eltrombopag group compared with 0 weeks 
(range 0 to 23.7 weeks) in the placebo group. Amongst splenectomised participants, it was 6.0 
weeks (range 0 to 23.7 weeks) in the eltrombopag group compared with 0 weeks (range 0 to 
19.7 weeks) in the placebo group. 
 
A6. Need for rescue medication during treatment 
The need for rescue medication was reported by the RAISE trial.  Rescue medication was 
defined as a composite of new ITP medication, increased dose of concomitant ITP 
medication, platelet transfusion, and/or splenectomy during the intervention. Overall, 40% 
(25/62) of participants in the placebo group required rescue medication compared with 18% 
(25/135) in the eltrombopag group (p < 0.001). Similar results were observed for placebo 
compared with eltrombopag amongst non-splenectomised participants (15/41 [36.6%] vs. 
14/85 [16.5%], OR 0.34, 95% CI 0.14 to 0.79, p=0.013). The same direction of effect was 
observed for placebo compared with splenectomised participants although the difference was 
not statistically significant (10/21 [47.6%] vs. 11/50 [22.0%], OR 0.33, p=0.055). 
 
A7. Reduction in dose/frequency of concomitant ITP medications taken at baseline 
The manufacturer provided evidence on the reduction of concomitant ITP treatments for the 
RAISE trial in their response to the ERG clarification queries (Clarification report, Appendix 
1). There was a statistically significant reduction in concomitant treatments amongst those not 
splenectomised who received eltrombopag compared with the placebo group (placebo 5/18 
[27.8%] vs. eltrombopag 25/36 [69.4%], OR 5.87, 95% CI 1.67 to 20.59, p=0.006). The 
difference between eltrombopag and placebo amongst splenectomised participants was not 
statistically significant (placebo 5/13 [38.5%] vs. eltrombopag 12/27 [44.4%], OR 1.29, 95% 
CI 0.33 to 5.04, p=0.714). 
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A8. Results of haemostatic challenge during or after the intervention 
There were a small number of participants in the TRA100773A and B trials who needed 
surgery or in one case was involved in a car accident during treatment. None of the 
participants (0/4) from the eltrombopag arms needed rescue treatment compared with all of 
those (3/3) from the placebo arms (Table 4.8). Similarly, in the RAISE trial fewer participants 
in the eltrombopag arm needed rescue treatment as a result of haemostatic challenge 
compared with the placebo arm (28.6% [4/14] vs. 50.0% [2/4]). The ERG was not able to 
compare the severity of bleeding between the eltrombopag and placebo group as the event 
occurred too rarely.  In addition, the types of surgery experienced by the participants in the 
placebo group were not reported in detail. 
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Table 4.8  Results of haemostatic challenge during or after intervention  
Outcome reported Placebo  Eltrombopag 
30mg/day 
Eltrombopag 
50mg/day 
Eltrombopag 
75mg/day 
TRA100773A (6-week intervention) 
Number of participants 
facing a haemostatic 
challenge, n/N (%)  
1/27 (3.7%) 0/29 3/27 (11.1%) 0/26 
Type of challenge  Surgery  - 2 surgeries, 1 car 
accident.  
- 
Need for rescue treatment to 
prevent bleeding 
Needed  - Not needed and 
no bleeding 
complications 
- 
TRA100773B (6-week intervention)a 
Number of participants 
facing a haemostatic 
challenge, n/N (%) 
2/38 (5.3%) - 1/74 (1.4%) 
Type of challenge  Not reported - Teeth extraction 1week after 
intervention. 
Need for rescue treatment to 
prevent bleeding 
Needed for both  - Not needed and no bleeding 
complications 
TRA102537RAISE (6-month intervention)b 
Number of participants 
facing a haemostatic 
challenge, n/N 
4/62 (6.5%) 14/135 (10.4%) 
Type of challenge  Minor surgery Various from dental prosthetic work to open heart 
surgery 
Need for rescue treatment to 
prevent bleeding 
Needed by the 2/4 
(50.0%) who 
underwent dental 
procedures 
Needed by 4/14 (28.6%) participants who underwent 
tooth extraction, tooth extraction and skin biopsy, 
open heart surgery, and colonoscopy and 
hemicolectomia respectively. 
aInitial dose of eltrombopag was 50mg/day, adjusted to 75mg/day during treatment in some 
participants. 
bInitial dose of eltrombopag was 50mg/day, adjusted to between 25mg and 75mg/day during treatment. 
 
B. Safety 
B1. Death 
One participant in the 50 mg/day eltrombopag treatment group in the TRA100773A trial died 
during the study. At baseline this participant had chronic obstructive pulmonary disease, 
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asthma, and peripheral oedema. Following 21 days of treatment he developed pneumonia, 
hepatitis, and renal insufficiency and after 25 days he died from cardiopulmonary failure. 
 
B2. Incidence and severity of bleeding 
Although detailed data on the number of bleeding events and data by splenectomy status were 
requested from the manufacturer in the ERG clarification queries, such data from only the 
RAISE trial were provided.  
 
In non-splenectomised participants, 76% (65/85) of participants in the eltrombopag group 
experienced bleeding (any grade [1-4]) during treatment. This was statistically significantly 
less than that in the placebo group (95%, 38/40, p=0.007) (Table 4.9). Amongst 
splenectomised participants, 82% (41/50) of participants in the eltrombopag group 
experienced bleeding (any grade [1-4]) during treatment.  This was lower than in the placebo 
group (90%, 18/20) but the difference was not statistically significant (p=0.887). 
 
The manufacturer also reported odds ratios for clinically significant bleeding (WHO grade 2-
4). Statistically significantly fewer participants experienced a clinically significant bleed in 
the eltrombopag group compared with the placebo group, for both non-splenectomised (18/40 
[45%] vs. 25/85 [29%], p=0.020) and splenectomised participants (14/20 [70%] vs. 19/50 
[38%], p=0.041) (Table 4.9). 
 
Table 4.9  Incidence of bleeding any time from day 8 to end of treatment  
 Non-splenectomised participants Splenectomised participants 
 Placebo 
n=40  
EBAG 
n=85 
ORa, 95% CI, p-
value 
Placebo 
N=20  
EBAG 
n=50 
ORa, 95% CI, p-
value 
Any WHO grade 
(1-4) 
38 (95%) 65 (76%) 0.10 (0.02, 0.53) 
p=0.007 
18 (90%) 41 (82%) 0.87 (0.12, 6.07) 
p=0.887 
Clinically 
significant bleeding 
(Grade 2-4) 
18 (45%) 25 (29%) 0.31 (0.11, 0.83) 
P=0.020 
14 (70%) 19 (38%) 0.27 (0.08, 0.95) 
P=0.041 
aFrom logistic regression, adjusted for baseline concomitant ITP treatment use, platelet count, and 
bleeding scales. 
EBAG, eltrombopag. 
 
The manufacturer also provided the total number of bleeding events that occurred during 
treatment, in its response to ERG clarification queries. A similar proportion of WHO grade 3 
or 4 bleeding events occurred in the eltrombopag and placebo groups for both non-
splenectomised and splenectomised participants (Table 4.10). Fewer grade 1 or 2 bleeding 
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events occurred in the eltrombopag group compared with the placebo group regardless of 
splenectomy status. Brain stem haemorrhage that led to the death of one participant in the 
placebo group of the RAISE trial was not classified as a WHO grade 4 bleeding event since it 
was directly reported as an adverse event captured by CTCAE 3.0 criteria.  While this may fit 
with the trial protocol it does however lead to under-reporting of bleeding risk and represents 
a bias against eltrombopag. 
 
Table 4.10  Total number of bleeding events during treatment 
 Non-splenectomised participants Splenectomised participants 
 Placebo, n=41  Eltrombopag, n=85 Placebo, n=21  Eltrombopag, n=50 
Total number of 
assessments 
631 1393 364 862 
Grade 1 257 (41%) 242 (17%) 142 (39%) 216 (25%) 
Grade 2 87 (14%) 77 (6%) 72 (20%) 64 (7%) 
Grade 3 6 (<1%) 16 (1%) 4 (1%) 5 (<1%) 
Grade 4 0 0 0 0 
 
B3. Adverse events 
In the three eltrombopag RCTs, the risk of any adverse event ranged from 57% to 87%, the 
risk of a serious adverse event (not defined) ranged from 3% to 20%, the proportion of 
adverse events related to study medication ranged from 27% to 36%, and the proportion of 
adverse events leading to withdrawal of treatment ranged from 0 to 9% (Table 4.11). For each 
category, the risk of an adverse event appeared to be similar between the eltrombopag and 
placebo group in each RCT; however, no statistical comparisons were undertaken. 
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Table 4.11 Summary of adverse events (AEs) during intervention, number of 
participants (%)  
 Placebo  Eltrombopag 
30mg/day 
Eltrombopag 
50mg/day 
Eltrombopag 
75mg/day 
TRA100773A (6-week intervention) 
Any AE  18/29 (62%) 20/30 (67%) 17/30 (57%) 19/28 (68%) 
Any serious AE 4/29 (14%) 1/30 (3%) 6/30 (20%) 2/28 (7%) 
AEs related to study medication 11/29 (38%) 10/30 (33%) 8/30 (27%) 10/28 (36%) 
AEs leading to withdrawal 3/29 (10%) 0 2/30 (7%) 1/28 (4%) 
TRA100773B (6-week intervention) 
Any AE  14/38 (37%) - 45/76 (59%) 
Any serious AE 2/38 (5%) - 2/76 (3%)1 
AEs related to study medication 4/38 (11%) - 20/76 (26%) 
AEs leading to withdrawal 2/38 (5%) - 3/76 (4%) 
TRA102537RAISE (6-month intervention) 
Any AE  56/61 (92%) 118/135 (87%) 
Any serious AE 11/61 (18%) 15/135 (11%) 
AEs related to study medication 18/61 (30%)  48/135 (36%) 
AEs leading to withdrawal 4/61 (7%) 12/135 (9%) 
 
 
Table 4.12 lists the most common adverse events (5% or greater in any group) that occurred 
in the three eltrombopag RCTs. The manufacturer repeated the information on the numbers of 
participants who experienced any adverse event that was included in Table 4.11, however, 
different numbers were reported for Trial TRA100773A. The numbers reported in Table 4.11 
were 18 (62%) for placebo group, 20 (67%), 17 (57%) and 19 (68%) for eltrombopag groups, 
while the numbers reported in Table 4.12 were 17 (59 %), 14 (47%), 14 (47%) and 17 (61%) 
respectively, i.e. the rates in Table 4.11 were higher than those reported in Table 4.12 for 
placebo and eltrombopag groups. 
 
According to the description in Table 4.12, the most common adverse events (10% or greater 
in any of the RCTs) in the eltrombopag groups were headache (range 8% to 30%), diarrhoea 
(0 to 13%), nausea (8% to 12%), nasopharyngitis (7% to 10%), upper respiratory tract 
infection (10% in the RAISE trial), and fatigue (7% to 10%).  Other common adverse events 
(range 5% to 10% in any of the eltrombopag groups) were pain in extremity (0 to 7%),  
alanine transaminase  increase (7%), vomiting (5% to 7%), urinary tract infection (7%), 
arthralgia (0 to 7%), pharyngolaryngeal pain (7%), rash (0 to 7%), aspirate aminotranferase 
level increase (0 to 7%), myalgia (6%), pharyngitis (6%), and constipation (0 to 7%) (Table 
4.12).  
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Table 4.12  Adverse events in 5% or more participants in any study group, number of 
participants (%) 
Event  TRA100773A TRA100773B TRA102537RAISE 
Placebo, 
n=29 
EBAG 
30mg/d 
n=30 
EBAG 
50mg/d 
n=30 
EBAG 
75mg/d 
n=28 
Placebo, 
n=38 
EBAG 
≥50mg/d 
n=76 
Placebo, 
n=61 
EBAG 
≥25mg/d 
n=135 
Any AE 17 (59) 14 (47) 14 (47) 17 (61) 14/38 (37) 45/76 (59) 56 (92) 118 (87) 
Headache 6 (21) 4 (13) 3 (10) 6 (21) 4 (11) 6 (8) 20 (33) 41 (30) 
Diarrhoea 2 (7) 0 0 1 (4) 1 (3) 4 (5) 6 (10) 17 (13) 
Nausea - - - - 0 6 (8) 4 (7) 16 (12) 
Nasopharyngitis - - - - 3 (8) 5 (7) 8 (13) 14 (10) 
Upper 
respiratory tract 
infection 
- - - - - - 7 (11) 14 (10) 
Fatigue 5 (17) 0 1 (3) 2 (7) - - 8 (13) 13 (10) 
Pain in 
extremity 
1 (3) 2 (7) 0 0 - - 6 (10) 9 (7) 
Alanine 
transaminase 
increased 
- - - - - - 4 (7) 10 (7) 
Vomiting - - - - 0 4 (5) 1 (2) 10 (7) 
Urinary tract 
infection 
- - - - - - 4 (7) 9 (7) 
Arthralgia 3 (10) 1 (3) 0 0 - - 3 (5) 9 (7) 
Pharyngolaryng
eal pain 
- - - - - - 3 (5) 9 (7) 
Rash  1 (3) 1 (3) 0 2 (7) - - - - 
AST increased 0 1 (3) 0 2 (7) - - - - 
Myalgia - - - - - - 2 (3) 8 (6) 
Pharyngitis - - - - - - 1 (2) 8 (6) 
Aspirate 
aminotranferase 
increased 
- - - - - - 2 (3) 7 (5) 
Epistaxis 0 4 (13) 0 0 - - 6 (10) 7 (5) 
Back pain - - - - - - 3 (5) 7 (5) 
Influenza - - - - - - 3 (5) 7 (5) 
Cough - - - - - - 4 (7) 6 (4) 
Upper 
abdominal pain  
- - - - - - 5 (8) 6 (4) 
Constipation 2 (7) 1 (3) 0 2 (7) - - 5 (8) 6 (4) 
Dizziness - - - - - - 6 (10) 5 (4) 
Anaemia  2 (7) 1 (3) 1 (3) 1 (4) - - - - 
Taste 
disturbance 
2 (7) 0 0 1 (4) - - - - 
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Table 4.12  Cont’d Adverse events in 5% or more participants in any study group, 
number of participants (%) 
Event  TRA100773A TRA100773B TRA102537RAISE 
Placebo, 
n=29 
EBAG 
30mg, 
n=30 
EBAG 
50mg, 
n=30 
EBAG 
75mg, 
n=28 
Placebo, 
n=38 
EBAG 
≥50mg, 
n=76 
Placebo, 
n=61 
EBAG 
≥25mg, 
n=135 
Pruritus - - - - - - 5 (8) 4 (3) 
Cataract - - - - - - 4 (7) 4 (3) 
Hypertension - - - - - - 3 (5) 4 (3) 
Oedema 
peripheral 
2 (7) 0  1 (3) 1 (4) - - 6 (10) 2 (1) 
Dyspepsia - - - - - - 4 (7) 2 (1) 
Ecchymosis - - - - - - 4 (7) 2 (1) 
Insomnia - - - - - - 4 (7) 2 (1) 
Anxiety - - - - - - 3 (5) 2 (1) 
Conjunctival 
haemorrhage 
- - - - - - 3 (5) 2 (1) 
Contusion - - - - - - 3 (5) 2 (1) 
Neck pain - - - - - - 3 (5) 2 (1) 
Non-cardiac 
chest pain 
- - - - - - 3 (5) 2 (1) 
Abdominal 
distension 
2 (7) 1 (3) 0 0 - - 3 (5) 1 (<1) 
Conjunctivitis - - - - - - 4 (7) 1 (<1) 
Fall - - - - - - 3 (5) 1 (<1) 
Swelling face - - - - - - 3 (5) 1 (<1) 
Cellulitis - - - - - - 4 (7) 0 
Eye swelling - - - - - - 3 (5) 0 
Haemorrhoids 2 (7) 0 0 0 - - - - 
Gingival 
bleeding 
- - - - 3 (8) 0 - - 
Source: manufacturer’s submission, pages 85, 86, 88. 
EBAG, eltrombopag. 
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B4. Specific adverse events highlighted by the manufacturer 
The manufacturer highlighted adverse events relating to the eyes, liver function, bleeding, 
thromboembolism, malignancies, bone marrow fibrosis, phototoxicity, and cardio- or renal- 
toxicity (Table 4.13). 
 
A higher proportion of participants in the eltrombopag groups developed cataracts compared 
with placebo groups (1 vs. 0 in TRA100773A trial, 3/74 [4.1%] vs. 1/38 [2.6%] in 
TRA100773B trial).  Similarly, more participants in the eltrombopag group suffered a 
deterioration of an existing cataract (3/74 [4.1%] vs. 1/38 [2.6%] in TRA100773B). The 
manufacturer stated that most of the incidence or progression of cataract in the eltrombopag 
groups were due to the concomitant use of corticosteroids, which is a known risk factor for 
cataract. However, a similar proportion of participants in the placebo group also received 
corticosteroids during the study (90% vs. 88% in the eltrombopag group, response to ERG 
clarification queries, A6). 
 
A higher proportion of participants in the eltrombopag groups experienced disturbance of 
liver function (8.1% [6/74] in TRA100773B, 13% [number of participants not reported] in 
RAISE trial) compared with placebo (2.6% [1/38] in TRA100773B, 7% [number not 
reported] in the RAISE trial). 
 
The manufacturer repeated the information on bleeding adverse events in this section of the 
submission for the RAISE study but the numbers differed from those reported previously 
(Table 4.9), due to the two sources of data reporting different bleeding events captured by two 
different criteria (WHO and CTAE) (as stated by the manufacturer in their comments dated 6 
January 2009 on the version of the ERG report submitted to NICE on 17 December 2009). It 
was previously reported that 76% of non-splenectomised participants and 82% of 
splenectomised participants in the eltrombopag group had any degree of bleeding, and 29% of 
non-splenectomised participants and 38% of splenectomised participants in the eltrombopag 
group had clinically significant bleeding (WHO grade 2-4). This was higher than that reported 
in this section of the manufacturer’s submission (19% overall).  
 
Two (2%) participants in the eltrombopag group in the RAISE trial developed venous 
thromboembolism, both of whom had risk factors for this condition at baseline. 
 
One participant in the eltrombopag group in the RAISE trial developed rectosigmoid colon 
cancer, identified 91 days after the treatment began. No cases of bone marrow fibrosis, 
phototoxicity, cardio- or renal- toxicity occurred during the intervention.
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Table 4.13  Specific adverse events highlighted by the manufacturer 
 TRA100773A  
 
TRA100773B TRA102537RAISE 
Ocular-related 
adverse effects 
Cataract progression: 
(1) placebo, n= 0. 
(2) 75mg/day 
eltrombopag, n=1. 
Reported 181 days 
after intervention in a 
60y female smoker. 
Cataract: 
(1) placebo, n=1/38 (2.6%). 
(2) eltrombopag, n=3/74 
(4.1%).  
 
Cataract progression: 
(1) placebo, n=1/38 (2.6%). 
(2) eltrombopag, n=3/73 
(4.1%). 
None. 
Hepatobiliary 
events 
- Transaminase concentration to 
2x upper limit normal: 
(1) placebo, n=1/38 (2.6%). 
(2) eltrombopag, n=6/74 (8.1%) 
with 1 withdrawal 
Elevated transaminases and/or 
bilirubin level: 
(1) placebo, 7%; 
(2) eltrombopag, 13%; all 
returned to normal level either 
on-treatment or following 
discontinuation of treatment. 
Bleeding adverse 
events/transient 
decrease in 
platelet count 
- Platelet count less than baseline 
value in 4wk after intervention: 
(1) placebo, n=5 (13%). 
(2) eltrombopag, n=8 (11%), of 
whom 2 had bleeding problem 
(menorrhagia, gingival 
bleeding). 
Bleeding adverse events during 
intervention: 
(1) placebo: 31%. 
(2) eltrombopag: 19%. 
 
Serious bleeding events during 
intervention: 
(1) placebo: 7%. 
(2) eltrombopag: <1% 
(p=0.033). 
 
Transient decrease in platelet 
count after stopping 
intervention: 
(1) placebo: 7%. 
(2) eltrombopag: 7%, of whom 
one had bleeding problem 
(mouth haemorrhage, 
petechiae) 
Thromboembolic 
events  
- - Venous thromboembolic 
events: 
(1) placebo: 0. 
(2) eltrombopag: 2 (2%); both 
had risk factor(s) for 
thrmboembolism, resolved 
after discontinuing the 
treatment. 
Malignancies  - - (1) placebo: n=1, acute 
leukaemia. 
(2) eltrombopag: n=1, 
rectosigmoid colon cancer. 
Identified 91day after the start 
of eltrombopag treatment. 
Bone marrow 
fibrosis 
- - None  
Phototoxicity, 
cardiotoxicity, 
renal toxicity 
- - None  
y = year; wk = week 
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C. Health-related quality of life 
The SF-36 instrument, consisting of eight sub-domains (physical functioning, physical role, 
body pain, general health, vitality, social functioning, emotional role, mental health) and two 
component summary scores (physical health summary, mental health summary),  were used 
in all three eltrombopag RCTs. The FACT fatigue assessment subscale for thrombocytopenia 
(FACT-Th) was also used in the RAISE trial. The manufacturer did not report quality of life 
data in detail. In response to the ERG clarification queries the manufacturer provided data for 
the RAISE trial but not for trials TRA100773A and B. Data comparing eltrombopag with 
placebo at the end of the follow-up rather than change from baseline were not provided 
despite being requested. 
 
In TRA100773A and B, the SF-36 scores in the eltrombopag group at the end of the 
intervention (6 weeks) were not statistically significantly different from baseline except that 
in TRA100773A there was a statistically significant decrease from baseline in the mean 
emotional-role score for the group receiving 75mg/day of eltrombopag (p = 0.02).  
 
In the RAISE trial, the scores in all SF-36 sub-domains in the eltrombopag group were 
increased at the end of the study (6 months) compared with baseline (Table 4.14). The 
changes in scores were statistically significant in favour of the eltrombopag group for 
physical role (p = 0.030), vitality (p = 0.045), emotional role (p = 0.023), and the mental 
health component summary (p = 0.030).  The changes in other sub-domains were not 
statistically significant. The manufacturer also provided data for non-splenectomised and 
splenectomised participants separately in its response to ERG clarification queries, however 
no statistical comparison between the eltrombopag and placebo groups was made. 
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Table 4.14  Health-related quality of life in RAISE trial: SF-36, mean (SD) 
 Placebo  Eltrombopag  p-
valuea  Baseline 
n=58 
End of studyb 
n=57 or 58 
Baseline 
n=131 
End of studyb 
n=121 or 123 
Physical functioning  75 (22) 76 (23) 73 (27) 81 (22) 0.154 
Physical role 65 (27) 68 (27) 65 (30) 74 (25) 0.030 
Body pain 70 (23) 69 (25) 75 (28) 76 (27) NSc  
General health 54 (22) 53 (25) 56 (21) 57 (23) 0.243 
Vitality  57 (20) 58 (22) 55 (26) 60 (23) 0.045 
Social functioning 76 (22) 75 (26) 73 (28) 79 (24) NSc 
Emotional role 73 (25) 72 (27) 69 (31) 77 (25) 0.023 
Mental health 70 (19) 69 (23) 68 (21) 70 (22) 0.154 
Physical health summary  46 (8) 46 (8) 47 (10) 49 (9) NSc 
Mental health summary 46 (10) 45 (12) 44 (13) 47 (12) 0.030 
aComparing the changes of scores from baseline between eltrobompag group and placebo group. 
bIncluding some of those who withdrew from the study. 
cp value not reported. 
NS, not statistically significant. 
 
For FACT-Th scores reported in the RAISE trial, participants in the eltrombopag group had a 
statistically significant improvement in the activities and concerns or attitudes associated with 
thrombocytopenia and ITP, compared with the placebo group (p= 0.004). More detailed data 
were not reported. 
 
4.2.2  Comparison of eltrombopag with romiplostim 
In the mixed treatment analysis, the data were presented in such a way that an odds ratio 
greater than 1 favoured eltrombopag. The results, as shown in Table 4.15 and 4.16, suggest 
that eltrombopag may be less effective than romiplostim, with the difference in overall 
response rate statistically significant (OR 0.17, 95% CI 0.03, 0.82). Further analysis was 
conducted by the ERG to explore this finding (see Section 7.3). 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
 
 
36 
Table 4.15   Comparison between eltrombopag and romiplostim: durable response 
ratea  
Eltrombopag vs. placebo Romiplostim vs. placebo 
OR (95% CI) c 
n/N OR (95% CI) b n/N OR (95% CI) b 
All participants 
57/135 vs. 4/62 10.60 (3.64, 30.87) 41/83 vs. 1/42 40.02 (5.26, 304.70) 0.26 (0.03, 2.62) 
Non-splenectomised 
38/95 vs. 3/41 10.24 (2.93, 35.77) 25/41 vs. 1/21 31.25 (3.81, 256.24) 0.33 (0.03, 3.79) 
Splenectomised 
19/50 vs. 1/21 12.26 (1.52, 98.90) 16/42 vs. 0/21 26.77 (1.52, 472.41) 0.46 (0.01, 15.91) 
aDefined as weekly platelet count ≥ 50 x 109/L during six or more weeks of the last eight weeks of 
treatment excluding those who received rescue medication at any time during the study.  
bMeta-analysis (fixed effect model). 
cMixed treatment analysis (fixed effect model). 
Source: manufacturer’s submission. 
 
Table 4.16   Comparison between eltrombopag and romiplostim: overall response ratea  
Eltrombopag vs. placebo Romiplostim vs. placebo 
OR (95% CI) c 
n/N OR (95% CI) b n/N OR (95% CI)b 
All participants 
72/135 vs. 6/62 10.67 (4.31, 26.43) 69/83 vs. 3/42 64.07 (17.33, 236.82) 0.17 (0.03, 0.82) 
Non-splenectomised 
49/85 vs. 4/41 12.59 (4.12, 38.50) 36/41 vs. 3/21 43.20 (9.27, 2741.84) 0.29 (0.04, 1.95) 
Splenectomised 
23/50 vs. 2/21 8.09 (1.70, 38.49) 33/42 vs. 0/21 151.63 (8.39, 201.33) 0.05 (0, 1.43) 
aDefined as durable plus transient response (four or more weekly responses ≥ 50 x 109/L during the 
study without a durable platelet response from week 2 to 25). 
bMeta-analysis (fixed effect model). 
cMixed treatment analysis (fixed effect model). 
Source: manufacturer’s submission 
 
4.2.3 Comparator treatments  
The manufacturer’s systematic review presented the characteristics and results from each 
study but no statistical synthesis of the results was undertaken.  
 
Although the decision problem section listed a comprehensive list of treatment comparators, 
not all were considered as comparators in the economic models developed by the 
manufacturer. Efficacy data on the maximum time that a platelet response was achieved and 
data on platelet response at different time points during treatment were required and provided 
for the long-term economic model for anti-D (non-splenectomised patients only), IVIg, 
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rituximab, and romiplostim. Table 4.17 lists the sources of such data that the manufacturer 
used.  
 
Only one or two studies/reviews were used for each comparator to provide the efficacy data 
that were used in the economic model. Although the manufacturer stated that the best 
available evidence was used, the ERG identified other potentially reliable data for some of the 
comparators from other studies/reviews that were included in the manufacturer’s systematic 
review.  
 
For eltrombopag, the data from the RAISE trial were recalculated by excluding those 
participants who withdrew prematurely, i.e. per protocol analyses were used (Clarification 
B10-12). The platelet response rates were therefore much higher than those from the ITT 
analysis (Table 4.17). For example, if ITT analysis is used, the response rate (≥ 50 x 109/L) at 
4 weeks since treatment started was reduced to 52.4% from 65.5% for non-splenectomised 
patients, and reduced to 42.9% from 61.2% for splenectomised patients. 
 
For romiplostim, response rates using ITT analysis were used. Participants who prematurely 
withdrew were considered as non-platelet-respondents. 
 
For platelet response rate for IVIg, the manufacturer used the evidence from a RCT consisting 
of 116 participants.68 The ERG identified the ASH guideline where 14 case series on IVIg and 
anti-D were reported and a high quality systematic review where 28 RCTs on IVIg were 
reported (identified in HTA database).62 The platelet response rate (≥ 50 x 109/L) reported by 
the ASH guideline and the HTA review is higher than that used by the manufacturer: 75% vs. 
62.5%. 
 
For anti-D, the manufacturer used the evidence from a prospective case series consisting of 96 
participants.69 The ASH guideline reported a lower platelet response rate (≥ 50 x 10 9/L) than 
that used by the manufacturer: 50% vs. 65.6%. 
 
The evidence for rituximab was from two systematic reviews49,70 and a case series.53  The 
youngest participants in the primary studies included in the two systematic reviews were both 
16 years old. The range of age of the participants in the case series was 4 to 98 years old; in 
addition, this was a retrospective study. Considering that the quality of the two systematic 
reviews is relatively high and assuming that the majority of people included were 18 years old 
or more, the ERG considered that the use of evidence from the two systematic reviews was 
appropriate, but not the use of evidence from the Penalver study. Removing the Penalver 
study, however, did not affect the values used in the economic model.  
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Table 4.17 Validity of efficacy data used in long-term economic model  
 Data source, type of study Alternative data source Non-splenectomised Splenectomised 
   Values used Alternative values Values used Alternative values 
Eltrombopag RAISE trial, 6 month RCT,  
n=197 
No ≥ 50 x 109/L: 
4 week: 65.5% 
8 week: 70.2% 
≥ 50 x 109/L: 
4 week: 52.4% 
8 week: 59.5% 
≥ 50 x 109/L: 
4 week: 61.2% 
8 week: 69.4% 
≥ 50 x 109/L: 
4 week: 42.9% 
8 week: 46.0% 
Romiplostim Kuter 200867, two 6-month 
RCTs, n=125 in total 
No ≥ 50 x 109/L: 
4 week: 50% 
8 week: 68.9% 
12 week: 87.8% 
No  ≥ 50 x 109/L: 
4 week: 50% 
8 week: 64.3% 
12 week: 78.6% 
No  
IVIg Godeau 199368,71, 2-day RCT, 
n=18; 
Godeau 200268, 3-week RCT, 
n=116 
George 19967 (ASH 
guideline), consisting 14 
case series; 
Chen 200862, systematic 
review consisting 28 RCTs. 
≥ 30 x 109/L: 71.4% 
≥ 50 x 109/L: 62.5% 
≥ 30 x 109/L: no data 
available, assumed 
to be 75% to 100%. 
≥ 50 x 109/L: 75% 
Same as non-
splenectomised. 
Assumed to be the 
same as non-
splenectomised 
patients. 
Anti-D  Aledort 200769, Prospective case 
series, n=96  
ASH guideline 19967 , 
consisting 14 case series; 
- - ≥ 30 x 109/L: 52.7% 
≥ 50 x 109/L: 65.6% 
≥ 30 x 109/L: no data 
available. 
≥ 50 x 109/L: 50% 
Rituximab Arnold 200749, Systematic 
review consisting of 19 case 
series. 
Penalver 200653, case series, 
n=89. 
Vesely 200470, systematic review 
consisting of 8 case series. 
Removing Penalver study. ≥ 30 x 109/L: 67.6% 
≥ 50 x 109/L: 62.5% 
No  ≥ 30 x 109/L: 65.7% 
≥ 50 x 109/L: 58.5% 
No  
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4.2.4 Critique of submitted evidence synthesis 
Quality of reporting in the manufacturer’s submission 
The manufacturer submitted a substantial amount of evidence (more than 200 pages for the 
main submission, nearly 200 pages for a systematic review report and a CD with more than 
5000 pages reporting the results of the eltrombopag trials). The ERG did not go through the 
full clinical study reports except for those parts that were specifically referred to in the 
response to ERG clarification queries. 
 
Some outcomes (e.g. bleeding events, quality of life) relating to the eltrombopag RCTs were 
poorly reported. The ERG in its clarification queries requested more detailed data and a 
breakdown by splenectomy status (Clarification response: A2).   
 
Quality of the manufacturer’s review 
The ERG assessed the clinical effectiveness part of the manufacturer’s submission for its 
methodological quality as a systematic review using the questions contained in CRD report 4 
(Table 4.18). The methodological quality of the manufacturer’s systematic review was 
variable. 
 
Table 4.18  Quality assessment (CRD criteria) of the manufacturer’s review  
CRD Quality Item; score Yes/No/Uncertain with comments 
1.  Are any inclusion/exclusion criteria 
reported relating to the primary 
studies which address the review 
question? 
Yes except: 
• No criteria set for defining patients who are medically 
contraindicated to splenectomy. 
2. Is there evidence of a substantial 
effort to search for all relevant 
research? 
Partially 
• Only major sources searched. 
 
3.  Is the validity of included studies 
adequately assessed? 
Partially 
• 20 included RCTs were adequately assessed; 
• 96 included non-RCTs were not assessed. 
4.  Are sufficient details of the 
individual studies presented? 
Yes. 
Characteristics and results of all primary studies were 
reported in detail. 
5.  Are the primary studies summarised 
appropriately? 
Partially. 
• Only evidence from RCTs on eltrombopag were 
summarised adequately; 
• No synthesis undertaken of the primary studies 
reporting comparator treatments. 
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Representativeness of participants in the eltrombopag trials to UK chronic ITP patients 
Only 3/109 (2.8%), 10/114 (8.8%) and 9/197 (4.7%) participants in the three eltrombopag 
trials were from the UK (Clarification response: A5). The profile of UK chronic ITP patients 
is not available, so the extent to which the RCTs’ participants were representative of adult 
chronic ITP patients in the UK is unclear.  
 
The manufacturer argued that the participants in the three trials were comparable to the UK 
chronic ITP patients in terms of the baseline platelet count and bleeding symptoms. Table 
4.19 shows the baseline characteristics of participants in the three trials. The manufacturer 
added that two ITP experts in the UK (Professor Adrian Newland and Dr. Drew Provan 
approached by the manufacturer) had commented that the previous concomitant medications 
received by participants in the RAISE trial were reflective of UK clinical practise, and the 
populations in the TRA100773A and B trials were also reflective of the ITP ‘watch and 
rescue’ population managed within UK clinical practice.  
 
Table 4.19  Baseline characteristics of participants in eltrombopag groups in RCTs 
 TRA100773Aa, n= 88 TRA100773B, n=76 RAISE, n=135  
Age, median (range), years 18 - 81 47 (19 – 84) 47 (18 – 85) 
Men (%) 31 (35%) 33 (43%) 42 (31%) 
Previous treatment    
≥ 2 66 (75%) 56 (74%) 105 (78%) 
≥ 3 46 (52%) 42 (55%) 75 (56%) 
≥ 4 30 (34%) 30 (39%) 51 (38%) 
≥ 5 - 16 (21%) 35 (26%) 
Splenectomy  45 (51%) 31 (41%) 50 (37%) 
Bleeding symptoms    
Any grade - - 73% 
Clinically significant 
(WHO grade 2-4) 
- - About a quarter 
Duration of disease - 47 (41%) over 5 years - 
Platelet count at baseline    
≤ 15 x 109/L 48% 38 (50%) 67 (50%) 
Median  - - 16 x 109/L 
Concomitant treatment at 
randomisation 
32% 32 (42%) 63 (47%) 
aThe three eltrombopag groups were summed. 
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Efficacy of eltrombopag 
Efficacy evidence on eltrombopag was based on three eltrombopag RCTs. In general, the 
evidence showed that eltrombopag was statistically significantly more efficacious than 
placebo in terms of all outcomes other than: 
• Platelet response (≥ 50 x 109/L) at the end of the intervention for 30mg/day eltrombopag 
(27% vs. 11%, p=0.070; TRA100773A); 
• Need for rescue medication during treatment in splenectomised participants (48% vs. 22%, 
p=0.055; RAISE trial); and 
• Reduction in dose/frequency of concomitant ITP medications taken at baseline in 
splenectomised participants (39% vs. 44%, p=0.714; RAISE trial). 
 
For duration of platelet response, it was unclear whether rescue treatment was taken into 
account (RAISE trial). 
 
However, there were slight imbalances in patient baseline characteristics between the 
eltrombopag and placebo groups in studies TRA10077B and RAISE. In study TRA100773B 
there were more women in the placebo group (71%, 27/38) than in the eltrombopag group 
(57%, 43/76) (Table 6.9 in the manufacturer’s submission).  In study TRA102537RAISE 
participants in the placebo group were older than those in the eltrombopag group (median 
52.5 vs. 47.0 years old) (Table 6.10 in the manufacturer’s submission). If women or older 
people were to have a poorer prognosis in relation to ITP treatments then the results might 
have favoured the eltrombopag group. The manufacturer did not conduct sensitivity analyses 
to explore the impact that these baseline imbalances might have had on the results.  
 
In addition, there were relatively large proportions of participants who withdrew or were lost 
to follow-up in the eltrombopag RCTs. In study TRA100773A there were more such 
participants in the placebo group (21%, 6/29) than the eltrombopag groups (10% [3/30], 
30mg/day; 7% [2/30], 50mg/day; 14% [4/28], 75mg/day), as there also were for study 
TRA100773B (18% [7/38] in the placebo group; 8% [6/76] in the eltrombopag group). In 
study TRA102537RAISE there were fewer such participants in the placebo group (11%, 7/62) 
than the eltrombopag group (17%, 23/135). Nearly half of these withdrawals were due to 
adverse effects. Other reasons for withdrawal included lack of efficacy, protocol violation, or 
participant choice. As participants who withdrew or were lost to follow-up were all 
considered as non-responders, and there were more such participants in the placebo group in 
TRA100773A and B, the results on platelet response from these two studies might have 
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favoured eltrombopag. For TRA102537RAISE, as there were more such participants in the 
eltrombopag group, the results on platelet response might have favoured placebo. 
 
Safety of eltrombopag 
Two participants in the eltrombopag group died during the intervention. One participant had a 
severe illness at baseline (TRA100773B) while the other had a baseline platelet count of only 
2 x 109/L (RAISE trial). 
 
The risk of adverse events appeared to be similar between the eltrombopag group and the 
placebo group in each RCT. However, no statistical comparisons were undertaken. There 
were differences in TRA100773A but not in TRA100773B or RAISE in the figures reported 
for total numbers of any adverse events (Table 4.11) and any adverse events in 5% or more 
participants (Table 4.12). There were relatively large differences in the figures reported for 
bleeding adverse events for the RAISE trial (Tables 4.9 and 4.13) due to the two sources of 
data reporting different bleeding events captured by two different criteria (WHO and CTAE). 
 
Quality of life 
In the RAISE trial, baseline data on health-related quality of life were not available for a 
small number of participants who received treatment (4/135 [3.0%] in the eltrombopag group, 
4/62 [6.5%] in the placebo group). Also, data were not available for a small number of 
participants (10/135 [7.4%] in the eltrombopag group, 1/62 [1.6%] in the placebo group) who 
withdrew during the study. If assuming that the most ill people did not return to provide data 
at the end of the study, the results might have favoured eltrombopag. If assuming that the 
healthier people did not return, the results might have favoured placebo.  
 
Comparator treatments 
The ERG considered that the efficacy data used for comparator treatments in the long-term 
economic model were highly selective. Alternative methods, e.g. median and range, could 
have been explored. Even based on the best available evidence, the manufacturer failed to 
identify the best evidence for IVIg and anti-D (Table 4.17). 
 
Comparison of eltrombopag with romiplostim 
The manufacturer stated that the RAISE trial and the two romiplostim RCTs were comparable 
in terms of baseline participant characteristics, trial methodology, and follow-up (all 6 
months). However more participants in the RAISE study received concomitant medication 
(eltrombopag 55%, placebo 69%) than those in the romiplostim trials (romiplostim 28%, 
placebo 38%). Concomitant medication may have positive effects on treatment, but on the 
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other hand patients receiving concomitant medication may have more severe ITP. Therefore, 
the direction of bias caused by the baseline imbalance in concomitant medication is uncertain.  
There is an error in the “Conclusion of the meta-analysis / indirect comparison” section (see 
page 83 of the manufacturer’s submission). It states: 
 
“In particular, the fact that there is no significant between-treatment difference when the 
splenectomised and non-splenectomised participants are considered separately casts doubt on 
the robustness of the indirect comparison reported for the combined population.”  
 
The widths of the confidence intervals for the between-treatment odds ratios are dependent 
upon the amount of data available from which to calculate them. All other things being equal, 
a larger sample size will produce a smaller confidence interval. It can be seen from the 
formula used to calculate an approximation to the variance of the log odds ratio that fewer 
participants in a trial will produce a larger variance. Bucher’s method72 of indirect comparison 
involves adding together the variances of the log odds ratios, so this maintains the larger 
variance, hence wider confidence intervals.  
  
For this reason and despite the discussion about the best way to combine the two Kuter 2008 
trials,67  once that is done it is erroneous to claim that the lack of statistical significance in the 
subgroup analyses casts doubt over the significant result for all subjects. The authors 
themselves suggest that with only one study for each drug (allowing a synthesis of the two 
Kuter 2008 trials) comparing them “is far from ideal and negates the possibility of exploring 
possible subgroups” (page 84, first bullet point). Therefore, subgroup results should not 
detract from the all patient results. 
 
4.2.5  Summary   
The ERG’s main concerns with regard to evidence synthesis were: 
 
• Representativeness of participants in the eltrombopag trials to UK chronic ITP patients is 
uncertain (see Table 4.19). 
• There were some discrepancies in the figures reporting on total number of adverse events 
for TRA100773A (see Table 4.11 and 4.12), and relative large discrepancies in the figures 
reporting bleeding events (see Table 4.9 and 4.13). It is unclear which figures were 
correct. 
• More participants in the RAISE trial (eltrombopag) received concomitant ITP treatments 
than in the romiplostim trials. The effect that this imbalance might have had on the indirect 
comparison results is uncertain.  
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
  
 
44 
• In the indirect comparison between eltrombopag and romiplostim, participants who 
prematurely withdrew were considered as non-responders. As there were more such 
participants in the eltrombopag study, the results might have favoured romiplostim. The 
ERG conducted further analysis to explore this (see Section 7.3). 
 
Minor concerns: 
• More reliable sources of evidence might have been sought to generate values for 
comparator treatments IVIg and anti-D in the economic model.  
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5 ECONOMIC EVALUATION: Cost effectiveness comparison of chronic ITP 
`Watch and Rescue` consisting of active management and/or rescue 
medication, with or without Eltrombopag 
 
As part of the manufacturer’s submission, 2 de novo economic evaluations were conducted by 
GlaxoSmithKline and are as follows: 
 
• De novo economic evaluation 1
 
: Cost effectiveness comparison of chronic ITP `Watch 
and Rescue` consisting of active management and/or rescue medication, with or without 
eltrombopag 
• De novo economic evaluation 2
 
: Cost-effectiveness evaluation of chronic ITP long-term 
continuous treatments as part of a treatment sequence with and without eltrombopag 
In Chapter 5 we address the first of these analyses.  Chapter 6 addresses the second long term 
evaluation model for eltrombopag.  In each economic evaluation, the analysis was split for 
splenectomised and non splenectomised patients. 
 
GlaxoSmithKline found an error in their original watch and rescue model.  An addendum and 
revised economic model was provided on October 23rd 2009 by the manufacturer detailing the 
corrections made to the model together with the corresponding analysis, figures and tables.  
The critique presented here refers to the main submission document and is supplemented by 
information from the addendum where appropriate 
 
5.1 Introduction and overview of manufacturer’s economic evaluation 
The economic evaluation of eltrombopag for the treatment of chronic immune or idiopathic 
thrombocytopenic purpura (ITP) included: 
• A systematic literature review to identify all relevant cost-effectiveness or cost-utility 
studies in relation to the relative efficiency of eltrombopag for the treatment of chronic 
adult ITP.  Section 7.1 of the GlaxoSmithKline report details the processes used to 
identify the relevant studies and Appendix 3 provides further detail on the search strategy 
used.   
• A report on the de novo economic evaluation for watch and rescue care plan conducted 
by GlaxoSmithKline (p104 – 155).  Patient characteristics including inclusion and 
exclusion criteria for the trial based model were presented (p110 – 112). A description of 
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the model (including a model schematic) can be found on page 114. A table of the key 
assumptions used is given in table 7.3 (p117). 
• Tables 7.4 and 7.5 of the manufacturer’s submission provide information in relation to the 
costing approach used in the watch and rescue model.  Costs are estimated using a macro 
and micro costing approach.  Macro costing is used in the base case and micro costing as 
a sensitivity analysis. 
• Results of the analysis are provided separately for splenectomised and non-
splenectomised patients (Section 7.3 of the original manufacturer’s submission).  The 
base case analysis (pp 131-133); subgroup analysis (pp134-138) and sensitivity analysis 
(pp 139-153) can be found on the pages quoted. 
• The manufacturer also provided a Microsoft Excel based electronic copy of the model 
used. 
 
Following receipt of the submission, the ERG responded by requesting a number of points for 
clarification from GlaxoSmithKline.  Specifically in relation to the de novo economic 
evaluation 1, the following points for clarification were sought: 
 
• Whether eltrombopag is always used within its licensed indication within the model and 
if not to provide information as to why this was the case. 
• What relevance US rates of ITP have in relation to predicting the UK rates of the disease? 
• In relation to the use of the clinical expert opinion used for parameters and assumptions, 
the manufacturer was asked to clarify how these opinions were elicited and to confirm 
that they were indeed representative of general UK practice. 
• Further information was sought in relation to a survey (DEMAND) conducted by 
GlaxoSmithKline of 50 UK clinicians to determine the number of patients tho may be 
treated with eltrombopag in the UK. 
• Further in depth information was sought in relation to the reported SF-6D scores used in 
the submission and the differences between treatment arms.  Also, clarification in relation 
to how mortality was incorporated into these scores was requested. 
• Further information in relation to quality of life measurement was sought in particular in 
relation to a breakdown of how QALYs were calculated. 
• The manufacturer was asked to provide a within trial economic evaluation which would 
be superior if the patient group truly represented the UK population as it would more 
fully reflect differences between patients.   
• Further clarification and information in relation to adverse events was sought as the 
submission only reported adverse events in relation to bleeding. 
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• The manufacturer was asked to conduct an analysis for drug prices and specifically to 
estimate the price required for eltrombopag to be cost-effective at various different ICER 
thresholds. 
 
The following section will focus on the manufacturer’s submission using updated information 
and addendums as provided by GSK where appropriate. 
 
5.2 Cost-effectiveness analysis methods 
As per Section 7.1 of the manufacturer’s submission, a systematic review was conducted to 
identify any cost-effectiveness or cost-utility studies relating to the cost-effectiveness of 
eltrombopag for the treatment of chronic adult ITP.  The company developed their search 
strategy specifying the inclusion/exclusion criteria with no limit on the date of publication.  
Searches were conducted on June 16th 2009, using the same databases as were used for the 
clinical effectiveness review. These searches were also supplemented by hand searching of 
the proceedings of the European Haematology Association and the American Society of 
Haematology.  
 
The full search strategies are detailed in Appendix 10.3 of the manufacturer’s submission and 
are reproducible. The searches comprised MeSH and keyword terms relating to ITP and 
combined, using the Boolean operator AND, with several cost- and economic - related terms. 
While the search was broad, as the manufacturer stated, it did not fully utilise the indexing 
features available in MEDLINE and EMBASE; in particular specifically searching with 
MeSH or Emtree terms such as exp "costs and cost analysis"/ or exp economic evaluation/ or 
for MEDLINE, using the economics subheading.  
 
The following section provides an overview of the cost-effectiveness analysis methods used 
by GlaxoSmithKline, including an overview of: natural history; treatment effectiveness; 
health related quality of life; resources and costs; discounting; sensitivity analysis; model 
validation and the results of cost-effectiveness analysis.  A detailed critique of the model, the 
submission and the assumptions underpinning the results will follow this overview. 
 
5.2.1 Natural history 
The manufacturer split the Chronic ITP population into two main sub-categories: (A) 
Splenectomised patients and (B) Non Splenectomised patients (where having a splenectomy 
was assumed to be medically contra indicated).  The economic “Watch and Rescue” model 
evaluation explores two pathways of care: (i) A standard of care approach plus placebo and 
(ii) standard of care plus eltrombopag.  Patients were assumed to have had previous ITP 
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treatment, may be on concurrant medication and are given rescue medication as required over 
the time horizon of the model.  As the treatment pathway for chronic ITP patients is ill 
defined, a trial based model using data from the RAISE trial was used for the submission.  
The RAISE trial is a placebo controlled double blinded RCT with patients randomised to 
either placebo or eltrombopag.  A schematic of the model structure is represented in Figure 
7.2 (p114) of the manufacturer’s submission. 
 
In the trial based model, adult patients enter the study on the basis that they have platelet 
counts <30 x109/L.  It is assumed that the patients entering the model are representative of the 
UK ITP patient population and the clinical opinion of ITP experts is used to support this 
assumption.   
 
The analysis refers to two biologically identifiable groups (splenectomised and non-
splenectomised patients) and the analysis is presented separately for each group.  Further sub 
groups considered included: 
 
• Individuals with a platelet count <15 x109/L  
• patients on concomitant medication. 
 
Due to a limited number of subjects, the subgroups were not analysed on the basis of 
splenectomy status. 
 
5.2.2 Treatment effectiveness 
The effectiveness of eltrombopag came from the eltrombopag arms of the three RCT trials 
identified in the manufacturer’s submission (Studies TRA100773A, TRA 100773B and 
RAISE). With regard to the modelling approach undertaken, the RAISE study was the 
primary reference point.  Data in relation to comparator treatments were confined to those 
used in the control arm of the RAISE trial.  Data in relation to alternative treatments for direct 
comparison to eltrombopag are non existent and so no data for relative comparators specified 
in the NICE scope has been included in the model aside from those used as part of standard of 
care.  
 
5.2.3 Health related quality of life 
The impact of health related quality of life on patients with ITP was measured using the Short 
Form 36 Item Version 2 (SF-36v2) questionnaire.  As part of TRA102537 RAISE, SF-36 
assessments were administered to all patients at weeks 0, 6, 14 and 26. The results of this 
were then translated using the Brazier and colleagues algorithm to preference based utility 
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scores in the form of the SF-6D.73 The overall HRQoL benefit on each arm was calculated 
using ‘method two` described in Manca and colleagues to adjust for differences in baseline 
characteristics between the two arms.74,74 This approach is discussed and critiqued in a later 
section.   
 
Utility values reflected two components, namely the utility gained from reduced risk of 
death/bleeding and the improvement in quality of life generated as a result of the treatment 
administered.  Appendix 4 (Table 10.4) details the utility values used for placebo and 
eltrombopag at weeks 0 (baseline), 6, 14 and 26 for each subgroup of the population analysed.  
Utility scores were recorded and transformed as described at each point estimate stage for 
both the placebo and eltrombopag arms of the study and QALY gains through the use of 
eltrombopag were thus calculated.  
 
The utility values used by the manufacturer are reproduced in Table 5.1 below: 
 
Table 5.1: Utility values used in the model for each subgroup based on SF-36 data 
from the RAISE trial mapped to SF-6D scores using Brazier, 2002 
EPAG = Eltrombopag 
 
Further details in relation to the calculation of QALYs were requested in the matters for 
clarification from GlaxoSmithKline specifically asking them to give details in relation to life 
years gained and incremental life years gained.  This information has been provided in the 
base case for each subgroup and is presented in Table 27 of the response to ERG clarification 
queries document.  Further information was requested in relation to how the estimation of 
utilities was actually conducted and also in relation to mortality.  Annual risk of having a fatal 
bleed10 was used to calculate the relative risk of mortality as described in figure 5, page 124 
Subgroup Week 0 Week 6 Week 14 Week 26 
 Placebo EPAG Placebo EPAG Placebo EPAG Placebo EPAG 
Splenectomised 0.699 0.699 0.687 0.703 0.709 0.705 0.691 0.708 
Non-
Splenectomised 
0.687 0.707 0.700 0.745 0.68 0.725 0.698 0.745 
Baseline <15 
x109/L 
0.672 0.714 0.679 0.731 0.687 0.713 0.673 0.735 
Patients receiving 
concomitant 
medication at 
baseline 
0.701 0.686 0.687 0.706 0.681 0.692 0.694 0.717 
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of the submission document.  No additional information in relation to the utility estimation 
process was provided. 
 
QALYs were for both arms of the study and both treatment groups. QALY estimates related 
to the 26 week follow-up period except for the loss of QALYs over an estimated patient 
lifetime caused by death in the 26 week follow–up period. 
 
5.2.4 Resources and costs 
Section 7.2.9 of the manufacturer’s submission describes the identification measurement and 
valuation of resource use.  Two alternative approaches to the costing process were presented 
in the submission and are as follows: 
 
• Micro costing approach
 
: Clinical expert opinion was used to estimate resource 
consumption for each grade of bleed severity. 
• Macro costing approach
 
: Clinical expert opinion was once again used.  Analogous costs 
were used as ITP cost and resource data were limited for each grade of bleed.  Grade of 
bleeding was as classified on the World Health Organisation bleeding scale. 
Details of the estimated costs of bleeding as calculated using expert opinion are presented in 
Table 7.5 of the submission and reproduced in Table 5.2.  The manufacturer has taken the 
macro costing approach as default in the model and has explored the associated uncertainty 
by conducting a sensitivity analysis using the micro costing approach in Section 7.3.3.1 of 
their submission.  One point on which the ERG requested further clarification was whether or 
not the expert opinion used was likely to be truly representative of expert opinion in the UK.  
The manufacturers provided the details of all expert opinion used to inform the model, stating 
that they were widely accepted experts in the field of ITP and were responsible for the 
treatment of a large number of ITP patients from throughout the UK.  Further detail is 
presented in point A.10, page 10 of the clarification document.  However, it remains unclear 
which clinical experts were used to inform which valuations or indeed if all experts had an 
input into each assumption/value identified through consultation with ITP experts. 
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Table 5.2 Costing approaches used through out the model 
Bleeding grade Micro-costing Macro-costing 
Grade 1 £12.50 £3.99 
Grade 2 £98.60 £125 
Grade 3 £431.47 £1,056.25 
Grade 4 £2,582.00 £8,277.09 
Grade 5 £2,582.00 £8,277.09 
One may question whether or not it is appropriate that the resource costs are similar for both a 
grade 4 and a grade 5 bleed in both approaches.  It would seem plausible to argue that perhaps 
the cost of treating a grade 5 bleed would in reality be greater than the cost of treating a grade 
4 bleed.   
 
Resource use and cost data were not taken directly from the RAISE trial with the exception of 
ITP medication consumption.  Resource consumption used for the costing approaches were 
estimated using clinical expert opinion as stated in section 7.2.9.1 of the main submission 
document. All costs were estimated from NHS Reference costs/eBNF and further validated 
through discussion with a clinical expert.  The anticipated prices of eltrombopag for use in 
chronic adult ITP patients in the UK market are £27.50 for a 25 mg tablet and £55.00 for a 
50mg tablet.  The consequences for variation in the quoted prices are explored in a sensitivity 
analysis, the results of which are presented in Section 5.2.8 of this report.   
 
The total cost of eltrombopag taken from the trial based model is a function of the total dose 
of eltrombopag administered and the price per mg of dosage over the period of 
administration.  Administration costs directly related to the administration of eltrombopag 
were not captured by the analysis nor are any routine management costs.  As it is an oral 
medication, taken un-supervised at home by the patient, these costs are unlikely to be 
significant.  Product wastage was not considered for any treatments.  The overall cost per 
patient over the 26 week trial period for both splenectomised and non-splenectomised patients 
and both treatment arms is shown in Table 5.4.  Costs beyond 26 weeks were not estimated.  
 
The costs of drugs used as concomitant medication were taken from the NHS reference costs 
2007-2008 wherever possible as well as the Personal Social Services Research Unit (PSSRU) 
and were further confirmed through informal clinical expert consultation.  Drug resource use 
data has been extracted directly from the RAISE trial. 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
  
 
52 
5.2.5 Discounting 
Only the loss of QALYs over an assumed lifetime of those estimated to have died during the 
26 week follow-up period were discounted.  These were discounted at a rate of 3.5% in 
accordance with NICE guidelines. 
 
5.2.6 Sensitivity analysis 
A number of deterministic and probabilistic sensitivity analyses were conducted and these are 
detailed in Section 7.3.3 of the manufacturer’s submission.  A summary of the analyses 
conducted is given here and the results of each analysis undertaken are summarised in Section 
5.2.8. 
 
Price of Eltrombopag 
At the time of submission, the price of Eltrombopag was given as a guide only.  Therefore, 
the acquisition cost of £55 was varied to a lower limit of £50 and an upper limit of £60 for a 
50 mg tablet. 
 
Utility 
Values for utility are varied at each assessment point to the upper and lower bounds of their 
confidence intervals at a 5% level of significance. 
 
Micro and Macro costing procedures 
The results of the micro costing approach were used in the sensitivity analysis to reflect the 
uncertainty surrounding the costs of bleeding events.  
 
Relative risk of a fatal bleed 
The base case analysis uses the relative risk of clinically significant bleeds (WHO grades 2-5) 
as a proxy for the relative risk of a fatal bleed.  In a sensitivity analysis of the uncertainty 
surrounding the risk of bleeding, relative risk of any bleeding event was used as a proxy for a 
fatal bleed.  Perhaps the manufacturer could have also conducted analysis at the other end of 
the scale, taking the risk of a serious grade 4 or grade 5 bleed as a proxy for a fatal bleed. 
 
The impact of varying the annual rate of fatal bleed on the ICER 
A one way sensitivity analysis was conducted on this figure given that fatal bleeds were one 
of the main determinants of QALYs and hence played a pivotal role in the estimation of 
ICERs. 
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A probabilistic sensitivity analysis was also conducted to inform the uncertainty around the 
point estimates presented in the base case.  One thousand iterations of the model were used 
and the results are presented in Section 7.3.3 (pp 139 – 142) of the manufacturer’s submission 
and in Appendix 10.5 for distributions used of the manufacturer’s submission.   
 
The ERG requested that GlaxoSmithKline conduct a wider sensitivity analysis around price 
and in particular to estimate the price at which Eltrombopag would comply with cost 
effectiveness thresholds of £10,000, £20,000 and £30,000.   This information is provided in 
Tables 22 and 23 of the response to ERG clarification queries document and reproduced in 
Table 5.3. 
 
Table 5.3  Acquisition cost required to achieve key ICERs in the base case analysis. 
 Acquisition cost for achieving key ICERs 
 £10,000 £20,000 £30,000 
Splenectomised £13.91 £20.11 £26.31 
    
Non Splenectomised £10.23 £15.89 £21.55 
 
5.2.7 Model validation 
The economic model used as part of this submission was validated through internal quality 
control checks.  In addition to this, the model was reviewed by Abacus International (an 
independent provider of health economics services).  It is stated in the submission that Abacus 
checks involved literature searches, and a quality check of the model (including cell inputs, 
calculations etc).  It was stated that this quality control process was conducted in line with the 
University of York Centre for Health Economics checklist.75  However, in spite of the quality 
control checks conducted both internally and by Abacus, a number of minor discrepancies 
were identified by the ERG.  These are discussed in section 5.4.2 below.   
 
5.2.8 Results 
Results for the base case analysis are presented separately for splenectomised and non-
splenectomised patient groups.  Non-splenectomised subjects are assumed by the 
manufacturer to be representative of the patient groups who are contra-indicated to having a 
splenectomy.  The revised results are presented in the addendum provided by 
GlaxoSmithKline to their original submission.  The base case analysis for both patient groups 
is presented in Table 5.4.   
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Table 5.4 Summary of base case results of the manufacturer’s model 
Group of 
Patients 
Results 
 Placebo Eltrombopag Incremental ICER 
(£ per 
QALY) 
 Cost 
(£) 
QALYs 
Cost 
(£) 
QALYs 
Cost 
(£) 
QALYs 
Splenectomised 3380 0.197 12,835 0.075 9455 0.122 77,496 
Non 
Splenectomised 
1894 0.193 11,917. 0.082 10,024 0.111 90,471 
Concomitant 
meds at baseline 
2832 0.193 11,951 0.067 9119 0.126 72,331 
Platelet count 
<15 x109/L 
3607 0.195 13,977 0.088 10,370 0.107 96,749 
<15 x109/L  
& death risk  
of 4.03% 
3607 0.285 13,977 0.130 10,371 0.155 66,880 
 
Sensitivity analysis results: 
GlaxoSmithKline provided probabilistic and deterministic sensitivity analyses for both 
splenectomised and non splenectomised patients, the findings of which are detailed in Section 
7.3.3 of the manufacturer’s submission. 
 
Table 5.5 details the results of the deterministic sensitivity analyses carried out by the 
manufacturer as part of its submission. 
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Table 5.5 Summary of sensitivity analysis results 
Sensitivity analysis Group of Patients Submission finding 
  Cost (£) QALY ICER 
 
 
 
 Default Sensitivity Analysis Default Sensitivity 
Analysis 
Default Sensitivity 
Analysis 
Splenectomised Micro costing 9,455 10,069 0.122 0.122 77,496 82,527 
Non Splenectomised 10,024 10,101 0.111 0.111 90,471 91,175 
        
Splenectomised All Bleed events 9,455 9,455 .122 0.095 77,496 99,379 
Non Splenectomised 10,024 10,024 .111 .112 90,471 89,850 
        
Price £50 not £55 Splenectomised 9,455 8,455 .122 .122 77,496 69,301 
Non Splenectomised 10,024 9,030 .111 .111 90,471 81,501 
        
Price £60 not £55 Splenectomised 9,455 9,030 .122 .122 77,496 85,690 
Non Splenectomised 10,024 11,017 .111 .111 90,471 99,441 
        
Splenectomised Utilities at lower bound 
of CI 
9,455 9,455 .122 .121 77,496 78,307 
Non Splenectomised 10,024 10,024 .111 .111 90,471 90,691 
        
Splenectomised Utilities at upper bound 
of CI 
9,455 9,455 .122 .123 77,496 76,820 
Non Splenectomised 10,024 10,024 .111 .111 90,471 90,299 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
  
 56 
All figures produced in Table 5.5 have been checked and are reproducible from the economic 
model as presented by GlaxoSmithKline. 
 
With regard to the probabilistic sensitivity analysis results, these are presented in Figures 
7.10–7.15 on pages 139–142 of the manufacturer’s submission.  For both the splenectomised 
and non-splenectomised groups there is little or no chance of eltrombopag being cost-
effective at the threshold of £30,000 per QALY.  The exact percentage, while given in the 
main submission document is omitted in the addendum to Section 7.  Similar results are 
indicated for each of the alternative subgroups which have been analysed throughout the 
submission document. 
 
5.3 Critical appraisal of the manufacturer’s submitted economic evaluation 
The ERG has critically appraised the manufacturer’s evaluation using the critical appraisal 
questions as outlined in Table 5.6.  The methods have also been compared with the criteria set 
out in the reference case.  The critical appraisal of the model refers to the addendum presented 
by the company in addition to its main submission document unless otherwise stated. 
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Table 5.6: Structured critical appraisal of manufacturer’s economic model 
Item Critical 
Appraisal 
Reviewer Comment 
Is there a well defined 
question 
Yes The economic model and submission 
assessed the cost-effectiveness of 
eltrombopag as part of a watch and 
rescue care programme for adult patients 
with chronic immune (idiopathic) 
thrombocytopenic purpura (ITP) 
Is there a comprehensive 
description of alternatives? 
Yes The modelled alternatives followed 2 
pathways as part of a watch and rescue 
care programme.  (i) Standard of care; (ii) 
Standard of care plus eltrombopag.  As 
this is a trial based model, only these two 
options that corresponded to the 
randomised groups were considered.  
Is the perspective of the 
analysis clearly stated 
Yes According to the submission document, 
the analysis was performed from the 
perspective of the NHS and PSS.   
Is the perspective employed 
appropriate? 
Unclear While the perspective is stated as being 
that of the NHS and PSS, there is limited 
evidence of costs falling onto the PSS in 
the submission.  Section 8 clearly deals 
with the financial impact for the NHS but 
there is no mention of the impact on 
PSSs.. 
Has the correct patient group 
/ population of  interest been 
clearly stated 
Partly Two groups of adult chronic ITP patients 
are modelled as part of the Watch and 
Rescue care plan:  
(i) Patients who have previously had 
a splenectomy and are refractory 
to that splenectomy  
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Item Critical 
Appraisal 
Reviewer Comment 
(ii) Non–splenectomised patients 
who are assumed to be contra-
indicated to having a 
splenectomy.  It is unclear how 
similar the trial population is to 
this group. 
Is the correct comparator 
used? 
Yes As this was a double blinded placebo 
controlled study, the comparator used 
was placebo.  Due to a lack of sound 
comparable data, no other comparators 
were considered.  Elsewhere in the 
submission a meta-analysis indirectly 
comparing romiplostim with eltrombopag 
was reported. These data were not used in 
this model. 
Is the study type reasonable? Yes A cost–utility study is used to estimate 
relative efficiency.  The model used is a 
trial-based model linked to the RAISE 
study. 
Is effectiveness of the 
intervention established? 
Possibly The only information in relation to 
Eltrombopag came from the 3 RCTs as 
previously mentioned.  However, the 
study period was short and UK 
participant numbers were small.  
Furthermore, the patient populations 
within the trials did not wholly match the 
population to be modelled.  It is assumed 
that those who have not had a 
splenectomy are the same as those that 
are contraindicated for splenectomy as 
stipulated for this STA.    
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Item Critical 
Appraisal 
Reviewer Comment 
Has a lifetime horizon been 
used for analysis (has a 
shorter horizon been 
justified)? 
No A lifetime horizon has not been used.  
The only extrapolation has been for the 
QALY loss for those who died during the 
26 week follow-up.  It was assumed that 
life expectancy of those who died was the 
same as the general population at the 
same age.   
Are the costs and 
consequences consistent with 
the perspective employed? 
Yes Yes, costs are attributed from an NHS 
viewpoint and a budget impact statement 
supports this perspective.  Consequences 
are measured in QALYs which is 
standard procedure.  However, QALY 
measurements do not account for adverse 
events apart from bleeding events.  
Therefore no adverse events attributable 
to eltrombopag or other treatments are 
modelled. 
Is differential timing 
considered? 
Yes As the model only covers a time period 
of 26 weeks, discounting was not 
necessary for the most part.  However 
QALYs lost due to death during the 26 
week follow-up period are discounted at 
3.5%, as per NICE guidelines. 
Is incremental analysis 
performed? 
Yes The results of the model were presented 
as incremental cost effectiveness ratios 
(ICERs). 
Is the sensitivity analysis 
undertaken and presented 
clearly? 
Yes A number of sensitivity analyses were 
carried out as part of the manufacturer’s 
submission, the results of which are 
described above.  Further sensitivity 
analyses could have been done to explore 
the impact of varying and/or relaxing a 
number of assumptions used (such as 
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Item Critical 
Appraisal 
Reviewer Comment 
considering a percentage of non-
splenectomised patients to be contra- 
indicated as opposed to 100%;  patient 
numbers; response rates to treatment; 
wider price analysis, etc. 
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Table 5.7 Comparison of economics submission with NICE reference case 
Attribute Reference 
Case 
Included in 
Submission 
Comment on whether de novo 
evaluation meets requirements of 
NICE reference case 
Comparator(s) Alternative 
therapies 
including 
those used 
routinely in 
the NHS 
Partly  Evidence on the effectiveness of 
comparators is not formally 
incorporated into the analysis.  It is 
assumed that the outcomes of standard 
of care of the RAISE trial, which 
involved the use of interventions used 
in the NHS is representative of NHS 
practice in the absence of eltrombopag 
Perspective – 
costs 
NHS & PSS Partly NHS cost perspective is clearly 
described.  No PSS costs were 
included.  It is unclear if there are any 
PSS costs which were relevant. 
Perspective – 
benefits 
All health 
effects on 
individuals 
Yes QALY benefits to treatment with 
eltrombopag relative to standard care. 
Differences in QALYs between 
treatments relate primarily to 
differences in bleeding events and 
death between the groups. 
Time Horizon Sufficient to 
capture 
differences in 
costs and 
outcomes 
No The economic model considered costs 
and benefits over the 26 week time 
period, the time period considered by 
RAISE.  Differences in outcomes apart 
from the loss of lifetime QALYs 
caused by death in the 26 weeks were 
excluded.  No disease progression was 
assumed or incorporated into the 
economic model. 
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Attribute Reference 
Case 
Included in 
Submission 
Comment on whether de novo 
evaluation meets requirements of 
NICE reference case 
Synthesis of 
evidence 
Literature 
Review and 
indirect 
comparisons 
Partly A comprehensive literature review was 
carried out to identify evidence on 
eltrombopag.  A review for comparator 
evidence, which is very limited, was 
conducted but not used in the model.   
Outcome 
Measure 
QALYs Yes The manufacturer’s submission 
generated QALYs from 2 different 
sources: (i) Utility change from 
baseline (using the SF-36 collected 
during the trial). 
(ii)  Utility benefit through reduction in 
mortality was calculated using the 
Cohen study using the mean annualised 
risk of fatal bleeding,10 QALY at 
baseline and UK average life 
expectancy. 
Health States for 
QALY 
measurement 
Described 
using a 
standardized 
and validated 
instrument 
Yes Health utility data were collected as 
part of the RAISE trial and are 
incorporated in the results of the model.  
Utility data were collected using the 
SF-36 questionnaire and transformed to 
the SF-6D using the Brazier 2002 
algorithm.   
NICE recommends the use of EQ-5D 
wherever possible. No justification for 
not using the EQ-5D was provided. 
Benefit Valuation Time trade 
off or 
standard 
gamble 
Standard 
Gamble 
Benefits have been tranformed into the 
SF-6D from SF-36 using Brazier 2002 
which is based on the standard gamble 
approach.   
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Attribute Reference 
Case 
Included in 
Submission 
Comment on whether de novo 
evaluation meets requirements of 
NICE reference case 
Source of 
preference data 
Sample of 
Public 
Yes The preference data used in utility 
calculation were derived from a sample 
of the UK general public and used to 
value the responses to the SF-36 
provided by participants of the RAISE 
trial which had centres in various 
international locations.  In response to 
the ERG clarification queries, the 
manufacturer stated that only 9 of the 
patients in the RAISE trial were from 
the UK.  This raises questions in 
relation to the applicability of the 
results as the responses to the SF-36 
may not be representative of UK 
patients. 
Discount rate Health 
Benefits and 
costs 
Yes where 
appropriate 
Discounting was only applied to   
QALYs lost by death. These are 
discounted at 3.5%. 
Equity No special 
weighting 
No No special weighting in relation to 
equity was undertaken.   
Sensitivity 
Analysis 
Probabilistic 
sensitivity 
analysis 
Yes Probabilistic sensitivity analysis was 
undertaken and is presented in the form 
of various scatter plots and cost 
effectiveness acceptability curves. 
 
5.3.1  Critical appraisal of economic evaluation methods 
The model presented appears to be quite transparent and most, if not all calculations are 
traceable and referenced.  Many key assumptions are clearly stated and their incorporation 
into the model is traceable and modifiable where necessary.  However, there are a number of 
points of uncertainty which are less clear from the model and these are addressed below.   
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Decision Problem, description of alternatives and perspective 
The decision problem is detailed in section 2 of the manufacturer’s submission (pp 8-9).  
Table 2 of the manufacturer’s submission describes the alternatives in the NICE scope as well 
as how the submission plans to deal with these.   
The scope states that the indication for eltrombopag is those patients who have previously had 
a splenectomy and are refractory to that splenectomy and non–splenectomised patients who 
are contra-indicated for splenectomy.  It is unclear whether any of the data used are actually 
relevant to the second patient group.  It should be noted that little of the existing data for any 
treatment appears to be precisely for this group. 
 
In the economic model the comparison is eltrombopag plus standard care versus standard care 
alone.  Standard care is based upon treatments provided in the RAISE trial and may not 
represent standard NHS practice or what might be described as current best practice. 
 
The perspective taken in the submission is that of NHS / PSS although information from the 
perspective of the PSS is not presented nor discussed.   
 
5.4 Modelling methods 
5.4.1 Modelling approach / model structure 
Type of Model used: Is it justified for the purpose 
The submission made by the manufacturer was based around a trial-based model developed in 
Microsoft Excel.  It has a very simple structure that arguably may be biased as it assumes that 
differences between treatments arise primarily due to death and bleeding events.  This 
potentially assumes away other outcomes e.g. side effects of treatments, etc, which may also 
influence costs and outcomes.  As a consequence it might be argued that such an approach 
will produce biased results.  However, a counter argument can be advanced that the modelling 
‘adds power’ to (for economic outcomes) an under powered study.  The ERG did ask that 
GlaxoSmithKline produce a within-trial analysis as this information would most likely lead to 
more accurate results.  GlaxoSmithKline provided further disaggregated costs and QALYs but 
further extra information from the trials was not provided.   
 
Rationale of the structure 
The model does not provide any facility to directly compare treatments.  While the model 
presented estimates eltrombopag’s cost-effectiveness against standard of care, it is unclear as 
to whether eltrombopag is more or less cost-effective than some other comparator treatments.   
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Structural assumptions 
Transparent and justified? 
Many of the assumptions used justified using clinical expert opinion.  However a lack of 
transparency into this method of evaluation for so many parameters raises questions as to how 
the expert opinion was obtained, whether it is accurate and whether it is representative of 
expert opinion in the UK.  The validity of some of these assumptions is questionable.  For 
example, the model assumes that all patients who have not undergone a splenectomy are 
contra-indicated to splenectomy.  The use of this assumption does not seem to reflect a real 
world situation.  The impact of this assumption on the cost-effectiveness of eltrombopag is 
unclear.   
 
Time horizon and cycle length? 
The model time horizon is for 26 weeks, the period of the RAISE trial.  The model does not 
include the continuing costs of survivors.  Given the data used within the model this 
represents a bias in favour of eltrombopag. 
 
Duration of treatment: 
Duration of treatment was for the 26 week period of the trial.  However, a number of 
participants dropped out of the trials for various reasons and these are detailed in Figure 6.4 of 
the manufacturer’s submission.  A number of participants in the RAISE study entered the 
EXTEND long term trial and this data has been used for the second economic evaluation 
model which will be assessed in the next chapter. 
 
5.4.2 Data 
Data identification process clear? 
Generally, a clear description of the source of effectiveness data was provided.  In all cases, 
the data in the model matched the data in the submission report and no discrepancies were 
found here.  However, what was rather unclear was the source of some data used in the model 
taken from the RAISE reanalysis pdf files.  A number of typographical errors were identified, 
specifically in relation to the dosage of certain ITP medications administered during the trial 
as rescue medication (on both the eltrombopag and placebo arms of the trial).  These errors 
appear to be genuine mistakes but all create a bias (admittedly small) in favour of 
eltrombopag.   
 
Secondly, in relation to figures presented by subgroups for the number of bleeding events, the 
source for this data was given as table 49 (RAISE CSR).  However, this table only details 
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bleeding events for all patients and not separately for each subgroup.  Therefore, the source of 
this data remains unclear and while it may be accurate was unable to be checked.  
 
Further issues in relation to model cell calculations 
In relation to certain cell calculations used in the model, there is uncertainty surrounding their 
accuracy.  For example, the method used to calculate incremental utilities over the 26 week 
period for both the placebo and eltrombopag arms seems to show inconsistencies in the 
calculation method used at each incremental stage of utility estimation.  The formulae used to 
calculate utilities for the placebo arm (weeks 14 – 26) and eltrombopag (weeks 14 – 26) seem 
to be inconsistent.  The eltrombopag calculation references the baseline as opposed to the 
placebo calculation which references the previous time point estimate. 
 
a
 
This yields a utility value of 0.0031 over that period.  However, when one looks at the 
placebo arm for the same time increment, the point estimate at week 26 is referenced to week 
14, (the previous point estimate).  It appears as if two separate methods have been employed 
here and it is unclear as to which method is being used and how the calculations are arrived 
at.  Further, the method used is method 2 from the Manca and colleagues’ paper,74 which 
recommends that in order to calculate correct utilities incrementally that one should adjust for 
baseline imbalances in utility.  However, the paper referenced states that this method is 
flawed and an alternative method 3 is suggested.  The submission document does not mention 
this method at all.  It is unclear as to why the recommended approach for the calculation has 
not been adopted.  Also, it is interesting to note that the method 2 used gives the lowest ICER 
value of all 3 methods identified by Manca and colleagues.   
A further issue arises in relation to the weighting of bleeding events in order to adjust for 
numbers of assessments in the placebo and eltrombopag arms.  The bleeding events are 
adjusted to reflect the fact that the eltrombopag arm of the trial has almost twice the number 
of patients by adjusting for the number of regular assessments.  However, in relation to 
spontaneous reporting, no adjustment is made.  The text of the submission suggests that it has 
been inflated but the formulae do not ascribe to this.  This represents a potential small bias 
against eltrombopag. 
 
 
 
                                                 
a For example, when calculating incremental utility for the Eltrombopag arm between weeks 14 and 26, 
Cell H56 takes the point estimate at week 26 and compares it with the point estimate at base line.   
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Is the pre model data analyses methodology based on justifiable statistical and 
epidemiological techniques? 
A number of assumptions are made throughout the model which may lead to questions about 
their justification.  For example, one patient in the placebo arm of the trial died as a result of 
ITP.  Therefore, data from other sources was used to justify a difference in mortality.  It is 
unclear whether any differences in mortality exist and if they do what is their magnitude and 
direction.  It is assumed that a difference in clinically significant bleeds is a legitimate proxy 
for differences in mortality rates.  A sensitivity analysis is however conducted to look at all 
bleeding events; unfortunately the sensitivity analysis is one way and does not explore the use 
of more serious bleeds as a proxy for mortality rates.  Given the mortality risk has a pivotal 
role in the model; such a sensitivity analysis would be useful.   
 
The model also assumes that mortality risk is the same for all patients, both splenectomised 
and non-splenectomised.  Little or no data are available about this and the net impact on the 
analysis is unknown.   
 
5.4.3 Quality of life / Utilities 
Are the utilities incorporated into the model appropriate?  Are methods used to derive utility 
weights justified? 
Throughout the model, QALYs are used to estimate the impact of ITP on Health. QALYs are 
estimated using the SF-36 questionnaire and are transformed into SF-6D using the Brazier 
2002 algorithm.73  This is a reasonable measure of health status utilities but it is not the 
method as recommended by NICE for use in the STA process. NICE recommends the use of 
EQ-5D where possible.  The manufacturer has however stated that both measures are widely 
accepted methods of preference based utility measurement.  In their response to clarification, 
question B16, the manufacturer acknowledged that each method had its own merits but 
presented no evidence to suggest that the measures were interchangeable. Both measures are 
none the less used interchangeably in the report.  The ERG notes that it is unclear whether or 
not this introduces a bias in the calculation of overall QALYs.  However, no reference to any 
studies comparing the measures has been made.  For example, Seymour and McNamee have 
completed some work in this field in an effort to compare the two methods using a quantile 
regression approach.76 Further work completed by Brunenberg77 concludes that it is incorrect 
to compare the two methods. The main point to note here is that the non-comparison of the 
methods adds uncertainty as to the accuracy of combining the two measures to derive an 
overall QALY measurement. 
 
5.4.4 Data incorporation 
Is the process of data incorporation transparent? 
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The process of data incorporation into the model was clear and transparent and the use of data 
between sections is clear and logical in the most part. The only section in which data has not 
been traceable is in relation to subgroup bleeding events, and potential errors in data entry as 
detailed previously.   
 
5.5 Comment on the validity of the results presented with reference to the 
methodology used? 
 
Apart from the points raised above the results appear valid in terms of the methods used.   
 
5.6 Summary of uncertainties and issues 
Were methodological, structural, heterogeneity, parameter uncertainties addressed? 
There are some concerns with regard to methodological uncertainties in the model.  Issues 
also arise in relation to uncertainty surrounding the costing assumptions used to inform the 
model.  There are large differences between macro and micro costing approaches.  It is likely 
that the true values lie somewhere between these two points.  Also, costing has been 
estimated largely with the use of clinical expert opinion, which may not be adequately 
representative of the wider UK population under consideration.  The effects and/or biases 
generated as a result of this uncertainty are unclear; however the ERG does feel that some 
bias will exist but the magnitude and direction is unclear. 
 
Also, in relation to the cost of eltrombopag, the ERG requested that the manufacturer estimate 
the price at which eltrombopag would have to be cost-effective at various cost effectiveness 
thresholds (for example £30,000/QALY).  This information was presented in response to 
ERG clarification queries document, the results of which are summarised in Table 5.3 above. 
 
The impact of the variation of certain structural assumptions on cost effectiveness will be 
explored in Chapter 7 of this report. 
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6 ECONOMIC EVALUATION: De novo economic evaluation 2 Cost-effectiveness 
evaluation of chronic ITP long-term continuous treatments as part of a 
treatment sequence with and without eltrombopag 
 
The manufacturer did not identify any significant errors in this model and therefore the 
relevant results are those presented in a second Section 7 included as a separate document to 
the main submission document and in the response to ERG clarification queries document.  
All page numbers, sections, tables and figures referred to in this section of the ERG report 
come from this second Section 7 unless otherwise stated. 
 
6.1 Introduction and overview of manufacturer’s economic evaluation 
This second de novo economic evaluation used a Markov model to assess the cost-
effectiveness of eltrombopag as part of a long term continuous treatment strategy to treat 
chronic adult ITP patients who have been unresponsive to or intolerant of non-selective 
immunosuppressive agents.  The model presents eltrombopag as part of a treatment sequence 
that may also include treatment with rituximab, IVIg, anti-D and romiplostim.   
 
The submission for the second de novo economic evaluation included: 
 
• A systematic literature review of any studies assessing the cost-effectiveness of 
eltrombopag in a long term continuous care setting. 
• Inclusion and exclusion criteria (Section 7.2.2), detailed description of comparator 
technology (7.2.3).  A schematic of the model and the Markov health states used are 
detailed in Figures 7.1 a & b.  Movement through the model and each treatment sequence 
considered is illustrated in Figure 7.1 c. 
• A list of model assumptions and justification for their inclusion are detailed in Table 7.2. 
• Results of the model are detailed in Section 7.3 (pp31 – 36).  Various sensitivity analyses 
were conducted on the assumptions and uncertainties within the model as identified by 
the manufacturer and these are presented between pages 37 and 52 of the second Chapter 
7. 
• Two separate Microsoft Excel copies were included (one for each population group: 
splenectomised and non-splenectomised). 
• Budget impact is detailed in Section 8  
 
As part of the review process, the ERG requested a number of points of clarification from the 
manufacturers in relation to uncertainties or discrepancies which were identified at an early 
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review stage of the model.  The issues on which the group required further clarification are as 
follows: 
 
• The manufacturer was asked to clarify a discrepancy in the modelling and reporting of 
disease progress and those reported in the source RAISE trial. 
• More detail was requested in relation to the pooling of the SF-36 data and the 
manufacturer was requested to elaborate on the calculations used.  Also, they were asked 
to clarify as to why two differing methods of utility estimation were used in the model 
and how accurate this mix and match approach was.  Further tables relating to SF-36 data 
are included in an appendix to the clarification document. 
• The manufacturer was asked to justify the assumption that that 80% of grade 4 bleeds are 
fatal. 
• Evidence that the data used in the model was in fact relevant to the study question was 
requested. 
• Estimates of life years as well as QALYs were requested i.e. full and complete tables for 
every analysis and every treatment. 
• Also a number of further non priority points were flagged for clarification. 
 
The manufacturer responded in detail to the requests made by the ERG and this evidence will 
be used where appropriate throughout the report.  It appears from the manufacturer’s response 
that a number of points are mentioned but are not discussed in any detail.  For example, the 
assumption of 80% of grade 4 bleeds being fatal is not adequately justified in the response 
document.  While information on life years is presented in selected treatment sequences, it is 
only available for the first two (not all) sequences on the cost-effectiveness frontier. Further 
information is only presented comparing treatment sequences with and without eltrombopag 
for the lead sequence on the frontier.  This fails to account for the fact that the lead sequence 
may not always be the most relevant to UK practice.  There is however little or no guidance 
available to dictate the order in which treatments are received.  One may however question 
the use of rituximab as first line treatment given that it is not licensed for the treatment of ITP. 
 
6.2 Cost-effectiveness analysis methods 
The identification of appropriate studies evaluating eltrombopag and the systematic review 
process is as described in section 5.1 above.  As reported in this section no relevant studies 
assessing the cost-effectiveness of Eltrombopag as part of a long-term continuous treatment 
programme were found.  As no economic evaluation was identified, the manufacturer based 
its evaluation on a Markov model to evaluate the cost-effectiveness of eltrombopag as part of 
a treatment sequence in the long term continuous management of chronic adult ITP for 
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patients who had previously received and been refractory to treatment using non-selective 
immuno-suppressive agents.  The following sections of this report summarise treatment 
background, HRQOL, resources, costs, results and sensitivity analyses as reported in the 
manufacturer’s submission and the subsequent clarification document. 
 
6.2.1 Natural history 
The submission addressed a small sub-group of patients with more severe chronic adult ITP 
who will require long-term treatment and who are not adequately responsive to treatment in a 
watch and rescue scenario.  The model addresses a hypothetical cohort of 25 patients given a 
regular stable dose of eltrombopag of 50 mg daily.   
 
One point on which the ERG requested further clarification was as to what patients actually 
entered the model as it is assumed that only a very small number of patients would be eligible 
for this treatment per year (in Table 8.2 of the manufacturer’s submission it is estimated that 
only between 22 and 23 patients will be eligible for treatment each year).  
 
The model framework is a simple repeated decision tree framework which supports a Markov 
(health state transition) structure, repeated per treatment within a treatment sequence (Figure 
7.1(a-b) of the manufacturer’s submission and are reproduced in Figure 6.1 below for 
completeness). Figure 6.2 further illustrates the treatment sequence approach used in the 
economic model. 
 
Figure 6.1 Markov health states 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment
Uncontrolled 
for 1st cycle
Uncontrolled 
for 2nd cycle
Uncontrolled 
for 3rd cycle Switch
Controlled Lose control
Bleed event 
(WHO 3 + 4)
Death Long-term 
(WHO 4)
Short-term 
(WHO 3)
Note: 
Each cycle is 4 weeks in length. 
Transition from 1st cycle to 2nd cycle 
and from 2nd to 3rd cycle only activated 
if applicable to the treatment under 
consideration e.g. assessment for 
patients on eltrombopag is 8 weeks, 
this enables transition from the 1st to 
the 2nd cycle.
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Figure 6.2 Treatment sequence approach to modelling 
 
 
 
 
 
 
 
 
 
 
Patients (over 18 years old) enter the model with a platelet count of <30 x109/L and who have 
had previous ITP therapy to which they are assumed to have had an inadequate response.  
Long-term treatment is assumed to be required until the patient reaches a platelet level of >50 
x109/L.  Patients who fail to a platelet count of 50 x109/L enter a sink state i.e. these patients 
will have failed to respond to all treatments within a sequence or will have survived a non 
fatal grade 4 bleed.  They remain in this state until the end of the model.  Patients with a fatal 
WHO grade 4 bleed exit the model as a result of death.  This model was considered by the 
manufacturer to be the most appropriate option in order to deal with the lack of evidence in 
relation to comparator treatments.  Also as the population group remains ill defined and there 
is no evidence to inform the most appropriate treatment course.  It was felt by the 
manufacturer that the Markov model used would therefore be the most appropriate in the 
circumstances. 
 
6.2.2 Treatment effectiveness 
Time to treatment switch is detailed in table 7.3 of the manufacturer’s submission and is 
based upon clinical expert opinion.  The manufacturer has provided details of clinical expert 
opinion used to assist the development of assumptions and parameters in response to question 
A.10 in the matters for clarification.  However, it is unclear which experts detailed provided 
information in this regard.  Patients enter the model in the first line of treatment and move 
through various treatment sequences.  The decision to move between treatment stages within 
the sequence is based on assessment of response and the occurrence, or not, of a significant 
bleeding event.  Efficacy data are taken from pooled SF-36 data obtained from the RAISE and 
EXTEND trial data.  Health effects in the model are measured in terms of life years and 
QALYs gained. 
 
First Treatment Option Second Treatment Option Third Treatment Option
Eltrombopag Safe count
Low count Rituximab
IV Ig
Safe count
Low count Safe count
Low count
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6.2.3 Health related quality of life 
Health related quality of life measurements are detailed in Section 7.2.8 of the manufacturer’s 
submission and are reported in terms of QALYs gained.  Measured health effects in the model 
include (utility weights applied to controlled and uncontrolled) platelet counts and the 
duration of a bleeding event.  Utility data for controlled and uncontrolled platelet counts are 
measured from pooled data in the RAISE and EXTEND trials and mapped to SF-6D using the 
Brazier and colleagues’ algorithm.  Utility measures of impact following a significant bleed 
event are measured using various indexes mapped to the EQ-5D measurement.  In response to 
an ERG clarification query, the manufacturer stated that both measures are widely accepted 
methods of measuring preference based utility scores.  While each method is acknowledged to 
have its own merits, the manufacturer presents no evidence to suggest that the measures are 
interchangeable. They are none the less used interchangeably in the report.  The ERG notes 
that it is unclear whether or not this introduces a bias in the calculation of overall QALYs.   
 
Adverse events other than bleeding events are not modelled and this is justified by the 
manufacturer on the grounds that they wanted to avoid double counting of effects captured in 
the SF-36 data.  However, there is no data provided that the utility differ between treatments 
other than because of response rates and bleeding events.  Numbers of bleeding events are 
reported in Tables 13-18 of the matters for clarification document.  Utility scores following a 
significant bleed are detailed in Table 7.6 of the main submission document. 
 
6.2.4 Resources and costs 
Section 7.2.9 of the manufacturer’s submission states that resource and cost measurements 
were detailed from a NHS and PSS perspective.  Within the model, it is assumed that all 
patients requiring a treatment switch will consult with a haematologist, the cost of which is 
estimated using the national schedule of reference costs to be £124.86.  Tables 7.8 and 7.9 
further estimate the resource use associated with grade 3 or grade 4 bleeding events.  These 
are macro costing assumptions analogous to GI bleeds and ICH bleeding respectively.  A four 
weekly liver function test for eltrombopag patients is also included and costed at £1.34 per 
test.  It is likely that a visit to a haematologist or a GP would be required for each liver test.  
This additional cost associated with obtaining getting a liver test does not appear to be 
included in the analysis and would likely result in a bias towards eltrombopag although the 
size of this bias in the context of the model is not likely to be significant.  Given that the cycle 
length is 8 weeks and liver test is required every 4 weeks for eltrombopag, it would appear 
plausible to assume an extra GP visit would need to be incorporated into the Eltrombopag 
treatment calculation.   
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Treatment costs are outlined in Table 7.10, while Table 7.11 and 7.12 detail the estimated 
short and long-term costs of WHO grade 3 and 4 bleeds.  All costs and resource usage 
estimates were informally validated through discussion with clinical experts.  Details of 7 
clinical experts used during the submission development are given in response to Q A.10 in 
the matters for clarification document but it is not specified which experts valued which 
resources or if all contributed to the valuation of each resource.  While resource use was not 
measured in RAISE directly, estimates were based on trial based events.  However, no 
adjustment of resource use over future periods was made.  The manufacturer took this step 
due to co morbidities and the uncertainty which would arise from making such an assumption.  
Some extrapolation to the future may have been appropriate to fully value the costs and 
resources which may be incurred over a longer time horizon due to varying treatment options. 
 
NHS reference costs were used to value costs and resources wherever possible.  However, the 
long term costs used for a grade 4 bleeding event were sourced from the literature based on an 
ICH bleeding event. 
 
The cost of eltrombopag is assumed to be similar to the watch and rescue model at £55 per 50 
mg tablet.  Costs are reported in 2008 prices and indexed to 2008 prices where necessary, 
however no details of where such indexing has occurred are provided. 
 
6.2.5 Discounting 
Both costs and benefits are discounted in the Manufacturer’s submission at the rate of 3.5% in 
accordance with NICE guidelines. 
 
6.2.6 Sensitivity analysis 
The manufacturer has conducted a number of sensitivity analyses in the model in order to 
explore various uncertainties surrounding certain assumptions made (Section 7.2.11 of the 
manufacturer’s submission).  The main sensitivity analyses undertaken in the model are as 
follows: 
 
• Varying the response rate in the model from >50 x109/L (base case) to >30 x109/L. 
• The impact on cost effectiveness of varying the price per day from £50 to £60. 
• Changing the time horizon of the model to the patient’s lifetime as opposed to a 2 year 
time horizon used in the base case. 
• A probabilistic sensitivity analysis was reported in Section 7.3.3 of the document for both 
splenectomised and non splenectomised patient groups over a 2 year time horizon and a 
response rate of >50 x109/L. 
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The ERG presents further sensitivity analyses that it feels are relevant later in this report. 
 
6.2.7 Model validation 
An independent supplier of health economic services (RTI) was used to develop the model.  
Two clinical experts were consulted independently through informal discussion to verify 
assumptions made and the patient population addressed in the modeling approach. One point 
on which the ERG required further information was in relation to how clinical expert opinion 
was obtained.  This information is provided in response to Question A.10 in the matters for 
clarification document.  Abacus Healthcare also checked the model for quality and robustness 
using the checklist of quality criteria developed by the Centre for Health Economics at the 
University of York. 
 
6.2.8 Results 
The results of the model and analysis are presented in Section 7.3 of the manufacturer’s 
submission and are summarised here for completeness.  These results are critiqued in Section 
6.3 of this report; further analysis conducted by the ERG is reported in section 7.5.   
 
Treatment sequences with eltrombopag are dominant over the same sequences without 
eltrombopag in cases where there has been prior treatment with rituximab (see Tables 7.15 
and 7.18 of the manufacturer’s submission for comparisons showing that the lead sequence 
with the inclusion of eltrombopag dominates the same sequence without eltrombopag for both 
splenectomised and non-splenectomised patient groups).  Detailed results are available in the 
manufacturer’s response to ERG clarification queries (Tables 31 – 54). 
 
The base case results for splenectomised and non-splenectomised patients are presented on 
pages 33 – 36 of the manufacturer’s submission and shown in Tables 6.1 and 6.2 below.  No 
further subgroup analyses were conducted due to the small number of patients passing 
through the model. 
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Table 6.1 Splenectomised population: Base case results 
 
Sequence 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous immunoglobulin 
RI-EP-RO-IV RI-EP-IV-RO RI-IV-EP-RO IV-RI-EP-RO 
 
Cost: 
Drug 
Bleed 
Treatment Switch 
18315.04 
128.19 
83.89 
20925.32 
124.99 
82.82 
25380.86 
119.81 
83.81 
60419.09 
127.31 
80.03 
Total Cost (£) 18,527 21,133 25,584 50,644 
 
Life Years 
Controlled platelet 
count 
Uncontrolled platelet 
count 
Bleed Related 
1.873 
 
0.008 
 
0.105 
1.877 
 
0.008 
 
0.101 
1.884 
 
0.007 
 
0.094 
1.359 
 
0.004 
 
0.065 
 1.986 1.986 1.986 1.986 
 
QALY 
Controlled platelet 
count 
Uncontrolled platelet 
count 
Bleed Related 
1.351 
 
0.005 
 
0.073 
1.354 
 
0.005 
 
0.070 
1.874 
 
0.008 
 
0.104 
1.352 
 
0.005 
 
0.072 
Total QALY 1.428 1.429 1.429 1.429 
 
ICER (relative to 
previous sequence) 
----------- 11,235,680 11,711,779 150,959,104 
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Table 6.2 Non – splenectomised population: Base case results 
 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous immunoglobulin; AD = 
Anti D 
For both patient groups, the ICERs for one treatment sequence over another are driven mainly 
by changes in drug related costs and show that eltrombopag is most cost-effective within a 
treatment sequence when used as second line treatment after a patient has previously received 
rituximab.  There is little difference in QALYs between treatments on the cost-effectiveness 
frontier as is evident from the above tables. 
 
Sensitivity analysis results: 
Tables 6.3 and 6.4 summarise the deterministic sensitivity analyses as conducted by the 
manufacturer. 
 
Table 6.3 Response rate >50x109/L, time horizon: life time: Splenectomised 
Sequence   
 Cost (£) Life years QALY ICER 
RI-EP-RO-IV 
RI-IV-EP-RO 
IV-RI-EP-RO 
£252,519.3 
£323,979.9 
£469,238 
42.308 
42.314 
42.314 
15.692 
15.694 
15.694 
- 
24,554,474 
29715911 
Sequence 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous immunoglobulin 
RI-EP-RO-IV-
AD 
RI-EP-IV-AD-
RO 
RI-IV-EP-AD-RO RI-IV-AD-EP-RO 
 
Cost: 
Drug 
Bleed 
Treatment Switch 
17,404.09 
105.92 
77.06 
19,812.38 
102.82 
76.97 
23,807 
102 
80 
26,751 
99 
82 
Total Cost (£) 17,587 19,992 23,986 26,932 
 
Life Years 
Controlled platelet 
count 
Uncontrolled platelet 
count 
Bleed Related 
1.907 
 
0.007 
 
0.072 
1.912 
 
0.006 
 
0.068 
1.917 
 
0.006 
 
0.064 
1.917 
 
0.006 
 
0.063 
 1.986 1.986 1.986 1.986 
 
QALY 
Controlled platelet 
count 
Uncontrolled platelet 
count 
Bleed Related 
1.376 
 
0.004 
 
0.050 
1.379 
 
0.004 
 
0.047 
1.383 
 
0.004 
 
0.044 
1.383 
 
0.004 
 
0.044 
Total QALY 1.43 1.43 1.43 1.43 
 
ICER (relative to 
previous sequence) 
----------- 10,749,060 15,402,007 164,623,320 
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Table 6.4 Response rate >50 x109/L, time horizon: life time: Non-splenectomised 
Sequence   
 Cost (£) Life years QALY ICER 
RI – EP – RO – IV – AD 
RI – IV – EP – AD - RO 
RI – IV –AD - EP - RO 
£260,119 
£325,257 
£386,796 
42.64 
42.65 
42.65 
15.82 
15.82 
15.82 
- 
24,727,254 
545,565,480 
 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim;  IV = Intravenous immunoglobulin; AD = 
Anti D 
Taking the lead sequence in each case and comparing it with the same sequence without 
eltrombopag, the sequence including eltrombopag is reported as being dominant for both 
population groups. 
 
The analysis in this case reports the lead sequence against the same sequence without 
eltrombopag for each price level and shows that in each case the sequence with eltrombopag 
is dominant over the sequence without it (Tables 6.5 and 6.6). 
 
Table 6.5 Varying price of eltrombopag between £50 and £60: Splenectomised 
Sequence  (£50) 
 Cost  Life years QALY ICER 
RI – RO –IV 
RI – EP – RO - IV 
21,544 
17,571 
1.985 
1.986 
1.425 
1.428 
- 
Dominant 
Sequence  (£55) 
 Cost  Life years QALY ICER 
RI – RO –IV 
RI – EP – RO - IV 
21,544 
18,527 
1.985 
1.986 
1.425 
1.428 
- 
Dominant 
Sequence  (£60) 
 Cost  Life years QALY ICER 
RI – RO –IV 
RI – EP – RO - IV 
21,544 
19,484 
1.985 
1.986 
1.425 
1.428 
- 
Dominant 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim; IV = Intravenous immunoglobulin 
 
Table 6.6 Varying price of Eltrombopag between £50 and £60: Non-Splenectomised 
Sequence  (£50) 
 Cost  Life years QALY ICER 
RI – RO –IV – AD 
RI – EP – RO – IV -AD 
21,910 
16,685 
1.986 
1.986 
1.428 
1.430 
- 
Dominant 
Sequence  (£55) 
 Cost  Life years QALY ICER 
RI – RO –IV – AD 
RI – EP – RO – IV -AD 
21,910 
17,587 
1.986 
1.986 
1.428 
1.430 
- 
Dominant 
Sequence  (£60) 
 Cost  Life years QALY ICER 
RI – RO –IV – AD 
RI – EP – RO – IV -AD 
21,910 
18,490 
1.986 
1.986 
1.428 
1.430 
- 
Dominant 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim; IV = Intravenous immunoglobulin; AD = 
Anti D 
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The variation in price does not change the resulting sequences in the long-term care model.  
However, it does lead to notable differences in cost value driven changes in drug related 
costs.  In all three cases in Tables 6.5 and 6.6, the inclusion of eltrombopag in a post 
Rituximab treatment sequence is dominant over the same lead sequence without the inclusion 
of eltrombopag. 
 
The impact of rerunning the model when the target platelet level was changed to >30 x109/L 
is detailed in Tables 6.7 and 6.8.  Once again the lead sequence with eltrombopag included 
dominates the treatment sequence without eltrombopag for both the splenectomised and non-
splenectomised patient populations (Tables 51 and 54 of the matters for clarification 
document). 
 
Table 6.7 Response Rate: >30 x109/L: Splenectomised 
Sequence   
 Cost (£) Life Years QALY ICER 
RI – EP – RO – IV 
RI – EP – IV – RO 
RI – IV – EP – RO 
IV – RI – EP - RO 
16,400.24 
18,285.44 
23,408.02 
54,336.58 
1.986 
1.986 
1.986 
1.986 
1.428 
1.429 
1.429 
1.429 
 
6,798.229 
13,565,519 
106,979,580 
 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim; IV = Intravenous immunoglobulin; AD = 
Anti D 
Table 6.8 Response Rate: >30 x109/L: Non- splenectomised 
Sequence   
 Cost (£) Life Years QALY ICER 
RI – EP – RO – IV – AD 
RI – EP – IV –AD - RO  
RI – IV – EP – AD - RO 
IV – RI – EP – AD – RO 
IV – EP – RI – AD - RO 
 
15,869.95 
17,233.26 
22,714.95 
54,482.72 
59,574.40 
1.986 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
1.43 
 
6,040,665 
99,227,335 
164,090,976 
219,607,583 
 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim; IV = Intravenous immunoglobulin; AD = 
Anti D 
Finally, a probabilistic sensitivity analysis is conducted for the sequences including 
eltrombopag in a post rituximab treatment sequence for each patient group. The results of the 
analysis are reported on pages 51 and 52 of the manufacturer’s submission.  Substantial 
variation in cost between the sequences is evident but there is very little variation in 
effectiveness.  This suggests that the results which favour Eltrombopag are very much cost 
driven in the model, thus confirming the details of the deterministic analysis presented.  
Unfortunately, the submission does not provide any cost-effectiveness plots or cost 
effectiveness acceptability curves (CEACs).  The manufacturer justifies this by stating that 
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because of the magnitude of the ICERs between sequences, CEACs would be uninformative.  
Further probabilistic analyses including such graphical illustrations are explored in Section 
7.6 of the ERG report. 
 
6.3 Critical appraisal of the manufacturer’s submitted economic evaluation 
 
Table 6.9 Structured critical appraisal of the manufacturer’s economic model 
Item Critical 
Appraisal 
Reviewer Comment 
Is there a well defined 
question 
Yes The economic model and submission 
assessed the cost-effectiveness of 
eltrombopag as part of a treatment 
sequence for long-term chronic ITP 
patients who have failed to respond 
adequately to non-selective immuno 
suppressive agents. 
Is there a comprehensive 
description of alternatives? 
Yes The alternatives presented for use in the 
model are detailed in Table 7.1 of the 
manufacturer’s submission.  Non-
selective immunosuppressive agents and 
corticosteroids are not included as it is 
assumed they have previously been used 
and have failed to control platelet counts.  
Any treatment rules are identified and the 
number of possible treatment sequences 
for splenectomised and non-
splenectomised patients are clearly 
defined. 
Is the perspective of the 
analysis clearly stated 
Yes The analysis was stated to be performed 
from the perspective of the NHS and 
PSS.   
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Item Critical 
Appraisal 
Reviewer Comment 
Is the perspective employed 
appropriate? 
Unclear While the perspective is stated as being 
that of the NHS and PSS, there is no 
detail of costs from a PSS perspective in 
the report.    
Has the correct patient 
group/population of interest 
been clearly stated 
Yes Two biologically identifiable groups are 
discussed in the models:  
- Patients who have previously had a 
splenectomy and are refractory to 
that splenectomy  
- Non–splenectomised patients who 
are assumed to be contra indicated to 
splenectomy 
This is in line with the NICE scope.  
Is the correct comparator 
used? 
Yes The list of comparators included in the 
model is broadly in line with the NICE 
scope.  Any omitted medications are 
justified in the submission and any 
relevant treatment rules are followed. 
Due to the population split, splenectomy 
has not been included as a treatment 
option in the model for non-
splenectomised patients as splenectomy 
is contraindicated in these patients. 
Is the study type reasonable? Yes A Markov model is used to evaluate the 
cost-effectiveness of eltrombopag within 
a sequence of treatments for long term 
chronic ITP patients who fail to respond 
to other commonly prescribed treatments, 
using a cohort of 25 patients.  Given the 
lack of comparable data for comparator 
drugs, this seems a reasonable way to 
proceed.   
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Item Critical 
Appraisal 
Reviewer Comment 
Is effectiveness of the 
intervention established? 
Yes, given the 
available 
evidence 
The only information in relation to 
eltrombopag comes from the 3 RCTs 
Effectiveness of the other treatments 
comes from generally small studies, none 
of which are comparative. The relative 
performance of eltrombopag is therefore 
unclear.   
The effectiveness of each treatment 
sequence in the model presented for long-
term care is calculated on the basis of 
response rates over various treatment 
cycles depending on the drug / treatment 
used at a particular point in time. Better 
comparative data between eltrombopag 
and the alternatives would undoubtedly 
improve the accuracy of conclusions.  
Has a lifetime horizon been 
used for analysis (has a 
shorter horizon been 
justified)? 
Yes A longer time horizon has been estimated 
over 50 years in order to predict model 
results over an average life time. 
Are the costs and 
consequences consistent with 
the perspective employed? 
Costs – Yes 
Consequences - 
Partly 
Costs are attributed from an NHS view 
point and a budget impact statement 
supports this perspective.  Consequences 
are measured in QALYs obtained using 
valuations from the RAISE and 
EXTEND trials together with studies 
from the literature where QALY 
information was not available through the 
trial data. 
No adverse events other than bleeding are 
modelled.  
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Item Critical 
Appraisal 
Reviewer Comment 
Is differential timing 
considered? 
Yes All costs and benefits are discounted 
where appropriate using the discount rate 
of 3.5% as recommended by NICE.   
No sensitivity analysis has been 
conducted around discount rates.   
Is incremental analysis 
performed? 
Yes The results of the model were presented 
as incremental cost effectiveness ratios 
(ICERs) measuring the incremental cost 
effectiveness between each sequence 
identified on the cost effectiveness 
frontier.  Detailed results are only 
presented for non-dominated options. 
The manufacturer also compares ICERs 
of the lead treatment sequence with 
eltrombopag compared to the same 
sequence without eltrombopag. 
Is the sensitivity analysis 
undertaken and presented 
clearly? 
Yes A number of sensitivity analyses are 
carried out.  The results of these are 
clearly presented and easily interpretable.   
Probabilistic sensitivity analyses are 
limited in there usefulness due to the 
manner presented and there is no 
multivariant analysis undertaken.  A 
range of further univariant and 
multivariant sensitivity analyses are 
explored in Section 7.5.  
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Table 6.10 Comparison of economics submission with NICE reference case 
Attribute Reference 
Case 
Included in 
Submission 
Comment on whether de novo 
evaluation meets requirements of 
NICE reference case 
Comparator(s) Alternative 
therapies 
including 
those used 
routinely in 
the NHS 
Yes The main comparators as indicated in 
the NICE scope document are included.  
All omissions are justified above. At 
the time of the manufacturer’s 
submission, romiplostim had been 
launched in the UK; however the 
Appraisal Committee’s preliminary 
recommendations had not been made. 
However, romiplostim was still 
considered within the model as a 
comparator technology.   
Perspective – 
costs 
NHS & PSS Possibly NHS cost perspective is clearly detailed 
in Section 8 of manufacturer’s 
submission. It is unclear as to whether 
PSS costs were included. 
Perspective – 
benefits 
All health 
effects on 
individuals 
NO QALY benefits are measured from the 
RAISE and EXTEND trials.  There is 
no utility decrement due to adverse 
events.  This is likely to have created 
some bias in the results, the direction of 
which is unclear.  Further, two different 
tools are used to measure utility gain 
from different effects.  The impact of 
using two different measures is unclear.  
Time Horizon Sufficient to 
capture 
differences in 
costs and 
outcomes 
Unclear The base case time horizon is 2 years, 
extended to 50 years in a sensitivity 
analysis.   
The economic model considered costs 
and benefits over 4 and 8 week cycles 
in a treatment sequence.  This may not 
be a long enough period to gain the full 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
  
 85 
Attribute Reference 
Case 
Included in 
Submission 
Comment on whether de novo 
evaluation meets requirements of 
NICE reference case 
benefits of certain treatments. For 
example, romiplostim performs much 
better when response rates are 
measured at 12 weeks. 
Synthesis of 
evidence 
Literature 
Review and 
indirect 
comparisons 
Yes A literature review was carried out for 
this submission.  Studies were selected 
for comparator treatments on the basis 
that they provided the ‘best’ data. 
Outcome 
Measure 
QALYs Yes QALY estimates in the manufacturer’s 
submission are derived from:  
(i) Utility levels associated with various 
platelet level responses. 
(ii)  The short and long term impact on 
utility from a significant WHO grade 3 
or 4 bleed event. 
They do not include other adverse 
events. 
Health States for 
QALY 
measurement 
Described 
using a 
standardized 
and validated 
instrument 
Yes Health status was collected as part of 
the RAISE and EXTEND trials using 
the SF-36 converted into SF-6D scores 
using the Brazier 2002 algorithm.   
Response utilities are measured using 
the SF-6D while impact of bleed events 
are measured using the EQ-5D. 
NICE recommends the use of EQ-5D 
where possible.   
Benefit Valuation Time trade 
off or 
standard 
gamble 
Standard 
Gamble 
The SF-6D scores are based upon 
valuations from a standard gamble 
exercise.  The EQ-5D scores are based 
upon mapping of the Barthel index on 
to the EQ-5D to measure the long and 
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Attribute Reference 
Case 
Included in 
Submission 
Comment on whether de novo 
evaluation meets requirements of 
NICE reference case 
short term impact of a significant bleed 
event. 
Source of 
preference data 
Sample of 
Public 
Yes The SF-6D and EQ-5D scores are 
derived from samples of the UK 
general population.   SF-36 scores used 
to convert to SF-6D are based on the 
RAISE and EXTEND trials.  It is 
important to note that only 9 patients 
on the RAISE trial were from the UK. 
Discount rate Health 
Benefits and 
costs 
Yes where 
appropriate 
Discounting for costs and benefits was 
at the rate of 3.5% as recommended by 
NICE.   
Equity No special 
weighting 
No No special weighting in relation to 
equity was undertaken.   
Sensitivity 
Analysis 
Probabilistic 
sensitivity 
analysis 
Yes Probabilistic sensitivity analysis was 
undertaken for rituximab lead 
sequences and the iterations are plotted 
on pages 50 and 51 of the 
manufacturer’s submission. 
 
6.3.1 Critical appraisal of economic evaluation methods 
As a general point, the model presented here is usable; however there are a large number of 
data sheets which are traceable but also quite cumbersome.  This makes it difficult to trace 
where certain figures originate from.   
 
Decision problem, description of alternatives and perspective 
The decision problem for this section is clearly defined as addressing the question of what is 
the most cost-effective sequence of treatments for long term continuous care of adult ITP 
patients who require treatment and have been unresponsive to or intolerant of non-selective 
immunosuppressive agents.  Section 2 of the manufacturer’s submission further presents the 
decision problem and this is discussed in Section 5.3.1 above.  
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The alternative treatments mentioned are romiplostim, IVIg, Anti D and rituximab.  This 
discussion seems to be broadly in line with the NICE scope.  Treatments mentioned in the 
scope and not dealt with in the model are identified and justified on the basis described in the 
second point in Table 6.9.  Section 7.2.3 of the manufacturer’s submission describes each 
alternative, its response rates in improving platelet count and its justification for inclusion as a 
comparator.  Treatment rules include not administering Anti-D to splenectomised patients and 
using IVIg in practice before Anti-D.  Both of these treatment rules are acknowledged and 
adhered to in the model.  The ERG is not aware of any other treatment administration rules 
which have been omitted from the submission.  However it should be noted that the licensed 
Anti-D preparation has been withdrawn from the market in the UK by its manufacturer due to 
safety concerns. 
 
The perspective taken for this evaluation is again that of the NHS and the PSS.  While Section 
8 of the manufacturer’s submission deals comprehensively with the budget impact for the 
NHS, there is no mention of the impact from a PSS viewpoint.   
 
6.4 Modelling methods 
6.4.1 Modelling approach / model structure 
Type of model used: Is it justified for the purpose 
The type of model used in this case appears to be justified.  An alternative simulation model 
was considered by the manufacturer but due to a lack of available data, the Markov model 
was adopted.  Within the model patients pass through a series of treatment sequences, all of 
which include eltrombopag.  As one treatment fails to elicit a response, the subject moves to 
the next treatment phase and so on.  Should a patient fail to respond to any treatments in a 
sequence it is stated that the patient would be treated in an experimental way.  The impact of 
this on costs and effects is excluded from the model. Therefore, given the limited data the 
approach used appears reasonable. 
 
Rationale of the structure 
The model is quite sensitive to the treatment sequence.  In the main, sequences appearing on 
the cost-effectiveness frontier only find eltrombopag to be conclusively more effective and 
less costly on average than other treatment sequences when the sequence involves prior 
treatment with rituximab, which is not licensed in the UK for this use.78  This begs the 
question as to whether rituximab is always likely to be administered before eltrombopag in 
clinical practice.   
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A number of the model assumptions rely heavily on clinical expert opinion, both in the 
estimation of the population group, uptake rates and other important assumptions.  The ERG 
requested further information with regards to who the clinical experts were and how they 
were remunerated.  It is important to note that while information in relation to clinical experts 
contacted by GSK is provided, no further information is available in relation to which experts 
contributed to which areas of the analysis.  Perhaps all clinicians had an input into each and 
every point which is referenced to clinical expert opinion; however there is no evidence to 
support this from the Manufacturer’s submission. 
 
It is also assumed that a response is measured as reaching a platelet threshold of > 50 x109/L.  
Within the UK a platelet threshold of 30 x109/L is more commonly adopted.  However a 
sensitivity analysis did consider a platelet threshold of 30 x109/L.   
 
A number of structural assumptions are also made which give rise to some questions as to 
their source and their relevance.  For example, it is assumed that 80% of grade 4 bleeds are 
fatal in the model.  The ERG requested in its queries for clarification that a reference for this 
be provided.  However, the manufacturer’s response was that the figure of 80% was assumed 
in the absence of any available data on the issue.  This is one area in which further sensitivity 
analysis is provided in Section 7.5 of the ERG report. 
 
The model only allows romiplostim to work over 8 weeks while the available evidence 
suggests that a maximum response is achieved at 12 weeks.  The effects of extending the time 
over which Romiplostim is given to 12 weeks is explored in further sensitivity analysis 
reported in Section 7.5 of the ERG report.  There are also further discrepancies between the 
response rates in the model and for the indirect treatment comparison described in Section 6 
of the manufacturer’s submission and critiqued in Chapter 4 of this report.  The response rates 
estimated as part of the indirect treatment comparison are much more favourable to 
romiplostim that the values used in the economic model.  The impact of incorporating this 
relative effectiveness data into the review is explored further in Chapter 7 of the ERG report. 
 
6.4.2 Structural assumptions 
Transparent and justified? 
A series of assumptions are made by the manufacturer and these are detailed in Table 7.2 of 
the manufacturer’s submission together with a justification for each assumption used in the 
model.  The assumptions are transparent, and justifications are provided and referenced as 
appropriate.   
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As mentioned above, some of the assumptions used may lead to biases for or against 
eltrombopag.  For example, it is assumed that patients who have not undergone a splenectomy 
are contra-indicated for splenectomy.  This is in accordance with the scope but there is no 
evidence from the RAISE trial on how many, if any, of the non-splenectomised patients were 
indeed refractory to such a treatment option.   Further sensitivity analysis may have addressed 
some of these uncertainties.  Perhaps splenectomy should have been included as a treatment 
option within the sequences for those who are non-splenectomised as in clinical practice. 
   
It is also assumed that patient’s in the treatment sequence are treated using one therapy only.  
No possibility of treatment interactions and possible combinations is allowed and this may be 
possible in practice for this group of patients.  Neither is there evidence that the treatment 
sequences appearing on the frontier will be those which are actually used in practice.  For 
example, a clinician may decide not to treat with rituximab first, a plausible option given that 
it is not licensed in the UK for the treatment of ITP. 
 
It is assumed that patients maintain their response rates through the model and no attenuation 
of response occurs.  This is unlikely to be a realistic assumption and it would have been 
interesting to see the effects of which treatments maintain response levels over time and 
which do not.  Inevitably, this assumption will have caused a bias in the results; however it is 
unclear whether this is in favour of or against eltrombopag. 
 
For simplicity, it was assumed that no risk of mortality associated with ITP was included 
apart from the risk of mortality from all causes.  This will undoubtedly boost life expectancy 
and HRQOL values in the model for all treatments in the sequence.  It is unclear if any 
treatment would affect mortality in other ways.    
 
Finally, adverse events are not modelled, with the exception of bleeding events.  The 
justification for this is that adverse events in the placebo and eltrombopag arms in the RAISE 
trial are quite similar.  However, it is unclear whether this would be the case for the 
treatments and the group of patients considered in the long-term model.  
 
Time horizon and cycle length? 
The model is run over two years in the base case and over 50 years in a sensitivity analysis.  
The longer term time horizon should capture all of the relevant costs and effects associated 
with each treatment sequence. 
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While varying the time horizon does not have an effect on sequence results in the univariant 
analysis, it is shown in Sections 7.5 that in a multivariant analysis longer time horizons tend 
to favour romiplostim over eltrombopag in the treatment sequences. 
 
Duration of treatment 
Treatment effectiveness was measured based on response rates indicated.  Cycle lengths of 4, 
6 and 8 weeks were selected based on the treatment used as this was assumed to be 
representative of clinical practice.  The time on each treatment is the time before a treatment 
can be changed if an adequate response has not been achieved.  It is important to note that 
specifically for romiplosim that response appears to increase by 12 weeks, and a shorter cycle 
of 8 weeks as used in the model may be a bias against this treatment.  This is acknowledged in 
the submission but has not been provided for in the economic model.  The implications of this 
for cost-effectiveness are explored in Section 7.5.  Further questions may be raised in relation 
to how response rates for rituximab are modelled given that the treatment would need to be 
repeated every 8-9 months on average in order to maintain a satisfactory response. 
 
6.4.3 Data 
Data identification process clear? 
Most of the data are clearly identified and referenced where required.  While the model is 
difficult to navigate through all of the relevant data, it is none the less traceable and 
calculations presented are referenced where appropriate.   
 
One issue that did arise was that the costs and QALYs as reported did not match those as were 
calculated in the model.  This point was acknowledged by the manufacturer in the matters for 
clarification and correct tables were provided.  While costs and QALYs were incorrectly 
reported, ICERs were not and so the error made no real impact on the cost-effectiveness 
outcomes. 
 
The ERG has not identified any further errors in data incorporation and all results presented in 
the response to ERG clarification queries are true reflections of those provided in the models. 
 
Is the pre model data analyses methodology based on justifiable statistical and 
epidemiological techniques? 
Assumptions linking the splenectomised and non-splenectomised groups together are quite 
similar and one may wish to question whether or not there may be a difference between the 
patient groups in reality.  Further statistical methods and observations are critiqued in Chapter 
4 of this report.  However, no parameter differences between the two patient groups are 
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identified.  It is assumed that all of the assumptions made are the same for splenectomised and 
for non-splenectomised patient groups.  This introduces an element of uncertainty and it is 
unclear whether or not the resulting impact on cost–effectiveness would favour eltrombopag. 
 
6.4.4 Quality of life / Utilities 
Are the utilities incorporated into the model appropriate? Are methods used to derive utility 
weights justified? 
Methods for deriving SF-6D are described in Section 5.2.3 above.  The utility decrement is 
also measured by changes in EQ-5D scores in relation to significant WHO grade 3 and 4 
bleeding events and was identified through the literature (Table 7.6 of the manufacturer’s 
submission).  A point of clarification was why two different utility measurements were used.  
The manufacturer’s response was that both were widely accepted preference measures. 
However, as stated previously, there is no evidence cited in the report to suggest that these 
measures can be used interchangeably, a point which is in fact acknowledged by the 
manufacturer in their clarification document (B.16, clarification document, page 42). 
 
The health effects of any further adverse events are also not modelled and this may or may 
not impact on the results of the model.  Furthermore, there is no information in relation to 
how surveys were conducted, what setting they were conducted in or how responses were 
elicited or recorded.  This is unlikely to significantly change treatment sequences, but does 
introduce further uncertainty. 
 
6.4.5 Data Incorporation 
Is the process of data incorporation transparent? 
Generally speaking, the process of data incorporation is clear and transparent as well as 
accurate in most cases.  However, a number of discrepancies arise.  Firstly, in relation to 
response rates, it appears that romiplostim response rates are similar in achieving a platelet 
count of >50 x109/L as they are to achieving a platelet count of >30 x109/L.  As only response 
rates for platelet counts >50 x109/L were available from the romiplostim study, this 
submission assumes their responses to be the same over 30 x109/L as for over 50 x109/L.  It is 
plausible that romiplostim will have a higher response rate at 30 x109/L.  On balance this 
assumption probably represents a bias against eltrombopag. 
 
Further discrepancies appear in the response measures of romiplostim and eltrombopag 
between the meta-analysis and the economic model.  These have been discussed above and 
are explored further in Chapter 7. 
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6.4.6 Comment on the validity of the results presented with reference to the methodology 
used? 
With reference to the methodology and assumptions employed, the ERG has found that the 
results appear to be valid in the context presented.  However, what is of concern is that some 
of the assumptions used do not seem entirely plausible, as noted above.   
 
Summary of uncertainties and issues 
Were methodological, structural, heterogeneity, parameter uncertainties addressed? 
It appears that the assumptions used to estimate the patient population which would be treated 
under this approach are unclear and may or may not be valid.  Much information was derived 
from an internal GlaxoSmithKline survey together with expert opinion which may or may not 
be reflective of UK clinical practice.  Patient numbers may increase to a greater level than 
GlaxoSmithKline predicts as eltrombopag represents a more convenient, less invasive method 
of administration than the intravenous medications e.g. IVIg, rituximab.  Also, as the second 
model deals with patients who are intolerant of the non-specific immune-suppressants then 
patients who wish to start eltrombopag may become `intolerant` of their current medication.  
The estimation of a small predicted patient population is based on a number of assumptions 
which are subject to a considerable amount of uncertainty.  The cost of eltrombopag to the 
NHS may be significantly greater than that suggested if the assumptions on patient numbers 
are incorrect.   
 
More importantly, however, is that while all of the issues discussed above may not be 
individually important to the results, taken together they lead to further uncertainty in the 
analysis.  The combination of uncertainties within multivariant sensitivity analyses was not 
explored in the manufacturer’s submission.  This and further probabilistic sensitivity analysis 
are reported in Chapter 7. 
 
The applicability of the analysis is also uncertain, as a judgement is required as to which 
patients will actually receive this drug and whether the model is entirely reflective of the 
relevant patient population. 
 
A further concern in relation to structural uncertainty is how patients move through the 
sequences and if the sequences are reflective of UK clinical practice.  Cost-effectiveness is 
very sensitive to patients entering the first line of treatment with rituximab.  It is however not 
entirely clear as to whether rituximab is likely to be prescribed as a first line treatment in 
practice, indeed would clinicians be comfortable prescribing an unlicensed drug (rituximab) 
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before a licensed drug (eltrombopag, romiplostim, IVIg)  If not, eltrombopag may be 
significantly less cost-effective as a result, when compared to alternative sequences. 
 
Finally, the manufacturer’s submission assumes many of the assumptions apply to 
splenectomised and non–splenectomised patient groups.  It may be argued that in reality, 
some of these assumptions and costs may vary depending on a patient’s splenectomy status.  
This has not been incorporated into the model and the resulting impact for cost–effectiveness 
results is unclear. 
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7  ADDITIONAL WORK UNDERTAKEN 
 
7.1  Independent literature searchers to identify additional studies 
 
7.1.1 Search strategy 
Due to concerns over the sensitivity of the manufacturer’s searches, the ERG undertook 
independent searches for eltrombopag and the clinical effectiveness of the comparators. The 
independent search strategies that were used are reported in Appendix 1. Inclusion and 
exclusion criteria used are the same as those listed in the final scope issued by NICE. 
 
7.1.2 Comparing results from additional studies and those in the submission 
The ASH guideline consisting of 14 case series reporting on IVIg or anti-D was identified, 
and a systematic review consisting of 28 RCTs reporting on IVIg (identified from the HTA 
Database search). 
 
For IVIg and anti-D, lower platelet response rates were reported in the ASH guidance and the 
HTA systematic review (see Table 4.17). It is unlikely that these data would have greatly 
affected the results of the long-term economic model. 
 
7.2  Screening included studies in the systematic review against inclusion criteria 
By screening of the 113 included studies in the manufacturer’s systematic review we 
identified a total of 36 (32%) studies that included children or adolescents, i.e. less than 18 
years old (see Table 4.3).  
 
7.3  Additional analysis for indirect comparison between eltrombopag and 
romiplostim 
7.3.1 Combining the two romiplostim trials 
In the manufacturer’s submission they combined the two romiplostim trials67 by using 
Mantel-Haenszel fixed effects meta-analysis. Since the populations from which each trial 
drew its participants are heterogeneous a different method of combining the trials is required 
to produce an odds ratio for all participants. 
The method chosen here is to estimate the odds ratio of romiplostim compared to a placebo 
from a logistic regression model. The data from all of the participants in both trials was put 
together, modelling the success of each patient against two binary variables: whether the 
participant received romiplostim or placebo, and whether the participant was splenectomised 
or not. The odds ratios shown for romiplostim versus placebo in the all participants sections, 
worst and best scenarios (see Section 7.3.2) of Tables 7.1 and 7.2 were calculated using this 
method.  
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7.3.2 Dealing with participants who did not complete eltrombopag or romiplostim 
treatment in trials 
In the manufacturer’s submission, participants who did not complete eltrombopag or 
romiplostim treatment in the trials, i.e. withdrew prematurely or were lost to follow-up, were 
counted as non-responders. As there were more of these participants in the eltrombopag trial 
than in the romiplostim trials (Table 4.10), assuming such participants were non-responders 
(worst scenario) might have led the indirect comparison results to favour romiplostim.  
 
To explore the impact of assuming participants who did not complete studies were non-
responders on the indirect comparison results, we did further analysis assuming all such 
participants were responders (best scenario). The indirect comparisons shown were calculated 
using Bucher’s method.72 
 
7.3.3 Results of the additional analysis 
The results of the comparison between eltrombopag and romiplostim are presented for 
durable response in Table 7.1 and overall response in Table 7.2. 
 
For durable response the additional analysis using the logistic regression method produced an 
indirect comparison between eltrombopag and romiplostim that is similar to that given in the 
manufacturer’s submission. Using the “best scenario” for handling participants who did not 
complete their treatment produced smaller estimates of the odds ratio than in the “worst 
scenario”, with the indirect comparison between eltrombopag and romiplostim having a point 
estimate that slightly favours eltrombopag. Therefore, the results of this analysis appear to be 
sensitive to the method used for handling those who do not complete their treatment. 
 
For overall response, the all participant indirect comparisons between eltrombopag and 
romiplostim show a significant (5% level) result in the manufacturer’s submission and in both 
additional analyses. This suggests that these results are not sensitive to the method used to 
handle those that did not complete their treatment. 
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Table 7.1 Comparison between eltrombopag and romiplostim: durable response ratea  
 Eltrombopag vs. placebo 
Romiplostim vs. placebo 
Indirect 
comparison 
 n/N OR (95% CI)  n/N OR (95% CI)  OR (95% CI)  
All participants 
Worst scenariob 57/135 vs. 4/62 10.60 (3.64, 30.87) 41/83 vs. 1/42 40.02 (5.26, 304.70) 0.26 (0.03, 2.62) 
Worst scenarioc 57/135 vs. 4/62 10.60 (3.64, 30.87) 41/83 vs. 1/42 44.99 (5.81, 348.4) 0.24 (0.02, 2.37) 
Best scenarioc 80/135 vs. 11/62 6.74 (3.23 ,14.09) 45/83 vs. 7/42 6.51 (2.52, 16.80) 1.04 (0.32, 3.44) 
Non-splenectomised 
Worst scenariob 38/85 vs. 3/41 10.24 (2.93, 35.77) 25/41 vs. 1/21 31.25 (3.81, 256.24) 0.33 (0.03, 3.79) 
Best scenarioc - - 27/41 vs. 5/21 6.17 (1.87, 20.36) - 
Splenectomised 
Worst scenariob  19/50 vs. 1/21 12.26 (1.52, 98.90) 16/42 vs. 0/21 26.77 (1.52, 472.41) 0.46 (0.01, 15.91) 
Best scenarioc - - 18/42 vs. 2/21 7.13 (1.47, 34.59) - 
aDefined as weekly platelet ≥ 50 x 109/l during six or more weeks of the last eight weeks of treatment excluding 
those who received rescue medication at any time during the study  
bManufacturer reported. 
cERG calculated (combining romiplostim trials using a logistic regression model). 
 
Table 7.2  Comparison between eltrombopag and romiplostim: overall response ratea  
 Eltrombopag vs. placebo 
Romiplostim vs. placebo 
Indirect 
comparison 
 n/N OR (95% CI)  n/N OR (95% CI)  OR (95% CI)  
All participants 
Worst scenariob 72/135 vs. 6/62 10.67 (4.31, 26.43) 69/83 vs. 3/42 64.07 (17.33, 236.82) 0.17 (0.03, 0.82) 
Worst scenarioc 72/135 vs. 6/62 10.67 (4.31, 26.43) 69/83 vs. 3/42 77.68 (19.47, 309.9) 0.14 (0.03, 0.72) 
Best scenarioc 95/135 vs. 13/62 8.95 (4.38, 18.29) 73/83 vs. 9/42 34.19 (11.36, 102.9) 0.26 (0.07, 0.97) 
Non-splenectomised 
Worst scenariob 49/85 vs. 4/41 12.59 (4.12, 38.50) 36/41 vs. 3/21 43.20 (9.27, 2741.84) 0.29 (0.04, 1.95) 
Best scenarioc - - 38/41 vs. 7/21 25.33 (5.74, 111.83) - 
Splenectomised 
Worst scenariob 23/50 vs. 2/21 8.09 (1.70, 38.50) 33/42 vs. 0/21 151.63 (8.39, 201.33) 0.05 (0.002, 1.43) 
Best scenarioc - - 35/42 vs. 2/21 47.50 (8.96, 251.77) - 
aDefined as durable plus transient response (four or more weekly response ≥ 50 x 109/l during the study without a 
durable platelet response from week 2 to 25) 
bManufacturer reported. 
cERG calculated (combining romiplostim trials using logistic regression model). 
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7.4 Additional cost-effectiveness sensitivity analysis conducted by the ERG 
A number of further sensitivity analyses have been conducted by the ERG for both economic 
models to explore the impact on the cost-effectiveness results of uncertainties raised in 
Chapters 5 and 6 of this report.  Details of all changes made to the models to achieve these 
results can be found in Appendix 2 of this report. 
 
7.4.1 Additional sensitivity analysis: Watch and Rescue model 
Additional sensitivity analyses were conducted in the following areas in relation to the Watch 
and Rescue model.  Analysis point 2 includes details of a typing error which was identified in 
the analysis. This has been incorporated into all other sensitivity analyses results presented.   
 
• Variation of discount rates: The ERG explored the possible impact of varying the 
discount rate used for costs and benefits in the model from 0% to 6% (base case 3.5%) to 
highlight the impact of uncertainty surrounding society’s true rate of time preference. 
• Correction of typing errors in the model:  A number of typing errors were identified in 
the Microsoft Excel based copy of the model and have been included as discussed in 
Chapter 5. 
• Variation of annual risk of a fatal bleeding event: The manufacturer’s submission uses 
an annual risk of a fatal bleed taken from Cohen 200010 for use within their model. The 
impact of varying this value within the bounds of its confidence interval is estimated in 
the probabilistic analysis.  The ERG has however incorporated it as an additional 
deterministic analysis (Table 7.3). 
• Multivariate analysis: As detailed in Table 7.3, the manufacturer has conducted some 
sensitivity analyses which have also been reported for completeness.  These analyses and 
those detailed above have been combined in a multivariate sensitivity analysis.  Analyses 
9 and 10 in Table 7.3 (splenectomised) and 7.4 (non-splenectomised) combine 
manufacturer and ERG analyses into best and worst case scenarios. 
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Table 7.3 Watch & Rescue model – (Splenectomised patients) 
Scenario Cost (£) QALY ICER 
1.   Baseline Results 
 
9455 0.122 77,496 
2.   Typo Correction 9547 0.122 78,253 
3.   Micro Cost  10,161 0.122 83,284 
4.   All Bleeding events  9547 0.095 100,350 
5.   0% Discount Rate  9547 0.2 47,712 
6.   6% Discount Rate  9547 0.092 103,500 
7.   Annual Risk of fatal Bleed     
      Cohen 200010 – lower bound 
9547 0.072 131,841 
8.   Annual Risk of fatal bleed 
      Cohen 200010 – upper bound  
9547 0.171 55,778 
9.   Combining 2,3,4,6 & 7  
       (Worst Case Scenario) 
10,161 0.044 231,195 
10. Combining 5 & 8  
       (Best Case Scenario) 
9455 0.282 33,561 
  
 
Table 7.4  Watch and Rescue Model – Non-splenectomised patients. 
Scenario Cost (£) QALY ICER 
1.   Baseline Results 
 
10,024 0.111 90,471 
2.   Typo Correction 10,024 0.111 90,471 
3.   Micro Cost  10,101 0.111 91,175 
4.   All Bleeding events  10,024 0.112 89,850 
5.   0% Discount Rate  10,024 0.180 55,622 
6.   6% Discount Rate  10,024 0.084 118,847 
7.   Annual Risk of fatal Bleed 
      Cohen 200010 – lower bound  
10,024 0.067 150,245 
8.   Annual Risk of fatal Bleed 
     Cohen 200010 – upper bound  
10,024 0.154 64,882 
9.   Combining 2,3,4,6 & 7 10,101 0.052 193,293 
10. Combining 5 & 8  10,024 0.253 39,657 
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7.4.2 Discussion of the results of additional sensitivity analysis 
The analysis (scenarios 1 – 4) presented in Tables 7.3 and 7.4 included sensitivity analyses 
from the manufacturer’s submission document, Scenarios 5 to 10 involved additional analysis 
conducted by the ERG.  In general, individual sensitivity analyses have less of an impact for 
the non-splenectomised group than for the splenectomised group.   
 
The results for scenarios 5 to 8 show that the ICER is sensitive to the discount rate used and 
the annual risk of a fatal bleed.  Given that there is much uncertainty around the true mortality 
rate from bleeding events, the analysis shows that there is a substantial impact on ICERs of 
varying the mortality risk between the upper and lower bounds of the confidence interval used 
in the Cohen study. 
 
The impact of sensitivity analyses for scenarios 1 to 4 has been discussed previously in 
Section 5 of this report and requires no further elaboration here. 
 
Of far greater importance is the effect on the ICER of a multivariate sensitivity analysis for 
each patient group.  The large variation in QALY results presented in analyses 9 & 10 results 
in large changes in the ICER from £33,561 in a best case scenario to £231,195 in a worst case 
scenario for the splenectomised group and £39,657 in a best case scenario to £193,293 in a 
worst case scenario for the non-splenectomised patient population.  It is only in these 
hypothetical best case analyses that the ICER begins to approach a value that society might be 
willing to pay for a QALY. 
 
The large difference between analyses 9 and 10 suggests that there is potentially considerable 
uncertainty surrounding the results presented in the model.  As correctly identified in the 
manufacturer’s submission, the results are quite sensitive to the relative risk of mortality.  
Given that this figure is taken from one study,10 one may argue that the result presents a bias 
in favour or against eltrombopag depending on what one assumes the relative risk of mortality 
to be. 
 
The results as presented above beg the same argument for both patient groups surrounding the 
large levels of uncertainty.  While the difference between best and worst case scenario is 
smaller for non-splenectomised patients than for the splenectomised patients, there is none the 
less a difference of over £150,000 in the ICERs presented.  This combined with the failure to 
model any uncertainty around adverse events draws further questions as to the accuracy and 
applicability of the results.  While some of the individual results presented do not have a 
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major impact on overall results, their impact is undoubtedly magnified when combined with 
other sensitivity analyses as is clearly illustrated in the tables above. 
 
Further, from a cost perspective to the NHS, as discussed in Chapter 2 of the report, there is 
much debate and variation in evidence as to the incidence rates of ITP.  Therefore given the 
price quoted for eltrombopag, it is likely that any discrepancies in a positive of negative 
direction would significantly impact on the projected budget impact figures for the NHS. 
 
7.5 Additional sensitivity analysis: Long term model 
The ERG conducted further research and analysis on the long-term models for both the 
splenectomised and non-splenectomised patient groups.  Analysis focused on the treatment 
sequences presented on the cost-effectiveness frontier and the aspects which influenced this 
derivation.   
 
7.5.1 Splenectomised patient group 
As with the watch and rescue model, the analysis from the manufacturer’s submission is 
included for completeness (Table 7.5).  The results presented in Table 7.5 were previously 
discussed in Chapter 6 of this report. 
 
Table 7.5 Long term model – Splenectomised patient group: manufacturer analysis 
Scenario Sequences Cost Life Years QALY Relative 
ICER 
1.  Base Case RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,527 
21,133 
25,584 
60,626 
1.986 
1.986 
1.985 
1.986 
1.428 
1.429 
1.428 
1.429 
 
11,235,680 
11,711,779 
150,959,104 
2.  Response Rate > 
30x109/L 
RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
16,400 
18,285 
23,408 
54,337 
1.986 
1.986 
1.986 
1.986 
1.428 
1.429 
1.429 
1.429 
 
6,798,229 
13,565,519 
106,979,580 
3.  Life Time Horizon RI-EP-RO-IV 
RI-IV-EP-RO 
IV-RI-EP-RO 
25,2519 
32,3980 
469,238 
42.308 
42.314 
42.314 
15.692 
15.694 
15.694 
 
24,554,474 
297,159,117 
 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D 
In Table 7.6 the impact of varying assumptions that have the tendency to favour romiplostim 
are explored.  Scenario 4 in Table 7.6 below allows romiplostim to work over a 12 week 
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period, the time period when it is most likely to have the highest response rate. While the lead 
sequence on the frontier remains the same, its relative effectiveness over the next sequence is 
much less than in the base case and hence the ICER falls to £6,520,304 from £11,235,680.  
This does not alter overall conclusion but the magnitude of the changes in the ICER of one 
sequence over another further serves to illustrate the point that there is a large amount of 
uncertainty evident from the model. 
 
The analysis in scenario 5 should be taken with some caution and is presented as an 
illustration and it is unlikely that eltrombopag performed as poorly as this compared to 
romiplostim.  However, the indirect meta-analysis reported by the manufacturer in Section 6.6 
of their analysis does suggest that eltrombopag may be less effective than romiplostim.  When 
eltrombopag is assumed to be 46% as effective as romiplostim, the lead sequences do not 
change but the margin between the first two sequences is much lower than in the base case.  
The actual figures do not really tell us that much in absolute terms, however the way in which 
they change between sequences in comparison to the base case illustrates the importance of 
this uncertainty in the relative effectiveness of eltrombopag.   
 
Table 7.6 The impact of varying parameter values: Splenectomised patients 
 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D 
Standard of care was not considered by GSK in their original submission as a comparator for 
the long term model.  However, it was included as an option within their model.  The ERG 
therefore undertook exploratory analysis to look at the impact of including standard of care in 
the model.  The results show that while standard of care results in a lower cost of treatment, it 
Scenario Sequences Cost Life Years QALY Relative 
ICER 
1. Base Case RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,527 
21,133 
25,584 
60,626 
1.986 
1.986 
1.985 
1.986 
1.428 
1.429 
1.428 
1.429 
 
11,235,680 
11,711,779 
150,959,104 
4. Changing cycle  
length for RO & EP to 
12 weeks 
RI-EP-RO-IV 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,664 
25,742 
50,802 
1.986 
1.986 
1.986 
1.428 
1.429 
1.429 
 
6,520,384 
150,959,106 
5. Varying EP 
Response rate – 46% 
as effective as RO 
RI-EP-RO-IV 
RI-RO-EP-IV 
RI-IV-RO-EP 
IV-RI-RO-EP 
18,910 
19,008 
25,925 
50,984 
1.985 
1.985 
1.986 
1.986 
1.425 
1.426 
1.427 
1.427 
 
96,008 
5,485,304 
150,959,109 
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is substantially less effective (as anticipated) than any of the main treatment sequences 
presented by the manufacturer. The least costly option (RI-EP-RO-IV) in the base case 
analysis is associated with an incremental cost per QALY of over £240,000 when standard of 
care is introduced.   
 
Table 7.7 The impact of varying structural assumptions: Splenectomised patients  
Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
1. Base Case RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,527 
21,133 
25,584 
60,626 
1.986 
1.986 
1.985 
1.986 
1.428 
1.429 
1.428 
1.429 
 
11,235,680 
11,711,779 
150,959,104 
6. Including Standard 
of Care in the Model 
SC-SC-SC-SC-SC 
RI-EP-RO-IV-SC 
RI-EP-IV-RO-SC 
IV-RI-EP-RO-SC 
1,179 
19,471 
22,504 
51,399 
1.972 
1.986 
1.986 
1.986 
1.354 
1.429 
1.429 
1.429 
 
245,430 
11,222,405 
150,959,107 
7. 0% of grade 4 
bleeds are fatal 
RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,574 
21,179 
25,628 
50,686 
1.988 
1.988 
1.988 
1.988 
1.429 
1.429 
1.429 
1.430 
 
11,989,449 
12,562,922 
162,955,886 
8. 100% of grade 4 
bleeds are fatal 
RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,515 
21,122 
25,574 
50,633 
1.985 
1.985 
1.986 
1.986 
1.428 
1.428 
1.429 
1.429 
 
11,061,897 
11,516,854 
148,231,088 
9.Discount Rate 0% RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,855 
21,511 
26,034 
51,493 
1.986 
1.986 
1.986 
1.986 
1.453 
1.453 
1.453 
1.454 
 
11,382,525 
11,835,733 
152,675,199 
10. Discount Rate 6% RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,306 
20,878 
25,281 
50,072 
1.986 
1.986 
1.986 
1.986 
1.412 
1.412 
1.412 
1.413 
 
11,135,695 
11,627,509 
149,793,912 
 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D; SC = standard of care 
The standard of care option as presented in the model is reflective of patients receiving 
routine concomitant and rescue medication as per the RAISE trial and the manufacturer’s 
watch and rescue economic evaluation.  While standard of care is the least costly option it 
may not be considered effective enough in the treatment of long-term chronic ITP patients 
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who are considered as part of this model.  Including standard of care also illustrates the 
importance of therapy on mortality.  In scenario 6 adopting an active treatment results in at 
least a gain of 0.065 life years (approximately an extra 24 days) over the two year time 
horizon of the model compared to standard of care. 
 
The model appears quite insensitive to changes in the percentage risk of WHO grade 4 bleeds 
being fatal, offering little or no difference in the relative ICERs (given their size in tens and 
hundreds of millions) between the extreme assumptions that 0% or 100% of grade 4 bleeds 
are fatal.   
 
Over the two year time horizon, the model is not sensitive to changes in the discount rate 
used.  However the results are likely to be magnified over a lifetime horizon.  While the 
impact of various sensitivity analyses outlined above is minor when analyses are considered 
in isolation, it is likely that a much greater effect will be evident when certain combinations of 
analyses are presented together.  Tables 7.8, 7.9 and 7.10 report the results of these additional 
analyses. 
 
The following tables present various plausible combinations of analyses which may or may 
not impact on the results.  The idea of this is to provide a sensitivity analysis looking at all 
possible scenarios and outcomes.  For clarification, Tables 7.8, 7.9 and 7.10 describe 3 
separate areas of uncertainty as follows: 
 
A) Changes comparing romiplostim and eltrombopag over various time horizons and 
discount rates: Table 7.8. 
B) Exploring the impact of a lower target value and low risk of a grade 4 bleed being 
fatal: Table 7.9. 
C) Exploring the impact of a lower target value and high risk of a grade 4 bleed being 
fatal: Table 7.10. 
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Table 7.8 Exploring changes between the effectiveness of eltrombopag as compared 
to romiplostim from the meta analysis 
Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
1. Base Case RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,527 
21,133 
25,584 
60,626 
1.986 
1.986 
1.985 
1.986 
1.428 
1.429 
1.428 
1.429 
 
11,235,680 
11,711,779 
150,959,104 
Combine 4 & 5 RI-EP-RO-IV 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
19,116 
19,638 
26,405 
51,465 
1.985 
1.985 
1.986 
1.986 
1.424 
1.426 
1.427 
1.428 
 
330,372 
3,861,481 
150,959,109 
Combine 3, 4 & 5 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
245,914 
331,336 
476,594 
42.036 
42.053 
42.054 
15.584 
15.592 
15.593 
 
10,012,979 
297,159,118 
Combine 3,4,5&6 SC-SC-SC-SC-SC 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
26,405 
289,105 
385,442 
530,699 
35.946 
42.136 
42.152 
42.153 
13.034 
15.622 
15.631 
15.631 
 
101,498 
11,292,240 
297,159,118 
Combine 3,4,5,6&9 SC-SC-SC-SC-SC 
EP -RI -RO-IV 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
62,202 
574,409 
604,850 
803,191 
1,014,078 
35.946 
42.094 
42.136 
42.152 
42.153 
24.204 
30.515 
30.554 
30.570 
30.571 
 
81,165 
772,868 
12,337,218 
277,352,420 
Combine 3,4,5,6&10 SC-SC-SC-SC-SC 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
16,598 
196,477 
262,524 
381,007 
35.946 
42.136 
42.152 
42.153 
9.489 
11.060 
11.066 
11.066 
 
114,518 
10,540,618 
297,671,551 
 
 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D; SC = Standard of care 
In general it is found that the model is quite robust to individual changes in the parameters, 
however, it is when analyses are combined, where the biggest changes from the base case 
occur.  While some of changes made in the sensitivity analysis reflect methodological or 
structural uncertainty other changes represent more fundamental uncertainty in parameter 
values e.g. what is the relative difference between eltrombopag and romiplostim?  There is a 
lack of direct evidence and the indirect treatment comparison while suggestive that 
eltrombopag is inferior to romiplostim is limited.  The ERG is not suggesting that these 
figures are representative of states of the world that are most likely to exist.  What these 
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analyses do illustrate, however, is the degree of uncertainty surrounding the results in the base 
case analysis with respect to judgements that can be made about what the model structure and 
input parameters.   
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Table 7.9 Exploring the impact of a lower target value and low risk of having a fatal 
grade 4 bleed: Splenectomised patients 
Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
1. Base Case RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
18,527 
21,133 
25,584 
60,626 
1.986 
1.986 
1.985 
1.986 
1.428 
1.429 
1.428 
1.429 
 
11,235,680 
11,711,779 
150,959,104 
Combine 2&7 RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
16,455 
28,338 
23,458 
54,384 
1.988 
1.988 
1.988 
1.988 
1.429 
1.429 
1.429 
1.430 
 
7,267,616 
14,607,421 
116,121,979 
Combine 2,7&5 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
17,041 
23,596 
54,522 
1.988 
1.988 
1.988 
1.426 
1.427 
1.428 
 
4,146,528 
116,121,979 
Combine 2,7,5&6 SC-SC-SC-SC-SC 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
1,658 
18,042 
24,850 
55,776 
1.988 
1.988 
1.988 
1.988 
1.357 
1.427 
1.428 
1.428 
 
236,218 
4,306,581 
116,121,981 
Combine 2,3,7,5&6 SC-SC-SC-SC-SC 
EP -RI -RO-IV 
RI-EP-RO-IV 
RI -RO-EP-IV 
RI-IV-EP-RO 
RI-IV-RO-EP 
IV-RI -RO-EP 
101,459 
276,089 
282,607 
303,607 
375,316 
407,153 
536,528 
43.419 
43.419 
43.419 
43.419 
43.419 
43.419 
43.419 
13.376 
15.526 
15.532 
15.542 
15.547 
15.549 
15.550 
 
81,242 
1,091,223 
2,064,885 
14,130,163 
15,116,174 
216,100,175 
Combine 2,7,5&9 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
17,341 
24,014 
55,433 
1.988 
1.988 
1.988 
1.450 
1.452 
1.452 
 
4,198,475 
117,565,327 
Combine 2,7,5&10 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
16,839 
23,314 
53,908 
1.988 
1.988 
1.988 
1.409 
1.411 
1.411 
 
4,111,200 
115,143,703 
Combine 2,7,5,3&9 EP -RI -RO-IV 
RO-EP-RI-IV 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
495,398 
502,862 
519,365 
695,496 
845,587 
43.419 
43.419 
43.419 
43.419 
43.419 
30.003 
30.011 
30.027 
30.040 
30.041 
 
891,370 
1,055,300 
13,558,183 
178,972,806 
Combine 2,7,5,3&10 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
168,992 
231,071 
345,761 
43.419 
43.419 
43.419 
10.970 
10.975 
10.976 
 
11,540,348 
223,440,050 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D; SC = Standard of care
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Romiplostim tends to perform better over a longer time horizon relative to eltrombopag.  
Again, the important point to note here is that there is considerable uncertainty surrounding 
the most cost-effective treatment sequences when various scenarios are combined.  Various 
other combinations of analyses over alternative time horizons, changing discount rates and 
including standard of care in the model are explored and illustrated above. 
Table 7.10 provides a similar analysis approach, the main difference being, it is assumed that 
patients with a grade 4 bleed are certain to die.  i.e it is assumed here that 100% of grade 4 
bleeds are fatal. 
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Table 7.10 Exploring the impact of a lower target value and high risk of having a fatal 
grade 4 bleed: Splenectomised patients 
 
Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
Combine 2,8 RI-EP-RO-IV 
RI -EP-IV-RO 
RI-IV-EP -RO 
IV-RI-EP-RO 
16,387 
18,272 
23,396 
54,325 
1.985 
1.985 
1.985 
1.985 
1.428 
1.428 
1.429 
1.429 
 
6,690,335 
13,328,015 
104,914,764 
Combine 2,8&3 RI -RO-EP-IV 
RI-EP-RO-IV 
RI-IV-EP-RO 
IV-RI -EP -RO 
251,851 
251,942 
323,740 
453,136 
41.325 
41.331 
41.341 
41.342 
15.473 
15.476 
15.481 
15.481 
 
32,641 
17,483,470 
161,436,920 
 
Combine 2,8&5 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
16,954 
23,523 
54,452 
1.984 
1.985 
1.985 
1.425 
1.427 
1.427 
 
3,799,045 
104,914,764 
 
Combine 2,8,5&6 SC-SC-SC-SC-SC 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
1,181 
17,957 
24,780 
55,709 
1.967 
1.984 
1.985 
1.985 
1.352 
1.426 
1.427 
1.428 
 
228,828 
3,945,349 
104,914,765 
Combine 2,8,5&9 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
17,251 
23,940 
55,362 
1.984 
1.985 
1.985 
1.449 
1.451 
1.451 
 
3,842,043 
106,080,161 
Combine 2,8,5,9&3 EP-RO- RI-IV 
RO-EP- RI –IV 
RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
430,152 
437,959 
455,092 
631,729 
781,855 
40.551 
40.566 
40.594 
40.616 
40.617 
29.378 
29.389 
29.411 
29.429 
29.430 
 
669,806 
790,908 
9,904,366 
128,602,590 
 
Combine 2,8,5&10 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
16,753 
23,243 
53839 
1.984 
1.985 
1.985 
1.408 
1.410 
1.410 
 
3,769,743 
104,123,143 
 
Combine 2,8,5,10&3 RI -RO-EP-IV 
RI-IV-RO-EP 
IV-RI -RO-EP 
157,865 
220,113 
334,820 
40.594 
40.616 
40.617 
10.863 
10.870 
10.871 
 
8,879,922 
170,861,833 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D; SC = Standard of care 
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The main conclusion from Tables 7.9 and 7.10 is that there is little or no effect on the 
treatment sequences in the model as a result of the percentage of grade 4 bleeds which are 
fatal. 
 
In none of the various analyses presented above have any of the more costly sequences got an 
incremental cost per QALY that approaches a threshold value that society might be willing to 
pay.  The introduction of the low cost ‘standard of care’ sequence means that no active 
treatment sequence is associated with an incremental cost per QALY that society might find 
acceptable. 
 
These analyses illustrate the considerable structural and parameter uncertainty contained 
within the model.  Some plausible changes and combinations of sequences favour 
eltrombopag and some do not.  The main point however; is that the model results are 
surrounded by a considerable degree of uncertainty which make it difficult to draw concrete 
conclusions with regard to overall cost-effectiveness. 
 
7.5.2 Non Splenectomised patient group 
Due to the similarity between the two models, the results for non-splenectomised patients are 
similar in many respects to those for the splenectomised patient group.  The only obvious 
difference is the fact that Anti D is included in the non-splenectomised model.  It does not 
however occupy any prominent positions within the treatment sequences identified as being 
on cost-effectiveness frontier for any of the analyses conducted.  Table 7.11 describes the 
results of the sensitivity analysis conducted by the manufacturer and again are only included 
for completeness. 
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Table 7.11 Long term model – Non Splenectomised patient group: manufacturer 
analysis 
 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D 
Table 7.12 The impact of varying parameter values: 
Scenario Sequences Cost Life 
Years 
QALY Relative 
ICER 
1. Base Case RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,587 
19,992 
23,986 
26,932 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
 
10,749,060 
15,402,007 
164,623,320 
4. Changing cycle 
length for RO & 
EP to 12 weeks 
RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI –IV-AD-EP-RO 
17,620 
19,963 
24,053 
27,040 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.431 
 
7,036,474 
7,313,726 
25,818,933 
5. Varying 
Eltrombopag 
Response rate – 
33% as effective as 
Romiplostim  
RI-RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI- IV-AD-RO-EP 
18,395 
24,794 
26,346 
1.986 
1.986 
1.986 
1.428 
1.429 
1.429 
 
 
4,756,246 
13,131,249 
Scenario 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D 
Sequences Cost Life 
Years 
QALY Relative 
ICER 
1. Base Case RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,587 
19,992 
23,986 
26,932 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
 
10,749,060 
15,402,007 
164,623,320 
2. Response Rate > 
30 x 109/L 
RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
IV-RI-EP-AD-RO 
IV -EP-RI -AD-RO 
15,870 
17,233 
22,715 
54,483 
59,574 
1.986 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
1.43 
 
6,040,665 
99,227,335 
16,4090,975 
219,607,583 
3. Life Time 
Horizon 
RI-EP-RO-IV-AD 
RI-IV-EP-AD-RO 
RI-IV-AD-EP-RO 
260,199 
325,257 
386,796 
42.643 
42.648 
42.648 
15.819 
15.821 
15.821 
 
24,727,254 
545,565,480 
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Table 7.13 The impact of varying the structural assumptions 
 
RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D; SC = Standard of care 
As Tables 7.12 and 7.13 illustrate single variant sensitivity analysis does not tend to change 
the lead sequence on the cost-effective frontier except when response rates are adjusted in line 
with the meta-analysis between eltrombopag and romiplostim.  The manufacturer’s 
submission correctly notes that these results should be taken with caution given the wide 
confidence intervals on the difference between the two drugs in the meta-analysis.  More 
importantly, the results show that the model is open to a considerable amount of uncertainty.  
Scenario Sequences Cost Life 
Years 
QALY Relative 
ICER 
1.  Base Case RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,587 
19,992 
23,986 
26,932 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
 
10,749,060 
15,402,007 
164,623,320 
6. Inclusion of 
Standard of care 
in the model 
SC-SC-SC-SC-SC-SC 
RI-EP-RO-IV-AD-SC 
RI-EP-IV-AD-RO-SC 
RI-IV-EP-AD-RO-SC 
RI-IV-AD-EP-RO-SC 
1066 
17930 
20490 
24259 
27365 
1.974 
1.986 
1.986 
1.986 
1.986 
1.362 
1.43 
1.43 
1.431 
1.431 
 
247,995 
11,441,574 
14,539,385 
173,529,204 
7. 0% of grade 4 
bleeds are fatal 
RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,627 
20,031 
24,023 
26,969 
1.988 
1.988 
1.988 
1.988 
1.430 
1.431 
1.431 
1.431 
 
11,458,651 
16,510,954 
174,256,186 
8. 100% of 
grade 4 bleeds 
are fatal 
RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,577 
19,982 
23,976 
26,923 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
10,585,305 
15,147,800 
162,379,358 
9. Discount 
Rate 0% 
RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,901 
20,353 
24,409 
27,411 
1.986 
1.986 
1.986 
1.986 
1.455 
1.455 
1.455 
1.455 
 
10,889,079 
15,559,291 
166,633,199 
10. Discount 
Rate 6% 
RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,377 
19,749 
23,700 
26,609 
1.986 
1.986 
1.986 
1.986 
1.413 
1.414 
1.414 
1.414 
10,653,673 
15,295,049 
163,254,173 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
  
 112 
This point is further illustrated in extra probabilistic sensitivity analysis which is reported in 
Section 7.6. 
 
As with the splenectomised model above, when results are combined we see that the 
treatment sequences change.  For example, based on the combination of the two sensitivity 
analyses conducted in the submission, the lead sequence on the cost-effectiveness frontier has 
romiplostim as the most cost effective treatment in a post rituximab treatment sequence.  
However, the magnitude of the ICERs reported are all still beyond those that might generally 
be considered acceptable.  Of more importance is the fact that the model is suspect to many 
different combinations of sensitivity analyses.  The multi–variant analyses conducted present 
quite similar conclusions to those already reported for the splenectomised model above.  
Therefore, they are reported in Appendix 3. 
 
7.5.3 Further analysis conducted 
Comparing the lead treatment sequence with a possible more clinically likely sequence 
As an additional exploratory analysis request by NICE, the ERG has compared the lead 
treatment sequence presented by the manufacturer, with an alternative sequence identified as 
clinically plausible.  The ERG feels that a likely clinically acceptable sequence would be to 
treat first with Rituximab and then IVIg.  This is compared in Table 7.14 to the lead treatment 
sequence identified in the manufacturer’s analysis. 
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Table 7.14 Comparing a selected clinically plausible sequence with the manufacturer’s lead 
sequence from the base case analysis 
Analysis Sequence Cost (£) Life 
Years 
QALY ICER 
Splenectomised 
2 year time horizon 
RI-EP-RO-IV 
RI-IV-SC 
19,471 
20,618  
1.986  
1.984  
1.429 
1.420 
Dominant 
 
Splenectomised  
50 year time horizon 
RI-EP-RO-IV 
RI-IV-SC 
292,593 
234,715 
42.377 
40.850 
15.719 
15.119 
96,507 
 
Non splenectomised 
2 year time horizon 
RI-EP-RO-IV-AD 
RI-IV-SC 
17,930 
19,039 
1.986 
1.985 
1.430 
1.422 
Dominant 
 
Non splenectomised 
50 year time horizon 
RI-EP-RO-IV-AD 
RI-IV-SC 
281,261 
224,655 
42.703 
41.118 
15.842 
15.227 
92,053 
 
 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim; IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D; SC =Standard of care 
Over a 2 year time horizon, for both splenectomised and non splenectomised patient groups, 
the lead sequence identified by the manufacturer is less costly and more effective than the 
additional identified sequence.  The manufacturer’s lead sequence therefore dominates the 
sequence involving treatment with treat first with rituximab and then IVIg as presented in 
Table 7.14. 
 
Over a longer life time horizon, for both patient groups, while the manufacturer’s base case 
lead sequence remains more effective, the selected sequence for comparison is less costly.  
For both patient groups the incremental cost per QALY for the manufacturer’s base case lead 
sequence is over £90,000 and this illustrates the importance of the choice of time horizon. 
 
Exploring the impact of comparing the lead sequence with the same sequence without 
romiplostim 
The manufacturer’s submission correctly details that when the lead sequence with the 
inclusion of eltrombopag dominates the same sequence without eltrombopag.  The ERG has 
undertaken further exploratory analysis to identify whether this is the case for romiplostim 
(one of eltrombopag’s main comparator treatments).  
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
  
 114 
Table 7.15  Exploring the impact of comparing the lead sequence with the same 
sequence without romiplostim 
Analysis Sequence Cost (£) Life 
Years 
QALY ICER 
Splenectomised 
2 year time horizon 
RI-EP-RO-IV 
RI-EP-IV 
18,527 
22,449 
1.986  
1.985 
1.428 
1.427 
Dominant 
 
Splenectomised  
50 year time horizon 
RI-EP-RO-IV 
RI-EP-IV 
252,519 
354,772 
42.303 
41.889 
15.691 
15.535 
Dominant 
 
Non splenectomised 
2 year time horizon 
RI-EP-RO-IV-AD 
RI-EP-IV 
17,930 
20,471 
1.986 
1.986 
1.430 
1.430 
Dominant 
 
Non splenectomised 
50 year time horizon 
RI-EP-RO-IV-AD 
RI-EP-IV 
281,261 
342,411 
42.703 
42.456 
15.842 
15.750 
Dominant 
 
 
RI = Rituximab; EP = Eltrombopag; RO = Romiplostim; IV = Intravenous Immunoglobulin; AD = 
Intravenous Anti D 
Table 7.15 shows that the lead sequence including romiplostim is less costly and more 
effective than the same sequence without romiplostim and is therefore dominant.  A similar 
result was also reported for a similar analysis involving eltrombopag.  The ERG therefore 
points out that the analysis presented by the manufacturer for eltrombopag should be 
interpreted cautiously.   
 
Changes in cost of eltrombopag to reflect threshold cost identified for watch and rescue 
model 
As correctly pointed out in the submission document, the models are very much cost-driven.  
Therefore the ERG has conducted some additional analysis assessing the impact on the 
treatment sequences of using the price of eltrombopag required to obtain a threshold of 
£20,000 per QALY in the watch and rescue model. The results are presented in Table 7.16. 
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Table 7.16 Treatment sequences at selected eltrombopag price level 
Group Sequence Cost (£) Life 
Years 
QALY ICER 
Splenectomised 
P = £20.11 
 
RI-EP-RO-IV 
RI-EP-IV-RO 
RI-IV-EP-RO 
IV-RI-EP-RO 
11,852 
14,458 
22,356 
47,415 
1.986 
1.986 
1.986 
1.986 
1.428 
1.429 
1.429 
1.429 
 
11,235,677 
20,779,355 
150,959,104 
Non 
Splenectomised 
P = £15.89 
RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
10,528 
12,933 
20,393 
26,932 
1.986 
1.986 
1.986 
1.986 
1.430 
1.430 
1.430 
1.430 
 
10,749,063 
28,769,959 
365,373,761 
 
P = price; RI = Rituximab; EP = Eltrombopag;  RO = Romiplostim;  IV = Intravenous 
Immunoglobulin; AD = Intravenous Anti D 
Surprisingly, changing the price of eltrombopag used in the model had little or no affect on 
the treatment sequences or indeed on the magnitude of one ICER relative to another.  Even if 
eltrombopag is assumed to be free of charge (for argument sake), only one sequence on the 
frontier is eltrombopag lead.  This is driven by the fact that rituximab lead sequences are 
marginally more effective than eltrombopag ones.  However, what is more important is that 
the model seems to fail to pick up adequately on changes to many of the core values.  
Therefore, there may be an inability to deal with uncertainty in this model. 
 
7.6 Probabilistic analysis: Long term model 
In order to further explore the uncertainty between sequences, the ERG analysed a selection 
of rituximab lead sequences together for both the splenectomised and non-splenectomised 
patient groups.  As deterministic analyses were difficult to interpret because of the degree of 
uncertainty present the ERG felt that any uncertainties in the model may be more clearly 
identified through further probabilistic sensitivity analysis.  The manufacturer’s submission 
was somewhat lacking in the in this respect although the model was well equipped to perform 
these tasks.  This section aims to elaborate on the analyses presented and further address the 
issue of uncertainties between treatment sequences.  The analysis presented in this section 
reports cost effectiveness acceptability curves for selected rituximab lead sequences over a 
two year and 50 year time horizon.  All analyses are calculated using 1000 iterations from the 
Monte Carlo simulation provided within the manufacturer’s model. 
 
Figures 7.1 and 7.2 refer to splenectomised patient group and show the CEACs for three 
common plausible treatment sequences over a two year period and a 50 year period. 
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Figure 7.1 Cost-effectiveness acceptability curve; 2 year time horizon: 
splenectomised patients 
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RERI= Rituximab, Eltrombopag, Romiplostim, IVIg 
RREI= Rituximab, Romiplostim, Eltrombopag, IVIg 
RIER= Rituximab, IVIg, Eltrombopag, Romiplostim 
 
The results in Figure 7.1 show that over a two year time horizon, it is very likely that a 
treatment sequence with Eltrombopag administered after Rituximab is the most cost-effective 
approach.  Figure 7.2 identifies the CEACs associated with the same treatment sequences 
over a 50 year time horizon. 
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Figure 7.2 Cost-effectiveness acceptability curve; 50 year time horizon: 
splenectomised patients 
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RERI= Rituximab, Eltrombopag, Romiplostim, IVIg 
RREI= Rituximab, Romiplostim, Eltrombopag, IVIg 
RIER= Rituximab, IVIg, Eltrombopag, Romiplostim 
 
The evidence from Figure 7.2 suggests that a treatment sequence where romiplostim is 
administered post rituximab is the most likely to be cost-effective.  This is in contrast with 
Figure 7.1 which favoured eltrombopag as a second treatment in a sequence.  The main point 
to take from this analysis is that the model is very sensitive to the time horizon chosen for the 
analysis.  The best data, which is admittedly limited relates to the shorter-term time horizon.   
 
Figures 7.3 and 7.4 apply the same analysis to the non-splenectomised patient group: 
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Figure 7.3 Cost-effectiveness acceptability curve: 2 year time horizon; non-
splenectomised patient group 
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As with the splenectomised patient group, Figure 7.4 clearly shows that a treatment sequence 
with eltrombopag prescribed post rituximab is the most likely to be cost-effective over a two 
year time horizon. 
 
Figure 7.4 Cost-effectiveness acceptability curve: 50 year time horizon; non-
splenectomised patient group 
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As with the splenectomised group, over a longer time horizon (50 years) the treatment 
sequence using romiplostim post rituximab is more likely to be cost effective than using 
eltrombopag post rituximab (Figure 7.5). 
 
What has not been shown is the effect of introducing a standard or care option into a 
probabilistic sensitivity analysis.  Were this to be done then this treatments sequence would 
be associated with the highest cost-effectiveness over all values for society’s willingness to 
pay that might be considered acceptable. 
 
7.7 Summary of results 
These additional analyses have demonstrated that the results of the cost-effectiveness analysis 
are not generally altered to any significant extent by univariant changes in the long term 
model.  With regards to the Watch and Rescue model however, the analysis concludes that the 
model is sensitive to:  
 
A) The costing approach adapted 
B) The annual risk of a fatal bleed 
C) Discount rate used in the analysis 
D) The WHO grade of bleed applied in the model. 
 
In addition to changes in these parameters, the results of the watch and rescue model are also 
sensitive to changes in the cost of eltrombopag, as reported in Chapter 5,  although the 
reductions in the price of eltrombopag are substantially greater than those initially considered 
by the manufacturer. 
 
However, the main limitation to the analysis as presented by the manufacturer was the lack of 
any multivariate sensitivity.  The tables detailed above illustrate that combining a changes in 
various assumptions in both models have a substantial effect on the ICERs presented.  Best 
and worst case scenarios illustrate the full scale of possible uncertainty in the model.  This is 
much clearer from the Watch and Rescue model than the long-term model.  However, in 
neither model are ICERs below typical thresholds considered worthwhile. 
 
The long term model is quite robust to deterministic sensitivity analysis.  However, 
introducing standard of care results in no active treatment sequence having a QALY below 
£30,000 and combining a life time horizon with a response rate of > 30x109/L alters the 
treatment sequences and tends to favour romiplostim over eltrombopag.  Of greater interest 
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however, is the probabilistic analysis which clearly favours eltrombopag over a two year time 
horizon and romiplostim over a 50 year time horizon when a standard of care option is not 
included in the analysis. 
 
This chapter has concentrated on sensitivity analysis that makes eltrombopag less cost-
effective.  It is important to note that there are other plausible changes that may serve to make 
eltrombopag appear more cost-effective than is detailed in the industry submission; however 
these have not been modelled.  The key issue from the analysis as a whole is that the direction 
and magnitude of these uncertainties are unknown.  Much of the uncertainty arises as a result 
of a lack of comparable evidence between treatments in the literature.  Further studies and 
trials may become available in the future and these would give a much clearer picture of the 
most appropriate and cost–effective treatment programme for chronic adult ITP patients.  For 
this to happen, there is a requirement for more RCTs of eltrombopag compared with its 
competitor drugs conducted in a setting relevant to the treatment of ITP in the UK. 
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8 DISCUSSION 
 
8.1 Summary of clinical effectiveness issues 
 
8.1.1 The systematic review and use of evidence reporting on comparator treatment 
The manufacturer identified 20 RCTs and 93 non-randomised comparative studies or case 
series in the systematic review reporting on eltrombopag or comparator treatments. However, 
36 studies reporting comparator treatments included children or adolescents (< 18 years old).  
 
The evidence on comparator treatments was not statistically described, e.g. using median and 
range, or statistically synthesised. Instead, evidence from one or two primary studies/ reviews 
was used for each comparator treatment in the economic model. The manufacturer stated that 
the evidence chosen for the economic model was the best available. However, by undertaking 
independent searches, the ERG identified the ASH guideline7 and a high quality systematic 
review62 where more reliable evidence on IVIg and anti-D was reported, although such data 
would be unlikely to affect the conclusions of the economic evaluation.  
 
8.1.2 Methodological quality of the three eltrombopag trials 
In terms of the representativeness of the study participants, only 3/109 (2.8%), 10/114 (8.8%), 
and 9/197 (4.7%) participants in the eltrombopag trials were from the UK. It is unclear 
whether the participants in the eltrombopag trials are representative of UK chronic ITP 
patients (see Table 4.19 for baseline characteristics of participants in the eltrombopag groups 
in the trials).  
 
In addition, the decision problem specified that one group of patients considered should be 
non-splenectomised patients for whom splenectomy is contraindicated. However, patients 
who were suitable for splenectomy might also have been included in the eltrombopag trials. 
 
ITT analysis was not used in TRA100773A and B as the manufacturer stated. A small number 
of randomised patients (8/109 [7.3%] in TRA100773A, 2/102 [2.0%] in TRA100773B) were 
excluded from the statistical analysis. Any degree of exclusion following randomisation may 
break the balance of the baseline patient characteristics achieved by randomisation.  
 
There were relatively large proportions of participants who withdrew or were lost to follow-
up in the trials, ranging from 7% to 21% across treatment groups. In TRA100773A and B 
there were more such participants in the placebo groups and in the RAISE trial there were 
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more such participants in the eltrombopag group. As such participants were counted as non-
responders (platelet count), the results for platelet response might have favoured eltrombopag 
in studies TRA100773A and B, and placebo in the RAISE study. 
 
8.1.3 Indirect comparison comparing platelet response rates between eltrombopag and 
romiplostim 
More participants in the eltrombopag trial received concomitant ITP treatments than in the 
romiplostim trials. Concomitant treatment may have beneficial effects on disease progression, 
but on the other hand patients who received concomitant treatment might have more severe 
illness. The effect that this imbalance might have had on the indirect comparison results is 
therefore uncertain. 
 
The manufacturer used an inappropriate method (Mantel-Haenszel fixed effect meta-analysis) 
to combine the two romiplostim trials. In addition, as there were more participants who did 
not complete the treatment (withdrew or were lost to follow-up) in the eltrombopag trial than 
in the romiplostim trials, assuming such participants were non-responders (worst scenario) 
might have biased the results in favour of romiplostim. 
 
In the further analysis conducted by the ERG the odds ratios of romiplostim compared with 
placebo were estimated using a logistic regression model and the participants who did not 
complete the trials were all counted as responders (best scenario). Data were available for all 
participants but not by splenectomy status.  
 
The results of further analysis indicate that the results for durable response appear to be 
sensitive to the method used for handling those who did not complete the trials but not the 
results for overall response rate, i.e. in the manufacturer’s results eltrombopag had a lower 
durable response rate than romiplostim (OR 0.26, 95% CI 0.03 to 2.62) but in the ‘best 
scenario’ there were no differences in durable response rates between eltrombopag and 
romiplostim (OR 1.04, 95% CI 0.32 to 3.44); and for durable response the results from the 
manufacturer’s submission (OR 0.17, 95% CI 0.03 to 0.82) and from the ‘best scenario’ (OR 
0.26, 95% CI 0.07 to 0.97) were consistent, with both results indicating that eltrombopag is 
associated with a significantly lower overall response rate than romiplostim.  
 
8.2 Summary of cost-effectiveness issues 
The manufacturer submitted two economic models for the use of eltrombopag in the treatment 
of chronic adult ITP patients.  The first was the use of eltrombopag as part of a watch and 
rescue management system and the second was the use of eltrombopag as part of a treatment 
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sequence in a longer term continuous care setting.  Both models considered the cost-
effectiveness of using eltrombopag for two patient groups: those who are splenectomised and 
those who are non-splenectomised (contra-indicated to having a splenectomy). 
 
8.2.1 Watch and Rescue model 
The watch and rescue model was informed mainly from the RAISE double blinded RCT and 
it compared for each patient group the cost-effectiveness of eltrombopag with a standard care 
package that did not including eltrombopag.  Further assumptions were made based on both 
published data and clinical expert opinion.  With respect to the expert opinion used it is not 
always clear how expert opinion was used to value parameters in the model and further which 
experts contributed to which issues.  Furthermore, it is unclear whether or not the evidence 
information used is representative of a UK ITP population.   
 
It is assumed that all patients in the non-splenectomised patient group are contra-indicated to 
having a splenectomy.  However, it is unclear whether the data available to model this patient 
group are applicable as it is unclear whether the non-splenectomised trial participants that 
contributed data were actually contra-indicated to splenectomy.  
 
The extent of uncertainty in parameter values may not be adequately described within the 
model as submitted by the manufacturer.  In particular, the model is sensitive to substantial 
changes in the cost of eltrombopag.  The price of the drug would need to be substantially 
below the anticipated market price for eltrombopag to be considered cost-effective at typical 
threshold values that society might be willing to pay.  The model is also sensitive to the rate 
of mortality used, as was illustrated in Chapter 7.  The additional analyses conducted by the 
ERG showed that the results are also quite sensitive to the discount rate applied in the model.   
 
One failure of the industry submission was the failure to conduct multi-variant sensitivity 
analysis.  Plausible changes to certain combinations of assumptions lead to substantial 
increases in the incremental cost per QALY for both patient groups. Further plausible 
combinations explored lead to substantial reductions in the ICERs reported.  However, none 
result in eltrombopag have an incremental cost per QALY of £30,000 or less other than 
substantial reductions in price.  The key point to gain from this is that there is substantial 
uncertainty in the model and the true ICER could lie anywhere between the best and worst 
case scenarios presented.  Even in the best case scenario, it is unlikely that Eltrombopag is 
cost-effective at the regular threshold value used by NICE unless the price is reduced as well. 
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8.2.2 Long-term model 
The long-term model assessed the use of eltrombopag as part of a treatment sequence for the 
treatment of ITP based on a cohort of 25 patients.  Expert opinion was used throughout the 
model to inform the choice of model structure and parameter values.  As these assumptions 
represent judgements made by the manufacturer and their advisors there basis can be 
questioned as alternative assumptions might have been made.   
 
It is also difficult to unravel how the basis for the manufacturer’s estimation of the population 
of patients who will require long term care.  There is likely to be considerable uncertainty 
surrounding this estimate, which includes uncertainty around incidence rates, uptake rates and 
the proportion of patients requiring long-term care.  Sensitivity analysis illustrates that 
changes in the assumptions used can lead to considerable variation in cost with little variation 
in QALYs gained in each treatment sequence. 
 
Specifically, in relation to the model structure, the ERG notes that rituximab is the first line of 
treatment in the majority of treatment sequences on the cost-effectiveness frontier identified 
by the manufacturer.  Rituximab is not licensed in the UK for the treatment of ITP patients 
and the relevance of these treatment strategies may be limited.   
 
The evidence base used to estimate effectiveness of treatments in this model is limited.  The 
data used is essentially observational and no directly comparative data were available.  The 
limited indirect comparative data for eltrombopag vs. romiplostim was not used. It is worth 
noting that, although not strong, these data were the best available and they favoured a 
comparator treatment (romiplostim) over eltrombopag.  Furthermore, apart from the use of 
Anti D, assumptions incorporated in both the splenectomised and non splenectomised models 
were essentially the same.   
 
With respect to health state utilities two different measures of utility were used to inform the 
model.  It is unclear how comparable these methods are for ITP patients.  More importantly, 
however, is the issue that the manufacturer did not incorporated and utility decrement due to 
adverse events associated with eltrombopag or any of the comparator treatments in the model.  
The only utility decrement measured is in relation to bleeding events.  The direction of the 
bias this introduces is unclear but it is quite plausible that it against eltrombopag. 
 
The sensitivity analysis conducted by the ERG in Chapter 7 highlights a number of issues of 
uncertainty.  In general the results for both patient groups appear robust in the deterministic 
analysis.  Various combinations of plausible variation are explored in further deterministic 
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analyses and multi-variant analyses.  It is found that the results are influenced and are most 
sensitive to changes in: 
• Time horizon 
• Response rate  
• Response target value 
 
In the long-term model individual changes do not appear to affect the treatment sequences of 
the model, however, when combined it is found that using a platelet response rate of 
>30x109/L and increasing the time horizon to a 50 years romiplostim replaces eltrombopag as 
the most cost–effective treatment option post rituximab.  Further combinations of analysis for 
both patient groups are discussed in Chapter 7.   
 
A further treatment sequence considered in the additional sensitivity analysis was the 
inclusion of a “standard of care” sequence, which essentially only allowed patients to use 
rescue medications.  The inclusion of this option may be debatable but it is worth noting that 
no treatment sequence including an active treatment was associated with an ICER below 
£30,000. 
 
The probabilistic analysis as presented by the manufacturer was limited and no CEACs were 
reported.  The ERG, as shown in Chapter 7, presented further sensitivity analyses to more 
fully explore issues of uncertainty in the model.  The results show that over a two year time 
horizon (where standard of care was not included in the treatment sequence), eltrombopag 
was, when used after rituximab in a sequence for both patient groups most likely to be cost-
effective.  However, over a 50 year time horizon, the results favoured romiplostim.  These 
results were applicable to both the splenectomised and non – splenectomised patient groups. 
 
The ERG recognises that there is a very limited evidence base for assessing the cost–
effectiveness of ITP treatments and that the evidence base for eltrombopag provided by the 
manufacturer was the best available source of evidence to inform the models.  These data 
were also of superior quality than the data available for any of the comparator treatments 
(romiplostim excepted).  To overcome the limitations of the overall evidence base, well 
designed and adequately powered RCTS of eltrombopag against its comparator drugs relevant 
to the UK are required. 
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8.3 Overall summary 
Based on the evidence submitted and the additional work conducted by the ERG, the 
following are the main issues that a decision maker needs to note. 
 
Effectiveness 
• Eltrombopag appears to be a safe treatment for ITP. 
• Eltrombopag has short term efficacy for the treatment of ITP. 
• There is no robust evidence on long-term efficacy of eltrombopag. 
• Eltrombopag appears to be less effective in achieving an overall response rate (four or 
more weeks platelet count ≥ 50 x 10 9/L) than romiplostim in a 6-month intervention 
period. 
• There is no robust evidence on long-term effectiveness of eltrombopag compared to other 
relevant comparators. 
 
Watch and Rescue model 
• Is clinical evidence used to support the model reflective of the UK population? 
• Substantial reductions in cost of eltrombopag are needed before the incremental cost per 
QALY is less than £30,000. 
• Increases in the chance of dying from a bleeding event will improve the cost-
effectiveness of eltrombopag.  If they tend towards the upper boundary considered by the 
manufacturer, and the price of eltrombopag is reduced then it is plausible that the cost per 
QALY could be reduced to less than £30,000. 
• Are adverse events likely to have a significant impact on patients using the drug?  Other 
than bleeding there is no evidence of adverse events in the economic model.  The effect 
of this exclusion is unclear but might represent a bias against eltrombopag. 
 
Long-term model 
• Is clinical evidence used to support the model reflective of the UK population? 
• The use of non-randomised non comparative data is likely to result in biased estimates.  
The magnitude and direction of these biases is uncertain. 
• The manufacturer chose to ignore the indirect treatment comparison data available for the 
comparison of eltrombopag with romiplostim.  Inclusion of such data along with other 
plausible changes in the effectiveness of romiplostim substantially alters the order of 
treatments in terms of cost-effectiveness.  A decision is needed as to whether such data 
are sufficiently robust. 
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• Inclusion of the standard of care sequence results in no active treatment sequence having 
an ICER below £30,000.  It is unclear whether such a sequence is plausible. 
• When excluding a standard of care sequence, a sequence where eltrombopag is used after 
rituximab is the least costly but least effective of the non-dominated sequences.  None of 
the other sequences have an ICER below £30,000. 
• The model is sensitive to the time horizon of the model.  If the time horizon is restricted 
to 2 years (the strongest data only pertain to this time horizon) then a treatment sequence 
where eltrombopag is given after failure to respond with rituximab would be most likely 
to be cost-effective.  A 50 year time horizon favours a sequence involving romiplostim.  
If a standard of care option were included it is less likely that an active treatment 
sequence would be considered worthwhile.  
• Has the manufacturer correctly estimated their target patient population and the numbers 
of patients who will require long-term treatments?  Many assumptions are used and a 
judgement is needed as to how applicable these are. 
 
8.4 Implications for research  
It is clear from the manufacturer’s submission that there is a paucity of good quality evidence 
for the burden of disease and the treatment of ITP. What can be concluded is that ITP patients 
are being exposed to drugs with considerable side-effect profiles but with little evidence for 
efficacy, safety, effectiveness or cost-effectiveness.  As a consequence of this dearth of 
evidence the following research recommendations are made: 
• Epidemiological research is required to determine the true prevalence of ITP in the UK, 
and the proportion of patients requiring treatment and developing complications of the 
disease and treatments.  
• Large good quality RCTs are needed to determine the best second/third line therapies 
comparing romiplostim, eltrombopag and possibly rituximab with each other. Such trials 
should include a full economic evaluation and hence have a long enough follow-up to 
capture the most important economic differences.  Consideration may be needed as to 
how such trials might be funded because such head to head studies may not be in the best 
commercial interest of individual manufacturers. 
• As so few medical treatments are actually licenced for use as treatments the use of 
romiplostim, eltrombopag and possibly rituximab should also be considered, and 
investigated, as first line therapy.  Such investigation should involve the design and 
conduct of large good quality RCTs comparing the use of these therapies against each 
other.  These trials should include economic evaluations. 
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10 APPENDICES 
 
Appendix 1 Independent searches undertaken by ERG 
 
Medline/Embase search for Eltrombopag 
Database: Ovid MEDLINE(R) (1996- Oct wk 2 2009), Ovid MEDLINE(R) In-Process (14th 
Oct 2009), EMBASE (1996-wk 41 2009) 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     purpura, thrombocytopenic, idiopathic/ use medf  
2     idiopathic thrombocytopenic purpura/ use emef  
3     idiopathic thrombocytop?enic purpura.tw.  
4    immune thrombocytop?enic purpura.tw.  
5     autoimmune thrombocytop?enic purpura.tw 
6     idiopathic thrombocytop?enia.tw.  
8     autoimmune thrombocytop?enia.tw.  
9       itp.tw 
10     aitp.tw.  
11     or/1-10  
12     eltrombopag.tw,rn.  
13     promacta.tw,rn.  
14     revolade.tw,rn 
15     (sb-497115$ or sb497115$).tw,rn.  
16     or/12-15  
17     11 and 16  
18     remove duplicates from 17  
19     from 18 keep 1-81  
 
Medline/Embase search for clinical effectiveness of  comparators 
Database: Ovid MEDLINE(R) (1966- Oct wk 2 2009), Ovid MEDLINE(R) In-Process (14th 
Oct 2009), EMBASE (1966-wk 41 2009) 
Search Strategy: 
-------------------------------------------------------------------------------- 
1. idiopathic thrombocytop?enic purpura.tw. 
2. immune thrombocytop?enic purpura.tw. 
3. autoimmune thrombocytop?enic purpura.tw. 
4. idiopathic thrombocytop?enia.tw. 
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5. immune thrombocytop?enia.tw. 
6. autoimmune thrombocytop?enia.tw. 
7. (itp or aitp).tw. 
8. purpura, thrombocytopenic, idiopathic/ use mesz 
9. idiopathic thrombocytopenic purpura/ use emez 
10. or/1-9 
11. exp steroid/ use emez 
12. exp steroids/ 
13. immunoglobulins, intravenous/ use mesz 
14. exp immunoglobulin/iv use emez 
15. (ivig or igiv or ivigg or igv).tw. 
16. (gammaglobulin$ or gamma globulin$).tw. 
17. (intravenous adj (immunoglobulin$ or immune globulin$ or ig)).tw. 
18. (iv immunoglobulin$ or intravenous antibod$).tw. 
19. (sandoglobulin or gamunex or flebogamma or gammagard or octagam or vigam).tw. 
20. "RHo(D) Immune Globulin"/ 
21. Rhesus D Antibody/ use emez 
22. Anti D.tw. 
23. Anti Rh$.tw. 
24. (rh$ adj3 (immune globulin$ or immunoglobulin$)).tw. 
25. (winrho or rhophylac).tw. 
26. rituximab/ 
27. antigens, CD20/ 
28. rituximab.tw,rn. 
29. ritux?n.tw,rn. 
30. mabthera.tw,rn. 
31. anti-CD20.tw,rn. 
32. danazol/ 
33. danazol.tw,rn. 
34. danol.tw,rn. 
35. (danatrol or danocrine).tw,rn. 
36. dapsone/ 
37. dapsone.tw,rn. 
38. azathioprine/ 
39. azathioprine.tw,rn. 
40. (im?uran or immurel or azamum or azamune).tw,rn. 
41. Mycophenolic Acid 2 Morpholinoethyl Ester/ 
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42. myfortic.tw,rn. 
43. cellcept.tw,rn. 
44. mycophenolate mofetil.tw,rn. 
45. mmf.tw. 
46. cyclosporine/ 
47. c?closporin$.tw,rn. 
48. (neoral or sandimmun$).tw,rn. 
49. cyclophosphamide/ 
50. (endoxan$ or se?doxan$ or neosar$ or cytoxan$ or procytox$).tw,rn. 
51. exp vinca alkaloids/ 
52. vinblastine/ or vinc alkaloid/ or vincristine/ or vindesine/ 
53. (vinblastine or vincristine or vindesine or vinorelbine).tw,rn. 
54. romiplostim.tw,rn. 
55. remiplistim.tw,rn. 
56. nplate.tw,rn. 
57. (amg 531 or amg531).tw. 
58. or/11-57 
59. 10 and 58 
60. exp clinical trial/ 
61. randomized controlled trial.pt. 
62. controlled clinical trial.pt. 
63. randomization/ use emez 
64. randomi?ed.ab. 
65. placebo.ab. 
66. drug therapy.fs. 
67. randomly.ab. 
68. trial.ab. 
69. groups.ab. 
70. comparative study/ use mesz 
71. follow-up studies/ use mesz 
72. time factors/ use mesz 
73. Treatment outcome/ use emez 
74. major clinical study/ use emez 
75. controlled study/ use emez 
76. clinical trial/ use emez 
77. (chang$ or evaluat$ or reviewed or baseline).tw. 
78. (prospective$ or retrospective$).tw. use mesz 
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79. (cohort$ or case series).tw. use mesz 
80. (compare$ or compara$).tw. use eme 
81. meta-analysis.pt. 
82. review.pt. 
83 meta-analysis/ 
84 systematic review/ 
85. randomized controlled trials/ 
86. (controlled or design or evidence or extraction).ab. 
87. (sources or studies).ab. 
88. or/60-87 
89. 59 and 88 
90. case report/ use emez 
91. case reports.pt. 
92. 89 not (90 or 91) 
93. exp child/ or exp infant/ 
94. exp adult/ 
95. 93 not 94 
96 92 not 95 
97. limit 96 to english language 
 
DARE  and HTA Databases (October 2009) 
NHS Centre for Reviews & Dissemination URL:http://nhscrd.york.ac.uk/welcome.htm 
 
# 1 MeSH Purpura, Thrombocytopenic, Idiopathic EXPLODE 1 2 3 4 5  
# 2 itp OR aitp   
# 3 "idiopathic thrombocytop* 
# 4 "immune thrombocytop* 
# 5 "autoimmune thrombocytop* 
# 6 #1 or #2 or #3 or #4  
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Appendix: 2 Description of calculations conducted in chapter 7: additional sensitivity 
analysis 
 
Appendix 2 details all of the changes to the economic models conducted by the ERG while 
completing the additional analyses in Chapter 7.  Any changes not directly referenced can be 
achieved by combining a number of the changes outlined in this Appendix. 
 
Watch and Rescue model: 
 
Table A1: Using Cell H38, settings tab to select the splenectomised patient group: 
Reference Details Tab CELL Original 
calculation 
ERG edit 
Table 7.3 
Line 2 Typing corrections made to  
the model 
ITP 
meds 
AH40 
AI40 
AG50 
12,000 
14,100 
14,100 
120,000 
140,000 
140,000 
Line 3 Sensitivity analysis using a 
micro costing approach 
Settings 
Tab 
H23 Macro Micro 
Line 4 Sensitivity analysis using all 
bleeding events 
Settings 
Tab 
H30 Clinically 
significant 
bleeding 
All 
Bleeding 
Line 5 Varying the discount rate 
for costs and benefits to 0% 
Death H26 3.5% 0% 
Line 6 Varying the discount rate 
for costs and benefits to 6% 
Death H26 3.5% 6% 
Line 7 Varying the annual risk of a 
fatal bleed to the lower 
bound reported in the Cohen  
2000 study10 
Death H32 2.76 1.6 
Line 8 Varying the annual risk of a 
fatal bleed to the upper 
bound of the Cohen 2000 
study10  
Death H32 2.76 3.9 
Line 9 Combining analyses 2,3,4,6 
& 7 above to detail a worst 
case scenario 
Combine changes in lines 2,3,4,6 and 7 above 
Line 10 Varying analyses 1,5 & 8 
above to detail a best case 
scenario 
Combine changes in lines 5 and 8 above 
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Table A2: Using cell H38, settings tab to select the non-splenectomised patient group 
Reference Detail Tab CELL Original 
calculation 
ERG edit 
 Table 7.4 
Line 2 Typing corrections made 
to  the model 
ITP meds AH40 
AI40 
AG50 
12,000 
14,100 
14,100 
120,000 
140,000 
140,000 
Line 3 Sensitivity analysis using 
a micro costing approach 
Settings 
Tab 
H23 Macro Micro 
Line 4 Sensitivity analysis using 
all bleeding events 
Settings 
Tab 
H30 Clinically 
significant 
bleeding 
All Bleeding 
Line 5 Varying the discount rate 
for costs and benefits to 
0% 
Death H26 3.5% 0% 
Line 6 Varying the discount rate 
for costs and benefits to 
6% 
Death H26 3.5% 6% 
Line 7 Varying the annual risk of 
a fatal bleed to the lower 
bound reported in the 
Cohen 2000 study10 
Death H32 2.76 1.6 
Line 8 Varying the annual risk of 
a fatal bleed to the upper 
bound of the Cohen 2000 
study10 
Death H32 2.76 3.9 
 
Line 9 
Combining analyses 
2,3,4,6 & 7 above to detail 
a worst case scenario 
 
Combine changes in lines 2,3,4,6 and 7 above 
 
Line 10 
Varying analyses 1,5 & 8 
above to detail a best case 
scenario 
 
Combine changes in lines 5 and 8 above 
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Long term continuous care model: Splenectomised 
Reference 
Table A3: Splenectomised patient group 
Detail Tab CELL Original 
calculation 
ERG edit 
 
Table 7.5 
line 2 Varying the 
response rate for 
the model to a 
platelet count of > 
30*109/L 
Main 
Control 
 Select C174 Select C176 
Line 3 Running the model 
over a life time 
horizon 
Results 
Batch 
E18 2 50 
 Table 7.6     
Line 4 Adjusting the cycle 
lengths for 
Romiplostim and 
Eltrombopag from 
8 to 12 weeks 
Data 
Response 
I69 
I70 
8 
8 
12 
12 
Line 5 Varying the 
response rate for 
Eltrombopag in line 
with the Meta 
analysis carried out 
by the manufacturer 
Data 
Response 
J23 
K23 
L23 
J23 
K23 
L23 
J23 = F24*.46 
K23 = G24*.46 
L23 = H24*.46 
 
 
Table 7.7 
Line 6 Allowing the model 
to include standard 
of care as a 
treatment option 
Main 
Control 
G129 Deselect 
Standard of Care 
Select Standard of 
Care 
Line 7 Assuming 0% of 
WHO grade 4 
bleeds are fatal 
Default 
Data 
 
Data – 
Bleed Risk 
H248 
 
 
I38 
I39 
80% 
 
 
I38 
I39 
0% 
 
 
I38 = F38 
I39 = F39 
Line 8 Assuming 100% of 
WHO grade 4 
Default 
Data 
H248 
 
80% 
 
100% 
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bleeds are fatal  
Data – 
Bleed Risk 
 
I38 
I39 
 
I38 
I39 
 
I38 = F38 
I39 = F39 
Line 9 Assuming a 
discount rate for 
costs and benefits 
of 0% 
Main 
Control 
F71 
F75 
3.5 
3.5 
0 
0 
Line 10 Assuming a 
discount rate for 
costs and benefits 
of 6% 
Main 
Control 
F71 
F75 
3.5 
3.5 
6 
6 
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Long term continuous care model: Non-splenectomised 
 
Table A4: Non-splenectomised patient group 
Reference Detail Tab CELL Original 
calculation 
ERG edit 
 
Table 7.11 
line 2 Varying the 
response rate for 
the model to a 
platelet count of > 
30*109/L 
Main 
Control 
 Select C174 Select C176 
Line 3 Running the model 
over a life time 
horizon 
Results 
Batch 
E18 2 50 
 
Table 7.12 
Line 4 Adjusting the 
cycle lengths for 
Romiplostim and 
Eltrombopag from 
8 to 12 weeks 
 
Data 
Response 
I69 
I70 
8 
8 
12 
12 
Line 5 Varying the 
response rate for 
Eltrombopag in 
line with the Meta 
analysis carried 
out by the 
manufacturer 
 
Data 
Response 
J23 
K23 
L23 
J23 
K23 
L23 
J23 = F24*.33 
K23 = G24*.33 
L23 = H24*.33 
 
 
Table 7.13 
Line 6 Allowing the 
model to include 
standard of care as 
a treatment option 
Main 
Control 
G129 Deselect 
Standard of 
Care 
Select Standard of 
Care 
Line 7 Assuming 0% of 
WHO grade 4 
Default 
Data 
H248 
 
80% 
 
0% 
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bleeds are fatal  
Data – 
Bleed Risk 
I38 
I39 
I38 
I39 
I38 = F38 
I39 = F39 
Line 8 Assuming 100% of 
WHO grade 4 
bleeds are fatal 
Default 
Data 
 
Data – 
Bleed Risk 
H248 
 
I38 
I39 
80% 
 
I38 
I39 
100% 
 
I38 = F38 
I39 = F39 
Line 9 Assuming a 
discount rate for 
costs and benefits 
of 0% 
Main 
Control 
F71 
F75 
3.5 
3.5 
0 
0 
Line 10 Assuming a 
discount rate for 
costs and benefits 
of 6% 
Main 
Control 
F71 
F75 
3.5 
3.5 
6 
6 
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Appendix 3: Additional multi-variant sensitivity analysis for non – splenectomised 
patients 
 
Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
1.Base Case RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
RI- IV-AD-EP-RO 
17,587.07 
19,992.16 
23,985.54 
26,931.85 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
 
10,749,060 
15,402,007 
164,623,320 
Combine 4&5 RI-EP-RO-IV-AD 
RI -RO-EP-IV-AD 
RI -RO -IV-AD-EP 
RI-IV-RO-AD-EP 
IV-RI –AD-RO-EP 
18,594 
18,843 
22,109 
25,026 
26,643 
1.985 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
1.43 
 
131,277 
3,409,416 
3,649,945 
8,272,760 
 
Combine 3,4&5 RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI –IV-AD-RO-EP 
255.789 
340.418 
372.302 
42.446 
42.467 
42.469 
15.742 
15.752 
15.753 
 
8,376,638 
27,099,473 
 
Combine 3,4,5&6 SC-SC-SC-SC-SC 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI -IV-AD-RO-EP 
24,557 
280,588 
371,512 
411,704 
36.451 
42.538 
42.559 
42.561 
13.253 
15.777 
15.787 
15.788 
 
101,450 
8,999,707 
34,161,055 
 
Combine 3,4,5,6&9 SC-SC-SC-SC-SC 
EP -RO -RI-AD-IV 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI - IV-AD-RO-EP 
58,227 
575,080 
594,124 
784,342 
877,936 
36.451 
42.487 
42.538 
42.559 
42.561 
24.712 
30.942 
30.989 
31.009 
31.012 
 
82,964 
399,187 
9,473,536 
39,712,006 
 
Combine 3,4,5,6&10 SC-SC-SC-SC-SC 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI –IV-AD-RO-EP 
15,367 
189,275 
251,004 
276,444 
36.451 
42.538 
42.559 
42.561 
9.627 
11.144 
11.152 
11.152 
 
114,622 
8,587,977 
30,571,396 
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Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
Combine 2&7 RI-EP-RO-IV-AD 
RI-EP-IV-AD-RO 
RI-IV-EP-AD-RO 
IV-RI-EP-AD-RO 
IV -EP-RI-AD-RO 
15,916 
17,278 
22,759 
54,526 
59,617 
1.988 
1.988 
1.988 
1.988 
1.988 
1.430 
1.431 
1.431 
1.431 
1.431 
 
6,439,218 
106,122,394 
178,118,731 
241,279,108 
 
Combine 2,7&5 RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI - IV-AD-RO-EP 
IV-RI-AD-RO-EP 
17,048 
23,371 
24,501 
56,267 
1.988 
1.988 
1.988 
1.988 
1.428 
1.430 
1.430 
1.430 
 
3,667,494 
5,769,531 
178,118,729 
 
Combine 2,7,5&6 SC-SC-SC-SC-SC 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI - IV-AD-RO-EP 
IV-RI-AD-RO-EP 
1,258 
17,380 
23,788 
25,029 
56,795 
1.988 
1.988 
1.988 
1.988 
1.988 
1.377 
1.428 
1.430 
1.430 
1.430 
 
313,235 
3,716,588 
6,340,285 
178,118,729 
Combine 2,3,7,5&6 SC-SC-SC-SC-SC 
EP-RO-RI-IV-AD 
RO-EP-RI-IV-AD 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI - IV-AD-RO-EP 
IV-AD-RI-RO-EP 
IV-RI-AD-RO-EP 
86,812 
266,693 
271,968 
298,997 
401,328 
444,676 
533,200 
577,734 
43.419 
43.419 
43.419 
43.419 
43.419 
43.419 
43.419 
43.419 
13.767 
15.723 
15.730 
15.741 
15.751 
15.752 
15.753 
15.753 
 
91,993 
682,952 
2,442,697 
10,814,632 
31,827,023 
318,744,337 
361,557,605 
 
Combine 2,7,5&9 RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI –IV-AD-RO-EP 
IV-RI-AD-RO-EP 
17,351 
23,790 
24,941 
57,215 
1.988 
1.988 
1.988 
1.988 
1.452 
1.454 
1.454 
1.454 
 
3,712,281 
5,840,173 
180,337,224 
 
Combine 2,7,5&10 RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI –IV-AD-RO-EP 
IV-RI-AD-RO-EP 
16,843 
23,084 
24,204 
55,628 
1.988 
1.988 
1.988 
1.988 
1.411 
1.413 
1.413 
1.413 
 
3,637,013 
5,721,380 
176,615,069 
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Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
Combine 2,7,5,3&9 EP -RO -RI-IV-AD 
RO-EP-RI-IV-AD 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI –IV-ADRO-EP 
IV-RI-AD-RO-EP 
472,892 
478,908 
566,829 
757,335 
831,972 
986,353 
43.419 
43.419 
43.419 
43.419 
43.419 
43.419 
30.586 
30.597 
30.614 
30.631 
60.635 
60.636 
 
555,541 
5,119,389 
10,475,705 
27,312,189 
274,905,479 
 
Combine 2,7,5,3&10 RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI –IV-AD-RO-EP 
IV-RI-AD-RO-EP 
180,345 
244,825 
264,997 
382,945 
43.419 
43.419 
43.419 
43.419 
11.083 
11.090 
11.091 
11.092 
 
9,423,690 
21,108,797 
343,148,662 
Combine 2&8 RI-EP-RO-IV-AD 
RI -EP-IV-AD-RO 
RI-IV-EP –AD-RO 
IV-RI-EP-AD-RO 
IV-EP-RI-AD-RO 
15,858 
17,222 
22,704 
54,472 
59,564 
1.985 
1.986 
1.986 
1.986 
1.986 
1.43 
1.43 
1.43 
1.43 
1.43 
 
5,948,737 
97,641,449 
160,922,799 
214,784,911 
 
Combine 2,8&3 RI -RO-EP-IV-AD 
RI-EP-RO-IV-AD 
RI-IV-EP-AD-RO 
RI-IV-EP –AD-RO 
IV -EP-RI-AD -RO 
381,655 
272,798 
329,498 
341,137 
482,714 
42.013 
42.003 
42.030 
42.031 
42.032 
15.683 
15.688 
15.691 
15.691 
15.691 
 
328,815 
19,694,533 
42,588,318 
220,278,733 
 
Combine 2,8&5 RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI - IV-AD-RO-EP 
IV-RI-AD-RO-EP 
16,970 
23,310 
24,441 
56,209 
1.985 
1.985 
1.985 
1.985 
1.427 
1.429 
1.429 
1.429 
 
3,366,725 
5,301,319 
160,922,797 
 
Combine 2,8,5&6 SC-SC-SC-SC-SC 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI -IV-AD-RO-EP 
IV-RI-AD-RO-EP 
897 
17,303 
23,728 
24,971 
56,739 
1.972 
1.985 
1.985 
1.985 
1.986 
1.373 
1.427 
1.429 
1.430 
1.430 
 
301,907 
3,411,677 
5,824,927 
160,922,797 
Combine 2,8,5&9 RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI -IV-AD-RO-EP 
IV-RI-AD-RO-EP 
17,271 
23,727 
24,880 
57,156 
1.985 
1.985 
1.985 
1.985 
1.452 
1.453 
1.454 
1.454 
 
3,403,877 
5,360,398 
162,714,435 
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Scenario Sequences Cost (£) Life 
Years 
QALY Relative 
ICER 
Combine 2,8,5,9&3 EP-RO- RI-IV-AD 
RO-EP- RI–IV-AD 
RI -RO-EP-IV-AD 
RI-IV-RO-AD-EP 
RI -IV-AD-RO-EP 
IV-RI-AD-RO-EP 
427,185 
433,645 
522,257 
713,460 
788,201 
942,606 
41.410 
41.429 
41.459 
41.490 
41.495 
41.496 
30.148 
30.163 
30.187 
30.212 
30.216 
20.216 
 
428,543 
3,726,567 
7,690,522 
20,045,930 
197,520,133 
Combine 2,8,5&10 RI-EP-RO-IV-AD 
RI-IV-RO-AD-EP 
RI -IV-AD-RO-EP 
IV-RI-AD-RO-EP 
 
16,767 
23,029 
24,145 
55,571 
1.985 
1.985 
1.985 
1.985 
1.411 
1.412 
1.413 
1.413 
 
3,341,389 
5,260,977 
159,705,787 
 
Combine 2,8,5,10&3 RI-EP-RO-IV-AD 
RI-IV-RO-AD-EP 
RI -IV-AD-RO-EP 
IV-RI-AD-RO-EP 
 
172,566 
.237,261 
257,463 
375,422 
41.459 
41.490 
41.495 
41.496 
11.009 
11.018 
11.019 
11.019 
 
7,262,297 
16,247,797 
262,388,370 
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